microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft homepage hidechilds  false systemname  homepage   about us our purpose our background our leadership therapies hemophilia a hemophilia b manufacturing research  pipeline our pipeline clinical trials scientific  medical research community support humanitarian aid my life our future patient support sickle cell disease global sites corporate canada japan bioverativ – science matters because patients matter science matters because patients matter learn more   science that redefines whats possible our scientists brought the first major advances in hemophilia treatment in nearly two decades and we’re committed to developing new lifechanging medicines for people with rare blood disorders learn more   expanding access around the world we committed with sobi to donate up to  billion ius of factor therapy to the developing world already more than  people with hemophilia have been treated learn more   bioverativ in the news friday july    am bioverativ to report second quarter  financial results on august   read more our purpose  about us hidechilds  false systemname    about us our purpose our background our leadership therapies hemophilia a hemophilia b manufacturing research  pipeline our pipeline clinical trials scientific  medical research community support humanitarian aid my life our future patient support sickle cell disease global sites corporate canada japan bioverativ is a global biotechnology company dedicated to transforming the lives of people living with hemophilia and other blood disorders creating meaningful progress for patients our purpose at bioverativ we are dedicated to transforming the lives of people with hemophilia cold agglutinin disease and other rare blood disorders as an independent biotechnology company spun out of biogen’s hemophilia business we bring a strong legacy of innovation worldclass science and commitment to the rare blood disorders community we are united by a singular purpose to create progress where patients need it most we believe that great science conquers the toughest medical obstacles and we are inspired to push scientific boundaries to make a meaningful impact in the lives of people with rare blood disorders beginning with hemophilia we will lead by doing what’s right for patients and those who care for them and by actively working with the blood disorders community to accelerate innovation and develop lifechanging treatments   john g cox ceo our hemophilia therapies were the first major advancements in the treatment of hemophilia a and b in nearly two decades and are the first extended halflife clotting factors introduced to patients we will continue to explore the potential benefits and better understand the science of these therapies in areas of serious need including immune tolerance induction in hemophilia patients who develop inhibitors longterm joint health and women with bleeding disorders in the same spirit as in hemophilia we will carry forward a commitment to significantly impact the lives of people with other rare blood disorders including cold agglutinin disease sickle cell disease and beta thalassemia press releases watch creating progress together together we are committed to making a significant positive impact for patients and society through innovative programs that aim to improve access to treatment advance disease understanding and create true partnership with the community our commitment to that purpose is reflected in our name “bio” refers to our legacy of scientific innovation which we will build upon and “ver” refers to the latin word veritas meaning truth “ativ” is based on the word active —we will actively work with the community build trust and create change for patients × therapies hidechilds  false systemname    about us our purpose our background our leadership therapies hemophilia a hemophilia b manufacturing research  pipeline our pipeline clinical trials scientific  medical research community support humanitarian aid my life our future patient support sickle cell disease global sites corporate canada japan building on a legacy of innovation we’re dedicated to creating meaningful progress for people with hemophilia and other blood disorders delivering innovative therapies therapies hemophilia a eloctate®  read more  hemophilia b alprolix®  read more  manufacturing delivering quality medicine read more   bioverativ was formed by a spinoff of biogen’s hemophilia business biogen has initiated the transfer of various licenses including the biologics license applications for eloctate® and alprolix® until the transfers are completed bioverativ and biogen will have a relationship to the products contact us with any questions   our pipeline  research  pipeline hidechilds  false systemname    about us our purpose our background our leadership therapies hemophilia a hemophilia b manufacturing research  pipeline our pipeline clinical trials scientific  medical research community support humanitarian aid my life our future patient support sickle cell disease global sites corporate canada japan bioverativ’s research pipeline shows our scientists’ commitment to the discovery and development of new medicines to address areas of serious need for patients including hemophilia sickle cell disorders moving science forward to benefit patients our pipeline leaders in their fields our scientists are deeply committed to the discovery and development of new medicines to address areas of serious need for patients leveraging our deep understanding of the biology of hemostasis gained over  years of research we plan to accelerate the development of our innovative pipeline of programs in hemophilia cold agglutinin disease sickle cell disease beta thalassemia and other blood disorders our pipeline includes hemophilia programs that have been designed to provide lessfrequent prophylactic dosing for hemophilia a and subcutaneous dosing for hemophilia b and gene therapy programs for hemophilia a and b  it also includes programs to address cold agglutinin disease a rare and chronic autoimmune hemolytic condition for which there are no approved therapies bivv formerly tnt is the only therapy in development that is designed to selectively inhibit the classical complement pathway of the immune system bivv targets cs thereby impacting the central mechanism of this disease we are also pursuing several approaches that seek to target the root cause of sickle cell disease a profoundly debilitating disease that is linked to a shorter life expectancy and has few treatment options just as we have done in hemophilia we hope to bring forward new medicines that meaningfully advance the treatment of people with sickle cell disease   drug indication modality discovery preclinical clinical marketed bivv formerly tnt   bivv is a monoclonal antibody in development to treat cold agglutinin disease cagd there are no approved therapies for cagd which occurs in approximately  people per million globally bivv has been granted breakthrough therapy designation by the us fda for the treatment of hemolysis in patients with primary cagd and has also been granted orphan drug designation from the fda and the european medicines agency bivv formerly tnt indication cold agglutinin disease modality biologic   clinical   bivv is a monoclonal antibody in development to treat cold agglutinin disease cagd there are no approved therapies for cagd which occurs in approximately  people per million globally bivv has been granted breakthrough therapy designation by the us fda for the treatment of hemolysis in patients with primary cagd and has also been granted orphan drug designation from the fda and the european medicines agency bivv   bivv also known as rfviiifcvwfxten is a uniquely engineered factor viii molecule with a region of fc dimer von willebrand factor and xten a halflife extension technology licensed from amunix  bivv has been designed to provide onceweekly or less frequent prophylactic dosing intervals for hemophilia a  bivv indication hemophilia a modality biologic   preclinical   bivv also known as rfviiifcvwfxten is a uniquely engineered factor viii molecule with a region of fc dimer von willebrand factor and xten a halflife extension technology licensed from amunix  bivv has been designed to provide onceweekly or less frequent prophylactic dosing intervals for hemophilia a  collaboration with sangamo therapeutics   collaboration with sangamo therapeutics genome editing technology for beta thalassemia and sickle cell disease bioverativ has a worldwide collaboration with sangamo therapeutics for the treatment of inherited conditions that result from the abnormal structure or underproduction of hemoglobin the collaboration combines the extensive expertise of sangamo in developing their genome editing technology with bioverativs deep understanding of hematology our collaboration is focused on the goal of providing a singledose lasting treatment for both sickle cell disease and beta thalassemia collaboration with sangamo therapeutics indication beta thalassemia modality genome editing   preclinical indication sickle cell disease modality genome editing   preclinical   collaboration with sangamo therapeutics genome editing technology for beta thalassemia and sickle cell disease bioverativ has a worldwide collaboration with sangamo therapeutics for the treatment of inherited conditions that result from the abnormal structure or underproduction of hemoglobin the collaboration combines the extensive expertise of sangamo in developing their genome editing technology with bioverativs deep understanding of hematology our collaboration is focused on the goal of providing a singledose lasting treatment for both sickle cell disease and beta thalassemia bivv   bivv also known as rfixfcxten is a novel factor ix fusion protein that combines fc dimer and xten halflife extension technology licensed from amunix along with rl padua factor ix variant in the treatment of hemophilia b bivv has been designed to enable subcutaneous administration of factor ix with a goal of providing weekly or less frequent prophylactic dosing  bivv indication hemophilia b modality biologic   preclinical   bivv also known as rfixfcxten is a novel factor ix fusion protein that combines fc dimer and xten halflife extension technology licensed from amunix along with rl padua factor ix variant in the treatment of hemophilia b bivv has been designed to enable subcutaneous administration of factor ix with a goal of providing weekly or less frequent prophylactic dosing  bivv formerly tnt   bivv is a followon monoclonal antibody to treat cold agglutinin disease targeting activated cs with the potential for less frequent dosing and subcutaneous administration bivv formerly tnt indication cold agglutinin disease modality biologic   preclinical   bivv is a followon monoclonal antibody to treat cold agglutinin disease targeting activated cs with the potential for less frequent dosing and subcutaneous administration collaboration with san raffaeletiget   gene therapy collaboration with san raffaeletiget for the treatment of hemophilia a and b  bioverativ has a worldwide collaboration with the san raffaele telethon institute for gene therapy srtiget to jointly develop gene therapies for the treatment of both hemophilia a and b the collaboration combines the extensive expertise of srtiget in creating new gene therapy strategies and developing them from the bench to bedside with bioverativs deep understanding of hematology to potentially treat the underlying causes of hemophilia a and b  the collaboration centers on tiget’s advanced lentiviral gene transfer technology lentiviral vectors are engineered viruses designed to deliver working versions of defective genes responsible for causing certain diseases into the patients’ cells  the intent of this program is to provide a singledose lasting treatment for hemophilia a and b patients collaboration with san raffaeletiget indication hemophilia a modality gene therapy   discovery indication hemophilia b modality gene therapy   discovery   gene therapy collaboration with san raffaeletiget for the treatment of hemophilia a and b  bioverativ has a worldwide collaboration with the san raffaele telethon institute for gene therapy srtiget to jointly develop gene therapies for the treatment of both hemophilia a and b the collaboration combines the extensive expertise of srtiget in creating new gene therapy strategies and developing them from the bench to bedside with bioverativs deep understanding of hematology to potentially treat the underlying causes of hemophilia a and b  the collaboration centers on tiget’s advanced lentiviral gene transfer technology lentiviral vectors are engineered viruses designed to deliver working versions of defective genes responsible for causing certain diseases into the patients’ cells  the intent of this program is to provide a singledose lasting treatment for hemophilia a and b patients fviiia mimetic bispecific antibody program   fviiia mimetic bispecific antibody program  the aim of this program is to generate a bispecific antibody that better mimics the function of factor viii potentially eliminating the need for fviii in the clotting cascade fviiia mimetic bispecific antibody program indication hemophilia a inhibitors modality biologic   discovery   fviiia mimetic bispecific antibody program  the aim of this program is to generate a bispecific antibody that better mimics the function of factor viii potentially eliminating the need for fviii in the clotting cascade multiple early stage programs   sickle cell disease bioverativ has several small molecule programs in research that target the root cause of sickle cell disease  multiple early stage programs indication sickle cell disease modality sm molecules   discovery   sickle cell disease bioverativ has several small molecule programs in research that target the root cause of sickle cell disease  biogen  neurological and neurodegenerative diseases avonex®  interferon betaa fampyra® prolongedrelease fampridine tablets plegridy® peginterferon betaa tecfidera® dimethyl fumarate tysabri® natalizumab zinbryta® daclizumab spinraza® nusinersen benepali®  etanercept flixabi® infliximab gazyva® obinutuzumab rituxan® rituximab x corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom x menu close about us about us overview about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance research  pipeline research  pipeline overview pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal therapies therapies overview multiple sclerosis spinal muscular atrophy biosimilars partnered global impact global impact overview science that matters biogen foundation community lab supplier diversity grants office newsroom newsroom newsroom latest press releases events and webcasts patients medical professionals careers investors therapy sites therapy sites avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinraza® benepali®  flixabi® gazyva® rituxan® global sites global sites corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom about us research  pipeline therapies global impact newsroom home through cuttingedge science and medicine biogen discovers develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases x about us at biogen we develop market and manufacture therapies for people living with serious neurological autoimmune and rare diseases explore about us about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance x research  pipeline we aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry to us that means creating novel medicines that benefit individuals and society and bringing new scientific understanding to diseases for which there are no adequate treatments explore research  pipeline pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal x therapies we develop and provide therapies to people living with serious diseases like multiple sclerosis explore therapies multiple sclerosis avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinal muscular atrophy spinraza® biosimilars benepali®  flixabi® partnered gazyva® rituxan® x global impact working to make a positive impact for our patients the communities where we work and live and for society explore global impact science that matters biogen foundation community lab supplier diversity grants office x newsroom explore biogen’s latest news releases and media resources explore newsroom latest press releases events and webcasts x patients we work to transform the lives of the patients we serve meeting their individual needs is what drives our science and provides our focus supporting patients supporting patients x medical professionals at biogen we work with healthcare professionals to ensure the therapies we create can reach those that need them disclosure x careers everyone at biogen plays a vital role in the discovery and delivery of breakthrough therapies explore career opportunities at biogen internship  coop disclosure disclaimer fraudulent job postings x investors find current and historical stock information financial statements and reports or view upcoming events and latest webcasts read more annual report  annual report  annual report  x privacy policy our privacy policy outlines the policies and practices in place to safeguard personal information x terms  conditions these terms and conditions of use describe the terms and conditions applicable to your use of biogen inc’s “biogen” website x forwardlooking statements x community guidelines we use social media as part of our commitment to transparency and to provide information to our customers and stakeholders x sitemap x search x  x leadership hub vounatsos michel alexander susan ehlers michael kress jeanpaul mckenzie paul sandrock alfred papadopoulos stelios denner alexander dorsa caroline leaming nancy mulligan richard pangia robert posner brian rowinsky eric schenk lynn sherwin stephen vounatsos michel gregory ginger x scientist hub huang ron xiao guangqing dunah anthone peters rob oterogutierrez karel mikulskis alvydas goyal jaya silvian laura cosentino mark burkly linda wang qin mingueneau michaël arnold moore gardet agnès staropoli john juhasz peter bussiere thierry pepinsky robert blake wei dong weinreb paul coomaraswamy janaky stevenson lauren rabah dania mi sha wipke brian sun chao shen chase lin edward gianni davide thankamony sai hamann stefan lalioti maria kankel mark sen anindya donelson nathan enyedy istvan trinh kien ryan sarah xin zhili arndt joe ren shuyu cahirmcfarland ellen li kejie subramanyam meena stebbins christopher carulli john weihofen andreas larigan doug mccampbell alexander cameron thomas narayanan sarav lydeard john hronowski xiaoping wei ru martin jeffrey smith benjamin ehrenfels chris valencia antonio mccurley amy rushe mia preyer martin bajrami bekim henderson chris ransohoff richard danos olivier x therapies pmultiple sclerosisp pspinal muscular atrophyp pbiosimilarsp ppartneredp x story hub craig melanie michelle richard daniel kate rosemarie x our people hub bob k judann a cherie b pinky p mike g amanda m vinay b ehs award x bioverativ privacy policy x a transformative age of neurology as a leading company in the fight against multiple sclerosis biogen is applying its expertise to help address some of the most challenging and complex diseases of the brain learn more global impact working to make a positive impact for our patients the communities where we work and live and for society learn more watch video a transformative age of neurology as a leading company in the fight against multiple sclerosis biogen is applying its expertise to help address some of the most challenging and complex diseases of the brain learn more global impact working to make a positive impact for our patients the communities where we work and live and for society learn more watch video innovative therapies we develop medicines for debilitating medical conditions with the goal of making a meaningful difference in patients’ lives multiple sclerosis spinal muscular atrophy biosimilars partnered more about our therapies filter by all approved therapies multiple sclerosis spinal muscular atrophy biosimilars partnered multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis spinal muscular atrophy biosimilars biosimilars partnered partnered dedicated to new discoveries our pipeline is more than a list of medicines in development it reflects the work we do here every day to break new ground with science that makes a difference in the lives of patients filter by all disease areas all disease areas alzheimers disease fibrosis inflammatory bowel disease ibd lupus lymphoma multiple sclerosis ms myotonic dystrophy ophthalmology parkinsons disease sjögrens syndrome spinal muscular atrophy sma stroke trigeminal neuralgia all phases all phases filed phase  phase  phase  phase phase   phase  phase  filed aducanumab aβ mab alzheimer’s disease developed in collaboration with neurimmune alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in  the brain aducanumab is an antibody that binds to and may reduce amyloid plaques from the brain potentially slowing the progress of the disease more information about our aducanumab clinical trials  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  e bace inhibitor alzheimers disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain e is a smallmolecule inhibitor of betasecretase a protein that cleaves enzyme  bace by inhibiting bace e blocks amyloid production potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  ban aβ mab alzheimer’s disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain ban is an antibody that binds to amyloid which could reduce its presence in the brain and potentially slow the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  bg stx idiopathic pulmonary fibrosis ipf pulmonary fibrosis is a disease in which lung tissue becomes thickened and stiff due to scarring the formation of scar tissue is called fibrosis as the disease progresses it becomes harder for the lungs to work properly and the body cannot get the oxygen it needs this debilitating disease is almost always fatal how this therapy could help the tgfbeta brain cell pathway is involved in several fibrotic diseases the bg stx antibody may selectively block the tgfbeta pathway and may slow the development of fibrosis in ipf patients biib antibdca lupus this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help bdca is a protein present in specific cells within the immune system an antibody against bdca can potentially interrupt production of interferons inflammatory molecules that are increased in patients with lupus and contribute to disease activity  biib nav inhibitor trigeminal neuralgia tgn acquired in acquisition of convergence pharmaceuticals trigeminal neuralgia is an extremely painful condition usually involving one side of the face trigeminal neuralgia is characterized by sudden brief stabbing recurrent episodes of pain which frequently occurs spontaneously but is also commonly evoked by trivial stimuli including washing shaving smoking talking andor brushing the teeth trigger factors the pain follows one or more branches of the trigeminal nerve which provides nerve sensation from the mouth face and the front of the scalp the intensity of the pain and its unpredictability results in profound effects on the quality of life of patients how this therapy could help biib nav inhibitor is a novel state dependent small molecule sodium channel blocker that preferentially inhibits the nav  ion channel a therapeutic target implicated by genetics in human pain conditions biib is thought to penetrate the central nervous system and block nav channels in a novel manner and has the potential to provide a new and effective option for the treatment of trigeminal neuralgia biib glibenclamide iv stroke it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke the target indication for biib glibenclamide iv is large hemispheric infarction lhi a severe form of ischemic stroke where brain swelling cerebral edema often leads to a disproportionately large share of strokerelated morbidity and mortality how this therapy could help in preclinical studies biib glibenclamide iv has been shown to block surtrpm channels that mediate stroke related brain swelling clinical proofofconcept studies have demonstrated the potential of biib to reduce brain swelling disability and the risk of death in patients with lhi dapirolizumab pegol anticdl lupus developed in collaboration with ucb inc this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help cdl is a protein in b and t cells which helps regulate the immune system dapirolizumab pegol anticdl is an antibody that blocks cdl potentially lessening disease activity in lupus patients natalizumab αintegrin inhibitor acute ischemic stroke currently approved as tysabri® for relapsingremitting multiple sclerosis and crohn’s disease please visit tysabricom for prescribing and safety information it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke  how this therapy could help natalizumab is thought to reduce the inflammatory cells in the brain by blocking the lymphocytic infiltration known to occur in the brain following stroke which may reduce the extent of injury opicinumab antilingo multiple sclerosis ms this disease causes the body’s immune system to attack myelin a protective sheath covering nerve fibers damage to myelin “short circuits” communication between the brain spinal cord and other areas of the body severely impairing such neurological functions as mobility vision and thinking over time the nerves themselves can become damaged permanently how this therapy could help lingo is a cns specificprotein that is involved in the development of myelin in patients with ms lingo may inhibit myelin growth when it binds with its receptor data suggest that the antibody antilingo could block this process potentially allowing for the remyelination and restoration of nerve communication in ms patients xlrs gene therapy xlinked retinoschisis xlrs developed in collaboration with agtc xlrs is a disease that affects young males beginning in their teenage years it can lead to loss of vision and serious complications such as vitreous hemorrhage or retinal detachment during adulthood how this therapy could help the xlrs gene therapy is a recombinant adenoassociated virus vector raav delivering a transgene rs that expresses retinoschisin protein normal expression of retinoschisin could potentially improve longterm retinal function and preserve structural integrity biib antiαsynuclein parkinsons disease acquired from neurimmune parkinsons disease is a disorder of the central nervous system people who have this disease experience tremors slow movement muscle stiffness and impaired balance  as these symptoms become progressively worse patients have difficulty walking talking or completing other simple tasks how this therapy could help biib targets abnormal alphasynuclein protein that is associated with the destruction of nerve cells this progressive degeneration is the cause of parkinsons disease biib alzheimers disease alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting tau the protein that forms the deposits or tangles in the brain  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  biib alzheimers disease licensed from bristolmyers squibb alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting extracellular tau and may reduce the spreading of tau from one cell to the next potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  currently no results for this search see full pipeline our perspectives july   teaming up for als see all perspectives × important notice you are now leaving biogen’s corporate website we encourage you to read and evaluate terms of use privacy security and other similar policies of the destination site as they may differ from biogen’s standards third party sites biogen assumes no responsibility nor does it control endorse or guarantee any aspect of your use of any third party sites additionally the presence of this link does not imply the third party sites endorsement of biogen or this website thank you for visiting our site   cancel continue careers avonex®  interferon betaa fampyra® prolongedrelease fampridine tablets plegridy® peginterferon betaa tecfidera® dimethyl fumarate tysabri® natalizumab zinbryta® daclizumab spinraza® nusinersen benepali®  etanercept flixabi® infliximab gazyva® obinutuzumab rituxan® rituximab x corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom x menu close about us about us overview about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance research  pipeline research  pipeline overview pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal therapies therapies overview multiple sclerosis spinal muscular atrophy biosimilars partnered global impact global impact overview science that matters biogen foundation community lab supplier diversity grants office newsroom newsroom newsroom latest press releases events and webcasts patients medical professionals careers investors therapy sites therapy sites avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinraza® benepali®  flixabi® gazyva® rituxan® global sites global sites corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom about us research  pipeline therapies global impact newsroom home through cuttingedge science and medicine biogen discovers develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases x about us at biogen we develop market and manufacture therapies for people living with serious neurological autoimmune and rare diseases explore about us about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance x research  pipeline we aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry to us that means creating novel medicines that benefit individuals and society and bringing new scientific understanding to diseases for which there are no adequate treatments explore research  pipeline pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal x therapies we develop and provide therapies to people living with serious diseases like multiple sclerosis explore therapies multiple sclerosis avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinal muscular atrophy spinraza® biosimilars benepali®  flixabi® partnered gazyva® rituxan® x global impact working to make a positive impact for our patients the communities where we work and live and for society explore global impact science that matters biogen foundation community lab supplier diversity grants office x newsroom explore biogen’s latest news releases and media resources explore newsroom latest press releases events and webcasts x patients we work to transform the lives of the patients we serve meeting their individual needs is what drives our science and provides our focus supporting patients supporting patients x medical professionals at biogen we work with healthcare professionals to ensure the therapies we create can reach those that need them disclosure x careers everyone at biogen plays a vital role in the discovery and delivery of breakthrough therapies explore career opportunities at biogen internship  coop disclosure disclaimer fraudulent job postings x investors find current and historical stock information financial statements and reports or view upcoming events and latest webcasts read more annual report  annual report  annual report  x privacy policy our privacy policy outlines the policies and practices in place to safeguard personal information x terms  conditions these terms and conditions of use describe the terms and conditions applicable to your use of biogen inc’s “biogen” website x forwardlooking statements x community guidelines we use social media as part of our commitment to transparency and to provide information to our customers and stakeholders x sitemap x search x  x leadership hub vounatsos michel alexander susan ehlers michael kress jeanpaul mckenzie paul sandrock alfred papadopoulos stelios denner alexander dorsa caroline leaming nancy mulligan richard pangia robert posner brian rowinsky eric schenk lynn sherwin stephen vounatsos michel gregory ginger x scientist hub huang ron xiao guangqing dunah anthone peters rob oterogutierrez karel mikulskis alvydas goyal jaya silvian laura cosentino mark burkly linda wang qin mingueneau michaël arnold moore gardet agnès staropoli john juhasz peter bussiere thierry pepinsky robert blake wei dong weinreb paul coomaraswamy janaky stevenson lauren rabah dania mi sha wipke brian sun chao shen chase lin edward gianni davide thankamony sai hamann stefan lalioti maria kankel mark sen anindya donelson nathan enyedy istvan trinh kien ryan sarah xin zhili arndt joe ren shuyu cahirmcfarland ellen li kejie subramanyam meena stebbins christopher carulli john weihofen andreas larigan doug mccampbell alexander cameron thomas narayanan sarav lydeard john hronowski xiaoping wei ru martin jeffrey smith benjamin ehrenfels chris valencia antonio mccurley amy rushe mia preyer martin bajrami bekim henderson chris ransohoff richard danos olivier x therapies pmultiple sclerosisp pspinal muscular atrophyp pbiosimilarsp ppartneredp x story hub craig melanie michelle richard daniel kate rosemarie x our people hub bob k judann a cherie b pinky p mike g amanda m vinay b ehs award x bioverativ privacy policy x careers top join our team we work together to bring lifechanging therapies to patients every day start here to find the fulfilling career opportunity that’s right for you explore opportunities learn more about the company moving biogen forward employees from around the world share what excites them about working at biogen watch our people it takes passion persistence creativity collaboration and focus to do what we do see what inspires us bob k vice president north american operations “from the first day i walked in to the manufacturing facility i was intrigued by the intersection of science technology and engineering” watch now judann a global marketing “biogen has been a role model to me in the entrepreneurial way of life  innovation that’s biogen” watch now cherie b research  development “being at biogen has changed me as a scientist and the way i think about asking questions that could potentially make a difference for patients” watch now vinay b the son of a biogen scientist vinay attended our community lab as a teen learn what inspired him to pursue a career here watch now pinky p pharmaceutical operations  technology “the company’s commitment to the patients and diversity and inclusion is what’s kept me here for  years” watch now amanda m community lab coordinator “every day i get up and i think about the students i’m going to inspire” watch now environmental health safety  sustainability  global award winners each year we recognize employees who are leading examples of our values around safety sustainability and wellness meet this year’s winners watch now loading the player back excellence at work we feel strongly that biogen should be a place where people are proud to work everything we do is grounded in the core values of inclusiveness respect accountability and commitment to purpose learn more opportunities for college students as a company founded on and grounded in breakthrough science we hope to foster a new generation of scientific innovation launch your career in biotechnology here find internships  fellowships × important notice you are now leaving biogen’s corporate website we encourage you to read and evaluate terms of use privacy security and other similar policies of the destination site as they may differ from biogen’s standards third party sites biogen assumes no responsibility nor does it control endorse or guarantee any aspect of your use of any third party sites additionally the presence of this link does not imply the third party sites endorsement of biogen or this website thank you for visiting our site   cancel continue contact us avonex®  interferon betaa fampyra® prolongedrelease fampridine tablets plegridy® peginterferon betaa tecfidera® dimethyl fumarate tysabri® natalizumab zinbryta® daclizumab spinraza® nusinersen benepali®  etanercept flixabi® infliximab gazyva® obinutuzumab rituxan® rituximab x corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom x menu close about us about us overview about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance research  pipeline research  pipeline overview pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal therapies therapies overview multiple sclerosis spinal muscular atrophy biosimilars partnered global impact global impact overview science that matters biogen foundation community lab supplier diversity grants office newsroom newsroom newsroom latest press releases events and webcasts patients medical professionals careers investors therapy sites therapy sites avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinraza® benepali®  flixabi® gazyva® rituxan® global sites global sites corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom about us research  pipeline therapies global impact newsroom home through cuttingedge science and medicine biogen discovers develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases x about us at biogen we develop market and manufacture therapies for people living with serious neurological autoimmune and rare diseases explore about us about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance x research  pipeline we aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry to us that means creating novel medicines that benefit individuals and society and bringing new scientific understanding to diseases for which there are no adequate treatments explore research  pipeline pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal x therapies we develop and provide therapies to people living with serious diseases like multiple sclerosis explore therapies multiple sclerosis avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinal muscular atrophy spinraza® biosimilars benepali®  flixabi® partnered gazyva® rituxan® x global impact working to make a positive impact for our patients the communities where we work and live and for society explore global impact science that matters biogen foundation community lab supplier diversity grants office x newsroom explore biogen’s latest news releases and media resources explore newsroom latest press releases events and webcasts x patients we work to transform the lives of the patients we serve meeting their individual needs is what drives our science and provides our focus supporting patients supporting patients x medical professionals at biogen we work with healthcare professionals to ensure the therapies we create can reach those that need them disclosure x careers everyone at biogen plays a vital role in the discovery and delivery of breakthrough therapies explore career opportunities at biogen internship  coop disclosure disclaimer fraudulent job postings x investors find current and historical stock information financial statements and reports or view upcoming events and latest webcasts read more annual report  annual report  annual report  x privacy policy our privacy policy outlines the policies and practices in place to safeguard personal information x terms  conditions these terms and conditions of use describe the terms and conditions applicable to your use of biogen inc’s “biogen” website x forwardlooking statements x community guidelines we use social media as part of our commitment to transparency and to provide information to our customers and stakeholders x sitemap x search x  x leadership hub vounatsos michel alexander susan ehlers michael kress jeanpaul mckenzie paul sandrock alfred papadopoulos stelios denner alexander dorsa caroline leaming nancy mulligan richard pangia robert posner brian rowinsky eric schenk lynn sherwin stephen vounatsos michel gregory ginger x scientist hub huang ron xiao guangqing dunah anthone peters rob oterogutierrez karel mikulskis alvydas goyal jaya silvian laura cosentino mark burkly linda wang qin mingueneau michaël arnold moore gardet agnès staropoli john juhasz peter bussiere thierry pepinsky robert blake wei dong weinreb paul coomaraswamy janaky stevenson lauren rabah dania mi sha wipke brian sun chao shen chase lin edward gianni davide thankamony sai hamann stefan lalioti maria kankel mark sen anindya donelson nathan enyedy istvan trinh kien ryan sarah xin zhili arndt joe ren shuyu cahirmcfarland ellen li kejie subramanyam meena stebbins christopher carulli john weihofen andreas larigan doug mccampbell alexander cameron thomas narayanan sarav lydeard john hronowski xiaoping wei ru martin jeffrey smith benjamin ehrenfels chris valencia antonio mccurley amy rushe mia preyer martin bajrami bekim henderson chris ransohoff richard danos olivier x therapies pmultiple sclerosisp pspinal muscular atrophyp pbiosimilarsp ppartneredp x story hub craig melanie michelle richard daniel kate rosemarie x our people hub bob k judann a cherie b pinky p mike g amanda m vinay b ehs award x bioverativ privacy policy x contact us biogen global offices corporate headquarters biogen  binney street cambridge ma  phone  directions corporate headquarters biogen  binney street cambridge ma  phone  directions corporate headquarters the americas argentina biogen argentina srl av del libertador  – th floor  vicente lopez – buenos aires argentina phone     fax     affiliate website brazil biogen brasil produtos farmacêuticos ltda edifício olimpia trade av dr cardoso de melo  º andar  vila olimpia  são paulosp  cep  brazil phone     fax     affiliate website canada biogen canada inc  burnhamthorpe road west suite  mississauga ontario lb c  canada phone     fax     affiliate website chile biogen chile spa av vitacura  piso ° las condes santiago de chile chile affiliate website research triangle park rtp nc po box   davis drive research triangle park nc  phone   fax   directions washington dc  pennsylvania ave nw suite  washington dc   directions weston ma  boston post road weston ma  phone  directions europe international hq  zug switzerland biogen international gmbh landis  gyrstrasse  ch  zug  switzerland phone     fax     directions international website austria biogen austria gmbh stellakleinlöwweg   vienna austria phone     fax      affiliate website belgium biogen belgium sanv park lane g culliganlaan g  diegem belgium phone      fax      affiliate website czech republic biogen czech republic sro na pankraci    prague  czech republic phone     fax     affiliate website denmark biogen denmark as orestads boulevard   copenhagen s denmark phone    fax    denmark manufacturing biogen denmark manufacturing aps biogen allé   hillerød denmark phone    fax    affiliate website finland biogen finland oy bertel jungin aukio c  espoo finland phone     fax     affiliate website france biogen idec france sas le capitole  avenue des champs pierreux  nanterre cedex france phone       fax       affiliate website germany biogen gmbh carlzeiss ring   ismaning germany phone      fax       affiliate website hungary biogen hungary kft dorottya udvar c épület  emelet bocskai út   budapest hungary phone     fax     affiliate website ireland biogen idec ireland ltd united drug house magna business park  magna drive citywest rd dublin  ireland phone     fax     affiliate website italy biogen italia srl centro leoni via spadolini    milano  italy phone      fax      affiliate website the netherlands biogen netherlands bv prins mauritslaan   lp badhoevedorp the netherlands phone     fax     affiliate website norway visitor address biogen norway as vitaminveien  a rd floor n oslo norway delivery address po box  – nydalen n oslo norway phone      fax      affiliate website poland biogen poland sp z oo ul salsy   warsaw  poland phone      fax      affiliate website portugal biogen portugal sociedade farmaceutica unipessoal lda avenida duque dávila   º andar  lisboa  portugal phone     fax     affiliate website slovak republic biogen slovakia s r o palisady    bratislava slovak republic phone      fax      affiliate website slovenia biogen pharma doo ameriska ulica   ljubljana slovenia phone     fax     affiliate website spain biogen spain sl paseo de la castellana   a  madrid spain phone      fax      affiliate website sweden biogen sweden ab kanalvägen a tr  upplands väsby sweden phone     fax     affiliate website switzerland biogen switzerland ag zählerweg  ch  zug switzerland phone     fax     affiliate website united kingdom biogen idec ltd innovation house  norden road maidenhead berkshire sl ay united kingdom phone    fax    affiliate website united kingdom  convergence pharmaceuticals convergence pharmaceuticals a biogen company maia building babraham research campus cambridge cb at united kingdom         directions asiaaustralia australia biogen australia pty ltd level   epping rd north ryde nsw  australia phone     fax     affiliate website japan biogen japan ltd nihonbashi chome mitsui building f  nihonbashi chome chuoku tokyo  japan phone     fax     affiliate website new zealand biogen nz biopharma ltd  carbine road po box  mt wellington  auckland new zealand phone     fax     affiliate website patient inquiries multiple sclerosis support sma support partnered therapies support all available ms therapies  avonexcom plegridycom tecfideracom tysabricom zinbrytacom sma°™ spinraza  spinrazacom rituxan® rituximab  rituxancom gazyva® obinutuzumab  gazyvacom   this product support information is applicable to patients who have been prescribed biogen therapies in the united states only for product support in countries outside of the us please contact the biogen affiliate in your country or email patientcenterbiogencom if your country is not represented for additional support resources please visit the patient services section of our site learn more about our clinical trials learn more about access to investigational therapies or expanded access programs eaps your doctor should always be the primary resource regarding treatment options safety information call your doctor for medical advice about side effects you may report side effects to the fda at fda media and investors media visit our newsroom page for company information news and events us public affairsmedia   publicaffairsbiogencom eu public affairsmedia     publicaffairseubiogencom investors visit our investors page for financial information and reporting investor relations   irbiogencom medical professionals biogen medical information team  medinfo   medinfobiogencom careers and employment verification please visit our careers section to explore current job openings or stay connected on relevant upcoming job postings by joining our talent community to obtain employment verification information for a current or former biogen employee see verification instructions us only download verification instructions compliance if you wish to report any compliance concerns regarding biogen or any of its employees or contractors you may do so in writing at the address provided below or confidentially and anonymously where permitted by local law by using the compliance helpline complaints submitted in this manner will be forwarded directly to the chair of the audit committee to submit a report in the us and canada through the compliance helpline call us tollfree at  click here for international compliance helpline dialin numbers click here to submit a report online or write to us at corporate compliance biogen inc  binney street cambridge ma  usa privacy if you have any concerns about the manner in which your personal information has been collected or handled by biogen or have any queries in regard to our privacy policy please call us tollfree at  click here for international compliance helpline dialin numbers or email us at privacybiogencom × important notice you are now leaving biogen’s corporate website we encourage you to read and evaluate terms of use privacy security and other similar policies of the destination site as they may differ from biogen’s standards third party sites biogen assumes no responsibility nor does it control endorse or guarantee any aspect of your use of any third party sites additionally the presence of this link does not imply the third party sites endorsement of biogen or this website thank you for visiting our site   cancel continue events  webcasts  biogen investors menu close corporate governance corporate governance overview our values our leadership governance documents committee composition and charters contact the board stock information stock information overview stock chart historical price lookup analyst coverage investor faq financial information financial information overview balance sheet income statement cash flow ratios gaap to nongaap reconciliation annual  quarterly reports sec filings presentations events  webcasts events  webcasts information request sign up for alerts login year month week day « prev   july    next » sunday monday tuesday wednesday thursday friday saturday                                                                                      q  earnings conference call replay  am edt                             upcoming events there are no scheduled events at this time please check back later event archive q  earnings conference call replay   am   am edt biogen  annual meeting of stockholders replay   am   am edt biogen at the bernstein rd annual strategic decisions conference replay   pm   pm edt q  earnings conference call replay   am   am edt biogen at the cowen  company th annual health care conference replay   pm   pm est biogen at the  rbc capital markets global healthcare conference replay   pm   pm est biogen at the leerink partners th annual global healthcare conference replay   pm   pm est q and yearend  earnings conference call replay   am   am est biogen at the th annual jp morgan healthcare conference replay   pm   pm est biogen spinoff bioverativ investor day webcast replay   am   pm est biogen at the goldman sachs healthcare ceos unscripted conference replay   pm   pm est biogen spinoff bioverativ at the goldman sachs healthcare ceos unscripted conference replay   pm   pm est biogen names michel vounatsos ceo audio webcast replay   am   am est biogen at the th annual credit suisse healthcare conference replay   am   am est q  earnings conference call replay   am   am edt biogen at the morgan stanley global healthcare conference replay   pm   pm edt biogen and ionis nusinersen endear interim webcast replay   am   am edt q  earnings conference call replay   am   am edt biogen annual meeting of stockholders replay   am   am edt privacy policy terms  conditions sitemap forwardlooking statements community guidelines contact us  biogen investors avonex®  interferon betaa fampyra® prolongedrelease fampridine tablets plegridy® peginterferon betaa tecfidera® dimethyl fumarate tysabri® natalizumab zinbryta® daclizumab spinraza® nusinersen benepali®  etanercept flixabi® infliximab gazyva® obinutuzumab rituxan® rituximab x corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom x menu close about us about us overview about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance research  pipeline research  pipeline overview pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal therapies therapies overview multiple sclerosis spinal muscular atrophy biosimilars partnered global impact global impact overview science that matters biogen foundation community lab supplier diversity grants office newsroom newsroom newsroom latest press releases events and webcasts patients medical professionals careers investors therapy sites therapy sites avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinraza® benepali®  flixabi® gazyva® rituxan® global sites global sites corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom about us research  pipeline therapies global impact newsroom home through cuttingedge science and medicine biogen discovers develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases x about us at biogen we develop market and manufacture therapies for people living with serious neurological autoimmune and rare diseases explore about us about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance x research  pipeline we aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry to us that means creating novel medicines that benefit individuals and society and bringing new scientific understanding to diseases for which there are no adequate treatments explore research  pipeline pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal x therapies we develop and provide therapies to people living with serious diseases like multiple sclerosis explore therapies multiple sclerosis avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinal muscular atrophy spinraza® biosimilars benepali®  flixabi® partnered gazyva® rituxan® x global impact working to make a positive impact for our patients the communities where we work and live and for society explore global impact science that matters biogen foundation community lab supplier diversity grants office x newsroom explore biogen’s latest news releases and media resources explore newsroom latest press releases events and webcasts x patients we work to transform the lives of the patients we serve meeting their individual needs is what drives our science and provides our focus supporting patients supporting patients x medical professionals at biogen we work with healthcare professionals to ensure the therapies we create can reach those that need them disclosure x careers everyone at biogen plays a vital role in the discovery and delivery of breakthrough therapies explore career opportunities at biogen internship  coop disclosure disclaimer fraudulent job postings x investors find current and historical stock information financial statements and reports or view upcoming events and latest webcasts read more annual report  annual report  annual report  x privacy policy our privacy policy outlines the policies and practices in place to safeguard personal information x terms  conditions these terms and conditions of use describe the terms and conditions applicable to your use of biogen inc’s “biogen” website x forwardlooking statements x community guidelines we use social media as part of our commitment to transparency and to provide information to our customers and stakeholders x sitemap x search x  x leadership hub vounatsos michel alexander susan ehlers michael kress jeanpaul mckenzie paul sandrock alfred papadopoulos stelios denner alexander dorsa caroline leaming nancy mulligan richard pangia robert posner brian rowinsky eric schenk lynn sherwin stephen vounatsos michel gregory ginger x scientist hub huang ron xiao guangqing dunah anthone peters rob oterogutierrez karel mikulskis alvydas goyal jaya silvian laura cosentino mark burkly linda wang qin mingueneau michaël arnold moore gardet agnès staropoli john juhasz peter bussiere thierry pepinsky robert blake wei dong weinreb paul coomaraswamy janaky stevenson lauren rabah dania mi sha wipke brian sun chao shen chase lin edward gianni davide thankamony sai hamann stefan lalioti maria kankel mark sen anindya donelson nathan enyedy istvan trinh kien ryan sarah xin zhili arndt joe ren shuyu cahirmcfarland ellen li kejie subramanyam meena stebbins christopher carulli john weihofen andreas larigan doug mccampbell alexander cameron thomas narayanan sarav lydeard john hronowski xiaoping wei ru martin jeffrey smith benjamin ehrenfels chris valencia antonio mccurley amy rushe mia preyer martin bajrami bekim henderson chris ransohoff richard danos olivier x therapies pmultiple sclerosisp pspinal muscular atrophyp pbiosimilarsp ppartneredp x story hub craig melanie michelle richard daniel kate rosemarie x our people hub bob k judann a cherie b pinky p mike g amanda m vinay b ehs award x bioverativ privacy policy x investors top investors relations we use innovative science to pursue novel treatments that address important medical challenges in neuroscience information request sign up for alerts events and webcasts view our upcoming events and latest webcasts view all events and webcasts our perspectives july   teaming up for als see all perspectives stock information find biogen’s current and historical stock information see all stock information nasdaq biib common stock volume todays open  previous close   week high   week low  cost basis post spinoff financial information  filings all documents see financial information sec filings search documents biogen has submitted to the us securities and exchange commission sec including proxy statements and quarterly and annual filings  sec filings presentations download presentations from prior investor conferences earnings calls and other related events  see company presentations dedicated to new discoveries our pipeline is more than a list of medicines in development it reflects the work we do here every day to break new ground with science that makes a difference in the lives of patients filter by all disease areas all disease areas alzheimers disease fibrosis inflammatory bowel disease ibd lupus lymphoma multiple sclerosis ms myotonic dystrophy ophthalmology parkinsons disease sjögrens syndrome spinal muscular atrophy sma stroke trigeminal neuralgia all phases all phases filed phase  phase  phase  phase phase   phase  phase  filed aducanumab aβ mab alzheimer’s disease developed in collaboration with neurimmune alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in  the brain aducanumab is an antibody that binds to and may reduce amyloid plaques from the brain potentially slowing the progress of the disease more information about our aducanumab clinical trials  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  e bace inhibitor alzheimers disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain e is a smallmolecule inhibitor of betasecretase a protein that cleaves enzyme  bace by inhibiting bace e blocks amyloid production potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  ban aβ mab alzheimer’s disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain ban is an antibody that binds to amyloid which could reduce its presence in the brain and potentially slow the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  bg stx idiopathic pulmonary fibrosis ipf pulmonary fibrosis is a disease in which lung tissue becomes thickened and stiff due to scarring the formation of scar tissue is called fibrosis as the disease progresses it becomes harder for the lungs to work properly and the body cannot get the oxygen it needs this debilitating disease is almost always fatal how this therapy could help the tgfbeta brain cell pathway is involved in several fibrotic diseases the bg stx antibody may selectively block the tgfbeta pathway and may slow the development of fibrosis in ipf patients biib antibdca lupus this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help bdca is a protein present in specific cells within the immune system an antibody against bdca can potentially interrupt production of interferons inflammatory molecules that are increased in patients with lupus and contribute to disease activity  biib nav inhibitor trigeminal neuralgia tgn acquired in acquisition of convergence pharmaceuticals trigeminal neuralgia is an extremely painful condition usually involving one side of the face trigeminal neuralgia is characterized by sudden brief stabbing recurrent episodes of pain which frequently occurs spontaneously but is also commonly evoked by trivial stimuli including washing shaving smoking talking andor brushing the teeth trigger factors the pain follows one or more branches of the trigeminal nerve which provides nerve sensation from the mouth face and the front of the scalp the intensity of the pain and its unpredictability results in profound effects on the quality of life of patients how this therapy could help biib nav inhibitor is a novel state dependent small molecule sodium channel blocker that preferentially inhibits the nav  ion channel a therapeutic target implicated by genetics in human pain conditions biib is thought to penetrate the central nervous system and block nav channels in a novel manner and has the potential to provide a new and effective option for the treatment of trigeminal neuralgia biib glibenclamide iv stroke it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke the target indication for biib glibenclamide iv is large hemispheric infarction lhi a severe form of ischemic stroke where brain swelling cerebral edema often leads to a disproportionately large share of strokerelated morbidity and mortality how this therapy could help in preclinical studies biib glibenclamide iv has been shown to block surtrpm channels that mediate stroke related brain swelling clinical proofofconcept studies have demonstrated the potential of biib to reduce brain swelling disability and the risk of death in patients with lhi dapirolizumab pegol anticdl lupus developed in collaboration with ucb inc this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help cdl is a protein in b and t cells which helps regulate the immune system dapirolizumab pegol anticdl is an antibody that blocks cdl potentially lessening disease activity in lupus patients natalizumab αintegrin inhibitor acute ischemic stroke currently approved as tysabri® for relapsingremitting multiple sclerosis and crohn’s disease please visit tysabricom for prescribing and safety information it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke  how this therapy could help natalizumab is thought to reduce the inflammatory cells in the brain by blocking the lymphocytic infiltration known to occur in the brain following stroke which may reduce the extent of injury opicinumab antilingo multiple sclerosis ms this disease causes the body’s immune system to attack myelin a protective sheath covering nerve fibers damage to myelin “short circuits” communication between the brain spinal cord and other areas of the body severely impairing such neurological functions as mobility vision and thinking over time the nerves themselves can become damaged permanently how this therapy could help lingo is a cns specificprotein that is involved in the development of myelin in patients with ms lingo may inhibit myelin growth when it binds with its receptor data suggest that the antibody antilingo could block this process potentially allowing for the remyelination and restoration of nerve communication in ms patients xlrs gene therapy xlinked retinoschisis xlrs developed in collaboration with agtc xlrs is a disease that affects young males beginning in their teenage years it can lead to loss of vision and serious complications such as vitreous hemorrhage or retinal detachment during adulthood how this therapy could help the xlrs gene therapy is a recombinant adenoassociated virus vector raav delivering a transgene rs that expresses retinoschisin protein normal expression of retinoschisin could potentially improve longterm retinal function and preserve structural integrity biib antiαsynuclein parkinsons disease acquired from neurimmune parkinsons disease is a disorder of the central nervous system people who have this disease experience tremors slow movement muscle stiffness and impaired balance  as these symptoms become progressively worse patients have difficulty walking talking or completing other simple tasks how this therapy could help biib targets abnormal alphasynuclein protein that is associated with the destruction of nerve cells this progressive degeneration is the cause of parkinsons disease biib alzheimers disease alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting tau the protein that forms the deposits or tangles in the brain  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  biib alzheimers disease licensed from bristolmyers squibb alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting extracellular tau and may reduce the spreading of tau from one cell to the next potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  currently no results for this search see full pipeline our leadership in multiple sclerosis for more than two decades biogen has been a leader in researching and developing innovative multiple sclerosis ms therapies for patients worldwide learn more about our scientific commitment to nextgeneration therapies our focus on helping to improve patient outcomes and see stories of individuals living with this disease learn more leaders with a shared passion our leaders share a passion for innovation and visionary science view all executive leadership profiles meet our board of directors michel vounatsos chief executive officer read bio susan alexander executive vice president chief legal corporate services and secretary read bio michael ehlers md phd executive vice president research  development read bio ginger gregory phd executive vice president and chief human resources officer read bio jeanpaul kress md executive vice president and president international and head of global therapeutic operations read bio paul mckenzie phd executive vice president pharmaceutical operations  technology read bio alfred sandrock jr md phd executive vice president and chief medical officer read bio bioverativ in  biogen spun off its leading portfolio of hemophilia assets into an independent publicly traded company learn more corporate governance biogen is committed to high ethical standards we strive to be accountable and transparent to everyone we serve learn more code of business conduct investors faq find answers to frequently asked questions see faqs × important notice you are now leaving biogen’s corporate website we encourage you to read and evaluate terms of use privacy security and other similar policies of the destination site as they may differ from biogen’s standards third party sites biogen assumes no responsibility nor does it control endorse or guarantee any aspect of your use of any third party sites additionally the presence of this link does not imply the third party sites endorsement of biogen or this website thank you for visiting our site   cancel continue jobs at biogen global sites corporate hq international hq argentina australia austria brazil belgium canada english french czech republic denmark finland france germany ireland italy japan the netherlands norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom hungary biogen our people our work your future the biogen effect stay connected menu close biogen our people our work your future the biogen effect stay connected we work fearlessly to change the lives of our patients james dean patient services career search keyword location explore jobs by category your career at biogen we foster a culture of excellence by emphasizing collaboration innovation diversity recognition and worklife balance our people biogen has almost  employees in more than  countries we have a wide variety of skills and backgrounds but we are united in focus read more our work teams across diverse business areas work together to discover manufacture and market therapies for patients around the world read more your future we encourage and expect employees to seek out growth opportunities both professionally and personally read more the biogen effect we are committed to having a positive impact on the world we create therapies that help patients foster a vibrant work environment contribute to our communities and strive for sustainability see how stay connected receive career updates your email address biogencareers privacy policy terms  conditions sitemap forwardlooking statements community guidelines please be advised that all legitimate correspondence from biogen will come from biogencom email accounts read more on fraudulent job postings all qualified applicants will receive consideration for employment without regard to sex gender identity or expression sexual orientation marital status race color national origin ancestry ethnicity religion age veteran status disability genetic information or any other basis protected by federal state or local law biogen is an everify employer in the united states biogen is committed to providing access to disabled veterans and individuals with disabilities consistent with our ada nondiscrimination and accommodation policy any applicant who needs an accommodation in connection with the hiring process or to perform the essential functions of the position for which the applicant has applied may make a request to the recruiter or hiring manager or may submit the request by calling  this contact is intended for job seekers with disabilities requiring accessibility assistance or an accommodation in the job application process or technical assistance requests to follow up on an application will not receive a response   biogen patients avonex®  interferon betaa fampyra® prolongedrelease fampridine tablets plegridy® peginterferon betaa tecfidera® dimethyl fumarate tysabri® natalizumab zinbryta® daclizumab spinraza® nusinersen benepali®  etanercept flixabi® infliximab gazyva® obinutuzumab rituxan® rituximab x corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom x menu close about us about us overview about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance research  pipeline research  pipeline overview pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal therapies therapies overview multiple sclerosis spinal muscular atrophy biosimilars partnered global impact global impact overview science that matters biogen foundation community lab supplier diversity grants office newsroom newsroom newsroom latest press releases events and webcasts patients medical professionals careers investors therapy sites therapy sites avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinraza® benepali®  flixabi® gazyva® rituxan® global sites global sites corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom about us research  pipeline therapies global impact newsroom home through cuttingedge science and medicine biogen discovers develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases x about us at biogen we develop market and manufacture therapies for people living with serious neurological autoimmune and rare diseases explore about us about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance x research  pipeline we aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry to us that means creating novel medicines that benefit individuals and society and bringing new scientific understanding to diseases for which there are no adequate treatments explore research  pipeline pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal x therapies we develop and provide therapies to people living with serious diseases like multiple sclerosis explore therapies multiple sclerosis avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinal muscular atrophy spinraza® biosimilars benepali®  flixabi® partnered gazyva® rituxan® x global impact working to make a positive impact for our patients the communities where we work and live and for society explore global impact science that matters biogen foundation community lab supplier diversity grants office x newsroom explore biogen’s latest news releases and media resources explore newsroom latest press releases events and webcasts x patients we work to transform the lives of the patients we serve meeting their individual needs is what drives our science and provides our focus supporting patients supporting patients x medical professionals at biogen we work with healthcare professionals to ensure the therapies we create can reach those that need them disclosure x careers everyone at biogen plays a vital role in the discovery and delivery of breakthrough therapies explore career opportunities at biogen internship  coop disclosure disclaimer fraudulent job postings x investors find current and historical stock information financial statements and reports or view upcoming events and latest webcasts read more annual report  annual report  annual report  x privacy policy our privacy policy outlines the policies and practices in place to safeguard personal information x terms  conditions these terms and conditions of use describe the terms and conditions applicable to your use of biogen inc’s “biogen” website x forwardlooking statements x community guidelines we use social media as part of our commitment to transparency and to provide information to our customers and stakeholders x sitemap x search x  x leadership hub vounatsos michel alexander susan ehlers michael kress jeanpaul mckenzie paul sandrock alfred papadopoulos stelios denner alexander dorsa caroline leaming nancy mulligan richard pangia robert posner brian rowinsky eric schenk lynn sherwin stephen vounatsos michel gregory ginger x scientist hub huang ron xiao guangqing dunah anthone peters rob oterogutierrez karel mikulskis alvydas goyal jaya silvian laura cosentino mark burkly linda wang qin mingueneau michaël arnold moore gardet agnès staropoli john juhasz peter bussiere thierry pepinsky robert blake wei dong weinreb paul coomaraswamy janaky stevenson lauren rabah dania mi sha wipke brian sun chao shen chase lin edward gianni davide thankamony sai hamann stefan lalioti maria kankel mark sen anindya donelson nathan enyedy istvan trinh kien ryan sarah xin zhili arndt joe ren shuyu cahirmcfarland ellen li kejie subramanyam meena stebbins christopher carulli john weihofen andreas larigan doug mccampbell alexander cameron thomas narayanan sarav lydeard john hronowski xiaoping wei ru martin jeffrey smith benjamin ehrenfels chris valencia antonio mccurley amy rushe mia preyer martin bajrami bekim henderson chris ransohoff richard danos olivier x therapies pmultiple sclerosisp pspinal muscular atrophyp pbiosimilarsp ppartneredp x story hub craig melanie michelle richard daniel kate rosemarie x our people hub bob k judann a cherie b pinky p mike g amanda m vinay b ehs award x bioverativ privacy policy x patients top committed to improving the lives of patients we work to transform the lives of the patients we serve nusinersen expanded access program eap for eligible patients with infantileonset consistent with type  spinal muscular atrophy sma learn more faq podcast innovative therapies we develop medicines for debilitating medical conditions with the goal of making a meaningful difference in patients’ lives multiple sclerosis spinal muscular atrophy biosimilars partnered more about our therapies filter by all approved therapies multiple sclerosis spinal muscular atrophy biosimilars partnered multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis spinal muscular atrophy biosimilars biosimilars partnered partnered extending our support in meaningful ways we believe our therapies can be even more effective when backed by services that support patients emotionally financially and medically patient services learn more financial assistance learn more patient safety learn more dedicated to new discoveries our pipeline is more than a list of medicines in development it reflects the work we do here every day to break new ground with science that makes a difference in the lives of patients filter by all disease areas all disease areas alzheimers disease fibrosis inflammatory bowel disease ibd lupus lymphoma multiple sclerosis ms myotonic dystrophy ophthalmology parkinsons disease sjögrens syndrome spinal muscular atrophy sma stroke trigeminal neuralgia all phases all phases filed phase  phase  phase  phase phase   phase  phase  filed aducanumab aβ mab alzheimer’s disease developed in collaboration with neurimmune alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in  the brain aducanumab is an antibody that binds to and may reduce amyloid plaques from the brain potentially slowing the progress of the disease more information about our aducanumab clinical trials  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  e bace inhibitor alzheimers disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain e is a smallmolecule inhibitor of betasecretase a protein that cleaves enzyme  bace by inhibiting bace e blocks amyloid production potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  ban aβ mab alzheimer’s disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain ban is an antibody that binds to amyloid which could reduce its presence in the brain and potentially slow the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  bg stx idiopathic pulmonary fibrosis ipf pulmonary fibrosis is a disease in which lung tissue becomes thickened and stiff due to scarring the formation of scar tissue is called fibrosis as the disease progresses it becomes harder for the lungs to work properly and the body cannot get the oxygen it needs this debilitating disease is almost always fatal how this therapy could help the tgfbeta brain cell pathway is involved in several fibrotic diseases the bg stx antibody may selectively block the tgfbeta pathway and may slow the development of fibrosis in ipf patients biib antibdca lupus this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help bdca is a protein present in specific cells within the immune system an antibody against bdca can potentially interrupt production of interferons inflammatory molecules that are increased in patients with lupus and contribute to disease activity  biib nav inhibitor trigeminal neuralgia tgn acquired in acquisition of convergence pharmaceuticals trigeminal neuralgia is an extremely painful condition usually involving one side of the face trigeminal neuralgia is characterized by sudden brief stabbing recurrent episodes of pain which frequently occurs spontaneously but is also commonly evoked by trivial stimuli including washing shaving smoking talking andor brushing the teeth trigger factors the pain follows one or more branches of the trigeminal nerve which provides nerve sensation from the mouth face and the front of the scalp the intensity of the pain and its unpredictability results in profound effects on the quality of life of patients how this therapy could help biib nav inhibitor is a novel state dependent small molecule sodium channel blocker that preferentially inhibits the nav  ion channel a therapeutic target implicated by genetics in human pain conditions biib is thought to penetrate the central nervous system and block nav channels in a novel manner and has the potential to provide a new and effective option for the treatment of trigeminal neuralgia biib glibenclamide iv stroke it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke the target indication for biib glibenclamide iv is large hemispheric infarction lhi a severe form of ischemic stroke where brain swelling cerebral edema often leads to a disproportionately large share of strokerelated morbidity and mortality how this therapy could help in preclinical studies biib glibenclamide iv has been shown to block surtrpm channels that mediate stroke related brain swelling clinical proofofconcept studies have demonstrated the potential of biib to reduce brain swelling disability and the risk of death in patients with lhi dapirolizumab pegol anticdl lupus developed in collaboration with ucb inc this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help cdl is a protein in b and t cells which helps regulate the immune system dapirolizumab pegol anticdl is an antibody that blocks cdl potentially lessening disease activity in lupus patients natalizumab αintegrin inhibitor acute ischemic stroke currently approved as tysabri® for relapsingremitting multiple sclerosis and crohn’s disease please visit tysabricom for prescribing and safety information it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke  how this therapy could help natalizumab is thought to reduce the inflammatory cells in the brain by blocking the lymphocytic infiltration known to occur in the brain following stroke which may reduce the extent of injury opicinumab antilingo multiple sclerosis ms this disease causes the body’s immune system to attack myelin a protective sheath covering nerve fibers damage to myelin “short circuits” communication between the brain spinal cord and other areas of the body severely impairing such neurological functions as mobility vision and thinking over time the nerves themselves can become damaged permanently how this therapy could help lingo is a cns specificprotein that is involved in the development of myelin in patients with ms lingo may inhibit myelin growth when it binds with its receptor data suggest that the antibody antilingo could block this process potentially allowing for the remyelination and restoration of nerve communication in ms patients xlrs gene therapy xlinked retinoschisis xlrs developed in collaboration with agtc xlrs is a disease that affects young males beginning in their teenage years it can lead to loss of vision and serious complications such as vitreous hemorrhage or retinal detachment during adulthood how this therapy could help the xlrs gene therapy is a recombinant adenoassociated virus vector raav delivering a transgene rs that expresses retinoschisin protein normal expression of retinoschisin could potentially improve longterm retinal function and preserve structural integrity biib antiαsynuclein parkinsons disease acquired from neurimmune parkinsons disease is a disorder of the central nervous system people who have this disease experience tremors slow movement muscle stiffness and impaired balance  as these symptoms become progressively worse patients have difficulty walking talking or completing other simple tasks how this therapy could help biib targets abnormal alphasynuclein protein that is associated with the destruction of nerve cells this progressive degeneration is the cause of parkinsons disease biib alzheimers disease alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting tau the protein that forms the deposits or tangles in the brain  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  biib alzheimers disease licensed from bristolmyers squibb alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting extracellular tau and may reduce the spreading of tau from one cell to the next potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  currently no results for this search see full pipeline clinical trials gaining insight through clinical trials biogen conducts clinical trials to assess new treatments and to investigate potential new uses and benefits for existing therapies learn more expanded access programs patients may potentially gain access to an investigational therapy three ways through clinical trials expanded access programs eaps and single patient access or emergency use learn more our perspectives july   teaming up for als see all perspectives × important notice you are now leaving biogen’s corporate website we encourage you to read and evaluate terms of use privacy security and other similar policies of the destination site as they may differ from biogen’s standards third party sites biogen assumes no responsibility nor does it control endorse or guarantee any aspect of your use of any third party sites additionally the presence of this link does not imply the third party sites endorsement of biogen or this website thank you for visiting our site   cancel continue biogen  wikipedia biogen from wikipedia the free encyclopedia   redirected from biogen idec jump to navigation search biogen type public traded as nasdaq biib nasdaq component sp  component sp  component industry biotechnology founded  from merger founders kenneth murray phillip allen sharp walter gilbert heinz schaller charles weissmann headquarters cambridge massachusetts us key people stelios papadopoulos chairman michel vounatsos ceo products alprolix avonex eloctate fampyra gazyva plegridy rituxan tecfidera tysabri spinraza revenue us  billion   operating income us  billion   net income us  billion  total assets us  billion  total equity us  billion  number of employees  december  website wwwbiogencom biogen inc previously known as biogen idec is an american multinational biotechnology company based in cambridge massachusetts specializing in the discovery development and delivery of therapies for the treatment of neurodegenerative hematologic and autoimmune diseases to patients worldwide contents  history  bioverativ  acquisition history  leadership  products  pipeline  references  external links historyedit biogen was founded in  in geneva by several prominent biologists including kenneth murray of the university of edinburgh phillip allen sharp of the massachusetts institute of technology walter gilbert of harvard who served as ceo during the startup phase heinz schaller university of heidelberg and charles weissmann university of zurich who contributed the first product interferon alpha gilbert and sharp were subsequently honored with nobel prizes gilbert was recognized in  with the nobel prize in chemistry for his work in understanding dna sequencing while sharp received the nobel prize in physiology or medicine in  for his discovery of split genes in  biogen merged with san diego californiabased idec pharmaceuticals formed in  by biotech pioneers ivor royston and howard birndorf and adopted the name biogen idec after the merger biogen idec became the rd largest biotechnology company in the world following shifts in research core areas the company has since shortened its name reverting to simply biogen biogen stock is a component of several stock indices such as the sp  sp  sp  and nasdaq and the company is listed on the nasdaq stock exchange under the ticker symbol biib in may  the company announced it would acquire cancer specialist conforma therapeutics for  million later in the same month the company announced its intention to acquire fumapharm ag consolidating ownership of fumaderm and bg an oral fumarate which is being studied for the treatment of multiple sclerosis and psoriasis in january  the company announced it would acquire syntonix pharmaceuticals for up to  million gaining syntonixs lead product for hemophilia b as well as the technology for developing inhalable treatments in february  bloomberg broke the news that biogen was planning the pay elan  billion for the full rights to tysabri used to treat multiple sclerosis in january  the company announced it will acquire convergence pharmaceuticals for up to  million with the acquisition aiming to accelerate the development of convergences pipeline inparticular cnv – a phase ii small molecule sodium channel blocking candidate in october  the company announced it will lay off  of its workforce effective immediately bioverativedit in may  the company announced that it will spin off its hemophilia drug business eloctate and alprolix into a public company in august the company announced that the spun off company would be called bioverativ in order to show heritage with biogen the company will trade on the nasdaq exchange under the ticker symbol bivv and will look to be spun off in early  acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list biogen biogen idec biogen founded  idec pharmaceuticals conforma therapeutics acq  fumapharm ag acq  syntonix pharmaceuticals acq  convergence pharmaceuticals acq  leadershipedit biogen is managed by an executive group composed of ten officers michel vounatsos chief executive officer and member board of directors susan h alexander executive vice president chief legal officer and corporate secretary spyros artavanistsakonas phd chief scientific officer paul j clancy executive vice president and chief financial officer paul mckenzie phd executive vice president of pharmaceutical operations  technology kenneth dipietro executive vice president of human resources alfred w sandrock jr md phdexecutive vice president head of development and worldwide medical and chief medical officer michael ehlers md phd executive vice president head of rd as is customary for a publicly traded company biogen is also overseen by a board of directors the executive chairman and chief executive officer both hold positions on the board of directors the directors are stelios papadopoulos chairman michel vounatsos ceo alexander j denner phd caroline dorsa nancy l leaming richard c mulligan robert w pangia brian s posner eric k rowinsky md the honorable lynn schenk and stephen a sherwin md productsedit therapy indication in united states unless otherwise noted year approved us year approved eu additional information alprolix™ coagulation factor ix recombinant fc fusion protein control and prevention of bleeding episodes perioperative management and routine prophylaxis in adults and children with hemophilia b   also approved in canada and australia biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of alprolix  avonex® interferon betaa relapsing forms of multiple sclerosis   includes the avonex pen autoinjector and the avostartgrip titration kit approved in the us in  eloctate™ antihemophilic factor recombinant fc fusion protein control and prevention of bleeding episodes perioperative surgical management and routine prophylaxis in adults and children with hemophilia a   biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of eloctate fampyra® prolongedrelease fampridine tablets multiple sclerosis walking ability   marketed by biogen in markets outside of the united states commercialized in the united states as ampyra dalfampridine extended release tablets by acorda therapeutics fumaderm™ fumaric acid esters psoriasis german use  germany only approved in germany acquired in acquisition of fumapharm ag in  gazyva® obinutuzumab chronic lymphocytic leukemia   the first medicine approved with the fda’s breakthrough therapy designation and is also currently in phase  trials for nhl and diffuse large bcell lymphoma currently commercialized in the united states by genentech a wholly owned subsidiary of roche spinraza™ nusinersen spinal muscular atrophy  — the first drug approved for the treatment of spinal muscular atrophy developed in collaboration with ionis pharmaceuticals eu approval process under way plegridy™ peginterferon betaa relapsing forms of multiple sclerosis   rituxan® rituximab nonhodgkins lymphoma nhl antitnf refractory rheumatoid arthritis ancaassociated vasculitis chronic lymphocytic leukemia     as mabthera the first monoclonal antibody for cancer developed by idec prior to merging with biogen currently commercialized by roche and its subsidiary genentech tecfidera® dimethyl fumarate relapsing forms of multiple sclerosis   tysabri® natalizumab relapsingremitting multiple sclerosis  reintroduced in   full rights purchased from partner elan in  pipelineedit biogen has focused its rd efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology hematology and immunology investigational ms medicines daclizumab highyield process dac hyp is being developed as a potential oncemonthly subcutaneous injection in the treatment of relapsingremitting multiple sclerosis rrms dac hyp is being developed in collaboration with abbvie inc in june  the companies announced positive topline results from the phase iii decide clinical trial where dac hyp demonstrated superiority over interferon betaa in annualized relapse rate antilingo biib opicinumab is the first candidate being investigated for its potential to remyelinate and repair neurons damaged by ms currently in phase  trials biogen has several candidates in phase  and  clinical trials in neurodegenerative and immunological diseases including ms alzheimer’s disease neuropathic pain spinal muscular atrophy and lupus nephritis phase a antilingo molecule opicinumab in acute optic neuritis phase b antitweak monoclonal antibody in lupus nephritis phase a stx in patients with idiopathic pulmonary fibrosis phase  neublastin for neuropathic pain in  phase  biib aducanumab biogen’s first clinical study in alzheimer’s disease phase  biib isissodrx for amyotrophic lateral sclerosis als in collaboration with ionis biogen also has several development agreements in place with ionis pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders in february  biogen formalized a joint venture with samsung creating samsung bioepis this joint venture brings biogen’s expertise and capabilities in protein engineering cell line development and recombinant biologics manufacturing to position the joint venture so biogen can participate in the emerging market for biosimilars in early  biogen entered into an agreement with eisai inc to jointly develop and commercialize two of their candidates for alzheimer’s disease which have the potential to reduce aβ plaques that form in the brains of patients as well as to slow the formation of new plaques potentially improving symptoms and suppressing disease progression referencesedit  a b biogen inc k report  securities and exchange commission retrieved november    biotechs comeback kid forbes retrieved    idec to merge with biogen in  billion deal new york times retrieved    biogen drops idec from name wall street journal retrieved    biogen idec inc stock quote  summary data nasdaq   httpwwwpharmatimescomnewsbiogenidecagreestobuyswisscompanyfumapharm  httpwwwbusinesswirecomnewshomeenbiogenidecacquirefumapharmagconsolidatesownership  httpwwwfiercebiotechcombiotechbiogentobuysyntonixmdeal  httpwwwbusinesswirecomnewshomeenbiogenidecacquiresyntonix  httpswwwbloombergcomnewsarticlesbiogentopayelanbillionforfulltysabrirights  biogen idec snaps up convergence for uptom  gen news highlights  gen   biogen is cutting  of its workforce   dsouza savio may   biogen to spin off hemophilia drug business into a public company reuters retrieved may     amid takeover chatter biogen introduces hemophilia spinoff bioverativ  fiercepharma   httpwwwbusinesswirecomnewsfinancialpostenbiogenannouncesbioverativhemophiliafocusedcompany  biogen unveils name for hemophilia drug spinoff bioverativ  the boston globe   biogen announces bioverativ as name of new hemophiliafocused company  biogen media   biogen idec inc biib top compensated officers business week retrieved    biogen announces departure of tony kingsley  business wire wwwbusinesswirecom retrieved    biogen idec biib chairman young to retire streetinsidercom retrieved    does biogen idec inc have a new blockbuster hemophilia therapy the motley fool retrieved    avonex national ms society   biogen idec’s eloctate gains fda approval the pharma letter retrieved    fampridine fampyra ms trust   biogen idec enters deal to acquire fumapharm first word pharma retrieved    fda approves gazyva for chronic lymphocytic leukemia fdagov retrieved    wadman meredith  december  updated fda approves drug that rescues babies with fatal neurodegenerative disease science   grant charley  surprise drug approval is holiday gift for biogen wall street journal issn  retrieved    biogen idec’s plegridy™peginterferon betaa approved in the us for the treatment of multiple sclerosis reuters   biogen idec’s plegridy approved in europe for relapsingremitting multiple sclerosis the pharma letter   fda approval for rituximab national cancer institute   update roche biogen end dispute over rituxan followons reuters retrieved    fda approves rituxan to treat two rare disorders fdagov retrieved    cell therapeutics buys zevalin from biogen idec for m with up to m extra plus milestones the pharma letter retrieved    tecifedra national ms society   tysabri national ms society   oncemonthly ms drug from biogen idec abbvie clears phase iii hurdle fierce biotech retrieved    lingo a promising remyelination target in ms multiple sclerosis research retrieved    aducanumab reduces amyloid plaques in early alzheimers prime   isis pharmaceuticals and biogen idec fierce biotech   biogen sees eloctate fda delay pushing marketing to mid businessweek retrieved    isis pharmaceuticals and biogen idec fierce biotech  external linksedit official website business data for biogen google finance yahoo finance reuters sec filings v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies companies portal coordinates °′″n °′″w﻿  ﻿°n °w﻿    retrieved from httpsenwikipediaorgwindexphptitlebiogenoldid categories companies in the nasdaq indexcompanies listed on nasdaqcompanies in the nasdaq biotechnology indexcompanies based in cambridge massachusettsbiotechnology companies of the united statesnational medal of technology recipientspharmaceutical companies of the united statespharmaceutical companies established in  establishments in massachusettsorphan drug companieslife sciences industry establishments in switzerlandbiotechnology companies established in spinal muscular atrophycompanies formed by mergerhealth care companies based in massachusettshidden categories pages using infobox company with unsupported parameterscoordinates not on wikidata navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdeutschفارسیfrançaisportuguêssuomi edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view biogen  wikipedia biogen from wikipedia the free encyclopedia   redirected from biogen idec jump to navigation search biogen type public traded as nasdaq biib nasdaq component sp  component sp  component industry biotechnology founded  from merger founders kenneth murray phillip allen sharp walter gilbert heinz schaller charles weissmann headquarters cambridge massachusetts us key people stelios papadopoulos chairman michel vounatsos ceo products alprolix avonex eloctate fampyra gazyva plegridy rituxan tecfidera tysabri spinraza revenue us  billion   operating income us  billion   net income us  billion  total assets us  billion  total equity us  billion  number of employees  december  website wwwbiogencom biogen inc previously known as biogen idec is an american multinational biotechnology company based in cambridge massachusetts specializing in the discovery development and delivery of therapies for the treatment of neurodegenerative hematologic and autoimmune diseases to patients worldwide contents  history  bioverativ  acquisition history  leadership  products  pipeline  references  external links historyedit biogen was founded in  in geneva by several prominent biologists including kenneth murray of the university of edinburgh phillip allen sharp of the massachusetts institute of technology walter gilbert of harvard who served as ceo during the startup phase heinz schaller university of heidelberg and charles weissmann university of zurich who contributed the first product interferon alpha gilbert and sharp were subsequently honored with nobel prizes gilbert was recognized in  with the nobel prize in chemistry for his work in understanding dna sequencing while sharp received the nobel prize in physiology or medicine in  for his discovery of split genes in  biogen merged with san diego californiabased idec pharmaceuticals formed in  by biotech pioneers ivor royston and howard birndorf and adopted the name biogen idec after the merger biogen idec became the rd largest biotechnology company in the world following shifts in research core areas the company has since shortened its name reverting to simply biogen biogen stock is a component of several stock indices such as the sp  sp  sp  and nasdaq and the company is listed on the nasdaq stock exchange under the ticker symbol biib in may  the company announced it would acquire cancer specialist conforma therapeutics for  million later in the same month the company announced its intention to acquire fumapharm ag consolidating ownership of fumaderm and bg an oral fumarate which is being studied for the treatment of multiple sclerosis and psoriasis in january  the company announced it would acquire syntonix pharmaceuticals for up to  million gaining syntonixs lead product for hemophilia b as well as the technology for developing inhalable treatments in february  bloomberg broke the news that biogen was planning the pay elan  billion for the full rights to tysabri used to treat multiple sclerosis in january  the company announced it will acquire convergence pharmaceuticals for up to  million with the acquisition aiming to accelerate the development of convergences pipeline inparticular cnv – a phase ii small molecule sodium channel blocking candidate in october  the company announced it will lay off  of its workforce effective immediately bioverativedit in may  the company announced that it will spin off its hemophilia drug business eloctate and alprolix into a public company in august the company announced that the spun off company would be called bioverativ in order to show heritage with biogen the company will trade on the nasdaq exchange under the ticker symbol bivv and will look to be spun off in early  acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list biogen biogen idec biogen founded  idec pharmaceuticals conforma therapeutics acq  fumapharm ag acq  syntonix pharmaceuticals acq  convergence pharmaceuticals acq  leadershipedit biogen is managed by an executive group composed of ten officers michel vounatsos chief executive officer and member board of directors susan h alexander executive vice president chief legal officer and corporate secretary spyros artavanistsakonas phd chief scientific officer paul j clancy executive vice president and chief financial officer paul mckenzie phd executive vice president of pharmaceutical operations  technology kenneth dipietro executive vice president of human resources alfred w sandrock jr md phdexecutive vice president head of development and worldwide medical and chief medical officer michael ehlers md phd executive vice president head of rd as is customary for a publicly traded company biogen is also overseen by a board of directors the executive chairman and chief executive officer both hold positions on the board of directors the directors are stelios papadopoulos chairman michel vounatsos ceo alexander j denner phd caroline dorsa nancy l leaming richard c mulligan robert w pangia brian s posner eric k rowinsky md the honorable lynn schenk and stephen a sherwin md productsedit therapy indication in united states unless otherwise noted year approved us year approved eu additional information alprolix™ coagulation factor ix recombinant fc fusion protein control and prevention of bleeding episodes perioperative management and routine prophylaxis in adults and children with hemophilia b   also approved in canada and australia biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of alprolix  avonex® interferon betaa relapsing forms of multiple sclerosis   includes the avonex pen autoinjector and the avostartgrip titration kit approved in the us in  eloctate™ antihemophilic factor recombinant fc fusion protein control and prevention of bleeding episodes perioperative surgical management and routine prophylaxis in adults and children with hemophilia a   biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of eloctate fampyra® prolongedrelease fampridine tablets multiple sclerosis walking ability   marketed by biogen in markets outside of the united states commercialized in the united states as ampyra dalfampridine extended release tablets by acorda therapeutics fumaderm™ fumaric acid esters psoriasis german use  germany only approved in germany acquired in acquisition of fumapharm ag in  gazyva® obinutuzumab chronic lymphocytic leukemia   the first medicine approved with the fda’s breakthrough therapy designation and is also currently in phase  trials for nhl and diffuse large bcell lymphoma currently commercialized in the united states by genentech a wholly owned subsidiary of roche spinraza™ nusinersen spinal muscular atrophy  — the first drug approved for the treatment of spinal muscular atrophy developed in collaboration with ionis pharmaceuticals eu approval process under way plegridy™ peginterferon betaa relapsing forms of multiple sclerosis   rituxan® rituximab nonhodgkins lymphoma nhl antitnf refractory rheumatoid arthritis ancaassociated vasculitis chronic lymphocytic leukemia     as mabthera the first monoclonal antibody for cancer developed by idec prior to merging with biogen currently commercialized by roche and its subsidiary genentech tecfidera® dimethyl fumarate relapsing forms of multiple sclerosis   tysabri® natalizumab relapsingremitting multiple sclerosis  reintroduced in   full rights purchased from partner elan in  pipelineedit biogen has focused its rd efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology hematology and immunology investigational ms medicines daclizumab highyield process dac hyp is being developed as a potential oncemonthly subcutaneous injection in the treatment of relapsingremitting multiple sclerosis rrms dac hyp is being developed in collaboration with abbvie inc in june  the companies announced positive topline results from the phase iii decide clinical trial where dac hyp demonstrated superiority over interferon betaa in annualized relapse rate antilingo biib opicinumab is the first candidate being investigated for its potential to remyelinate and repair neurons damaged by ms currently in phase  trials biogen has several candidates in phase  and  clinical trials in neurodegenerative and immunological diseases including ms alzheimer’s disease neuropathic pain spinal muscular atrophy and lupus nephritis phase a antilingo molecule opicinumab in acute optic neuritis phase b antitweak monoclonal antibody in lupus nephritis phase a stx in patients with idiopathic pulmonary fibrosis phase  neublastin for neuropathic pain in  phase  biib aducanumab biogen’s first clinical study in alzheimer’s disease phase  biib isissodrx for amyotrophic lateral sclerosis als in collaboration with ionis biogen also has several development agreements in place with ionis pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders in february  biogen formalized a joint venture with samsung creating samsung bioepis this joint venture brings biogen’s expertise and capabilities in protein engineering cell line development and recombinant biologics manufacturing to position the joint venture so biogen can participate in the emerging market for biosimilars in early  biogen entered into an agreement with eisai inc to jointly develop and commercialize two of their candidates for alzheimer’s disease which have the potential to reduce aβ plaques that form in the brains of patients as well as to slow the formation of new plaques potentially improving symptoms and suppressing disease progression referencesedit  a b biogen inc k report  securities and exchange commission retrieved november    biotechs comeback kid forbes retrieved    idec to merge with biogen in  billion deal new york times retrieved    biogen drops idec from name wall street journal retrieved    biogen idec inc stock quote  summary data nasdaq   httpwwwpharmatimescomnewsbiogenidecagreestobuyswisscompanyfumapharm  httpwwwbusinesswirecomnewshomeenbiogenidecacquirefumapharmagconsolidatesownership  httpwwwfiercebiotechcombiotechbiogentobuysyntonixmdeal  httpwwwbusinesswirecomnewshomeenbiogenidecacquiresyntonix  httpswwwbloombergcomnewsarticlesbiogentopayelanbillionforfulltysabrirights  biogen idec snaps up convergence for uptom  gen news highlights  gen   biogen is cutting  of its workforce   dsouza savio may   biogen to spin off hemophilia drug business into a public company reuters retrieved may     amid takeover chatter biogen introduces hemophilia spinoff bioverativ  fiercepharma   httpwwwbusinesswirecomnewsfinancialpostenbiogenannouncesbioverativhemophiliafocusedcompany  biogen unveils name for hemophilia drug spinoff bioverativ  the boston globe   biogen announces bioverativ as name of new hemophiliafocused company  biogen media   biogen idec inc biib top compensated officers business week retrieved    biogen announces departure of tony kingsley  business wire wwwbusinesswirecom retrieved    biogen idec biib chairman young to retire streetinsidercom retrieved    does biogen idec inc have a new blockbuster hemophilia therapy the motley fool retrieved    avonex national ms society   biogen idec’s eloctate gains fda approval the pharma letter retrieved    fampridine fampyra ms trust   biogen idec enters deal to acquire fumapharm first word pharma retrieved    fda approves gazyva for chronic lymphocytic leukemia fdagov retrieved    wadman meredith  december  updated fda approves drug that rescues babies with fatal neurodegenerative disease science   grant charley  surprise drug approval is holiday gift for biogen wall street journal issn  retrieved    biogen idec’s plegridy™peginterferon betaa approved in the us for the treatment of multiple sclerosis reuters   biogen idec’s plegridy approved in europe for relapsingremitting multiple sclerosis the pharma letter   fda approval for rituximab national cancer institute   update roche biogen end dispute over rituxan followons reuters retrieved    fda approves rituxan to treat two rare disorders fdagov retrieved    cell therapeutics buys zevalin from biogen idec for m with up to m extra plus milestones the pharma letter retrieved    tecifedra national ms society   tysabri national ms society   oncemonthly ms drug from biogen idec abbvie clears phase iii hurdle fierce biotech retrieved    lingo a promising remyelination target in ms multiple sclerosis research retrieved    aducanumab reduces amyloid plaques in early alzheimers prime   isis pharmaceuticals and biogen idec fierce biotech   biogen sees eloctate fda delay pushing marketing to mid businessweek retrieved    isis pharmaceuticals and biogen idec fierce biotech  external linksedit official website business data for biogen google finance yahoo finance reuters sec filings v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies companies portal coordinates °′″n °′″w﻿  ﻿°n °w﻿    retrieved from httpsenwikipediaorgwindexphptitlebiogenoldid categories companies in the nasdaq indexcompanies listed on nasdaqcompanies in the nasdaq biotechnology indexcompanies based in cambridge massachusettsbiotechnology companies of the united statesnational medal of technology recipientspharmaceutical companies of the united statespharmaceutical companies established in  establishments in massachusettsorphan drug companieslife sciences industry establishments in switzerlandbiotechnology companies established in spinal muscular atrophycompanies formed by mergerhealth care companies based in massachusettshidden categories pages using infobox company with unsupported parameterscoordinates not on wikidata navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdeutschفارسیfrançaisportuguêssuomi edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view biogen  wikipedia biogen from wikipedia the free encyclopedia   redirected from biogen idec jump to navigation search biogen type public traded as nasdaq biib nasdaq component sp  component sp  component industry biotechnology founded  from merger founders kenneth murray phillip allen sharp walter gilbert heinz schaller charles weissmann headquarters cambridge massachusetts us key people stelios papadopoulos chairman michel vounatsos ceo products alprolix avonex eloctate fampyra gazyva plegridy rituxan tecfidera tysabri spinraza revenue us  billion   operating income us  billion   net income us  billion  total assets us  billion  total equity us  billion  number of employees  december  website wwwbiogencom biogen inc previously known as biogen idec is an american multinational biotechnology company based in cambridge massachusetts specializing in the discovery development and delivery of therapies for the treatment of neurodegenerative hematologic and autoimmune diseases to patients worldwide contents  history  bioverativ  acquisition history  leadership  products  pipeline  references  external links historyedit biogen was founded in  in geneva by several prominent biologists including kenneth murray of the university of edinburgh phillip allen sharp of the massachusetts institute of technology walter gilbert of harvard who served as ceo during the startup phase heinz schaller university of heidelberg and charles weissmann university of zurich who contributed the first product interferon alpha gilbert and sharp were subsequently honored with nobel prizes gilbert was recognized in  with the nobel prize in chemistry for his work in understanding dna sequencing while sharp received the nobel prize in physiology or medicine in  for his discovery of split genes in  biogen merged with san diego californiabased idec pharmaceuticals formed in  by biotech pioneers ivor royston and howard birndorf and adopted the name biogen idec after the merger biogen idec became the rd largest biotechnology company in the world following shifts in research core areas the company has since shortened its name reverting to simply biogen biogen stock is a component of several stock indices such as the sp  sp  sp  and nasdaq and the company is listed on the nasdaq stock exchange under the ticker symbol biib in may  the company announced it would acquire cancer specialist conforma therapeutics for  million later in the same month the company announced its intention to acquire fumapharm ag consolidating ownership of fumaderm and bg an oral fumarate which is being studied for the treatment of multiple sclerosis and psoriasis in january  the company announced it would acquire syntonix pharmaceuticals for up to  million gaining syntonixs lead product for hemophilia b as well as the technology for developing inhalable treatments in february  bloomberg broke the news that biogen was planning the pay elan  billion for the full rights to tysabri used to treat multiple sclerosis in january  the company announced it will acquire convergence pharmaceuticals for up to  million with the acquisition aiming to accelerate the development of convergences pipeline inparticular cnv – a phase ii small molecule sodium channel blocking candidate in october  the company announced it will lay off  of its workforce effective immediately bioverativedit in may  the company announced that it will spin off its hemophilia drug business eloctate and alprolix into a public company in august the company announced that the spun off company would be called bioverativ in order to show heritage with biogen the company will trade on the nasdaq exchange under the ticker symbol bivv and will look to be spun off in early  acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list biogen biogen idec biogen founded  idec pharmaceuticals conforma therapeutics acq  fumapharm ag acq  syntonix pharmaceuticals acq  convergence pharmaceuticals acq  leadershipedit biogen is managed by an executive group composed of ten officers michel vounatsos chief executive officer and member board of directors susan h alexander executive vice president chief legal officer and corporate secretary spyros artavanistsakonas phd chief scientific officer paul j clancy executive vice president and chief financial officer paul mckenzie phd executive vice president of pharmaceutical operations  technology kenneth dipietro executive vice president of human resources alfred w sandrock jr md phdexecutive vice president head of development and worldwide medical and chief medical officer michael ehlers md phd executive vice president head of rd as is customary for a publicly traded company biogen is also overseen by a board of directors the executive chairman and chief executive officer both hold positions on the board of directors the directors are stelios papadopoulos chairman michel vounatsos ceo alexander j denner phd caroline dorsa nancy l leaming richard c mulligan robert w pangia brian s posner eric k rowinsky md the honorable lynn schenk and stephen a sherwin md productsedit therapy indication in united states unless otherwise noted year approved us year approved eu additional information alprolix™ coagulation factor ix recombinant fc fusion protein control and prevention of bleeding episodes perioperative management and routine prophylaxis in adults and children with hemophilia b   also approved in canada and australia biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of alprolix  avonex® interferon betaa relapsing forms of multiple sclerosis   includes the avonex pen autoinjector and the avostartgrip titration kit approved in the us in  eloctate™ antihemophilic factor recombinant fc fusion protein control and prevention of bleeding episodes perioperative surgical management and routine prophylaxis in adults and children with hemophilia a   biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of eloctate fampyra® prolongedrelease fampridine tablets multiple sclerosis walking ability   marketed by biogen in markets outside of the united states commercialized in the united states as ampyra dalfampridine extended release tablets by acorda therapeutics fumaderm™ fumaric acid esters psoriasis german use  germany only approved in germany acquired in acquisition of fumapharm ag in  gazyva® obinutuzumab chronic lymphocytic leukemia   the first medicine approved with the fda’s breakthrough therapy designation and is also currently in phase  trials for nhl and diffuse large bcell lymphoma currently commercialized in the united states by genentech a wholly owned subsidiary of roche spinraza™ nusinersen spinal muscular atrophy  — the first drug approved for the treatment of spinal muscular atrophy developed in collaboration with ionis pharmaceuticals eu approval process under way plegridy™ peginterferon betaa relapsing forms of multiple sclerosis   rituxan® rituximab nonhodgkins lymphoma nhl antitnf refractory rheumatoid arthritis ancaassociated vasculitis chronic lymphocytic leukemia     as mabthera the first monoclonal antibody for cancer developed by idec prior to merging with biogen currently commercialized by roche and its subsidiary genentech tecfidera® dimethyl fumarate relapsing forms of multiple sclerosis   tysabri® natalizumab relapsingremitting multiple sclerosis  reintroduced in   full rights purchased from partner elan in  pipelineedit biogen has focused its rd efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology hematology and immunology investigational ms medicines daclizumab highyield process dac hyp is being developed as a potential oncemonthly subcutaneous injection in the treatment of relapsingremitting multiple sclerosis rrms dac hyp is being developed in collaboration with abbvie inc in june  the companies announced positive topline results from the phase iii decide clinical trial where dac hyp demonstrated superiority over interferon betaa in annualized relapse rate antilingo biib opicinumab is the first candidate being investigated for its potential to remyelinate and repair neurons damaged by ms currently in phase  trials biogen has several candidates in phase  and  clinical trials in neurodegenerative and immunological diseases including ms alzheimer’s disease neuropathic pain spinal muscular atrophy and lupus nephritis phase a antilingo molecule opicinumab in acute optic neuritis phase b antitweak monoclonal antibody in lupus nephritis phase a stx in patients with idiopathic pulmonary fibrosis phase  neublastin for neuropathic pain in  phase  biib aducanumab biogen’s first clinical study in alzheimer’s disease phase  biib isissodrx for amyotrophic lateral sclerosis als in collaboration with ionis biogen also has several development agreements in place with ionis pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders in february  biogen formalized a joint venture with samsung creating samsung bioepis this joint venture brings biogen’s expertise and capabilities in protein engineering cell line development and recombinant biologics manufacturing to position the joint venture so biogen can participate in the emerging market for biosimilars in early  biogen entered into an agreement with eisai inc to jointly develop and commercialize two of their candidates for alzheimer’s disease which have the potential to reduce aβ plaques that form in the brains of patients as well as to slow the formation of new plaques potentially improving symptoms and suppressing disease progression referencesedit  a b biogen inc k report  securities and exchange commission retrieved november    biotechs comeback kid forbes retrieved    idec to merge with biogen in  billion deal new york times retrieved    biogen drops idec from name wall street journal retrieved    biogen idec inc stock quote  summary data nasdaq   httpwwwpharmatimescomnewsbiogenidecagreestobuyswisscompanyfumapharm  httpwwwbusinesswirecomnewshomeenbiogenidecacquirefumapharmagconsolidatesownership  httpwwwfiercebiotechcombiotechbiogentobuysyntonixmdeal  httpwwwbusinesswirecomnewshomeenbiogenidecacquiresyntonix  httpswwwbloombergcomnewsarticlesbiogentopayelanbillionforfulltysabrirights  biogen idec snaps up convergence for uptom  gen news highlights  gen   biogen is cutting  of its workforce   dsouza savio may   biogen to spin off hemophilia drug business into a public company reuters retrieved may     amid takeover chatter biogen introduces hemophilia spinoff bioverativ  fiercepharma   httpwwwbusinesswirecomnewsfinancialpostenbiogenannouncesbioverativhemophiliafocusedcompany  biogen unveils name for hemophilia drug spinoff bioverativ  the boston globe   biogen announces bioverativ as name of new hemophiliafocused company  biogen media   biogen idec inc biib top compensated officers business week retrieved    biogen announces departure of tony kingsley  business wire wwwbusinesswirecom retrieved    biogen idec biib chairman young to retire streetinsidercom retrieved    does biogen idec inc have a new blockbuster hemophilia therapy the motley fool retrieved    avonex national ms society   biogen idec’s eloctate gains fda approval the pharma letter retrieved    fampridine fampyra ms trust   biogen idec enters deal to acquire fumapharm first word pharma retrieved    fda approves gazyva for chronic lymphocytic leukemia fdagov retrieved    wadman meredith  december  updated fda approves drug that rescues babies with fatal neurodegenerative disease science   grant charley  surprise drug approval is holiday gift for biogen wall street journal issn  retrieved    biogen idec’s plegridy™peginterferon betaa approved in the us for the treatment of multiple sclerosis reuters   biogen idec’s plegridy approved in europe for relapsingremitting multiple sclerosis the pharma letter   fda approval for rituximab national cancer institute   update roche biogen end dispute over rituxan followons reuters retrieved    fda approves rituxan to treat two rare disorders fdagov retrieved    cell therapeutics buys zevalin from biogen idec for m with up to m extra plus milestones the pharma letter retrieved    tecifedra national ms society   tysabri national ms society   oncemonthly ms drug from biogen idec abbvie clears phase iii hurdle fierce biotech retrieved    lingo a promising remyelination target in ms multiple sclerosis research retrieved    aducanumab reduces amyloid plaques in early alzheimers prime   isis pharmaceuticals and biogen idec fierce biotech   biogen sees eloctate fda delay pushing marketing to mid businessweek retrieved    isis pharmaceuticals and biogen idec fierce biotech  external linksedit official website business data for biogen google finance yahoo finance reuters sec filings v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies companies portal coordinates °′″n °′″w﻿  ﻿°n °w﻿    retrieved from httpsenwikipediaorgwindexphptitlebiogenoldid categories companies in the nasdaq indexcompanies listed on nasdaqcompanies in the nasdaq biotechnology indexcompanies based in cambridge massachusettsbiotechnology companies of the united statesnational medal of technology recipientspharmaceutical companies of the united statespharmaceutical companies established in  establishments in massachusettsorphan drug companieslife sciences industry establishments in switzerlandbiotechnology companies established in spinal muscular atrophycompanies formed by mergerhealth care companies based in massachusettshidden categories pages using infobox company with unsupported parameterscoordinates not on wikidata navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdeutschفارسیfrançaisportuguêssuomi edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view biogen  wikipedia biogen from wikipedia the free encyclopedia   redirected from biogen idec jump to navigation search biogen type public traded as nasdaq biib nasdaq component sp  component sp  component industry biotechnology founded  from merger founders kenneth murray phillip allen sharp walter gilbert heinz schaller charles weissmann headquarters cambridge massachusetts us key people stelios papadopoulos chairman michel vounatsos ceo products alprolix avonex eloctate fampyra gazyva plegridy rituxan tecfidera tysabri spinraza revenue us  billion   operating income us  billion   net income us  billion  total assets us  billion  total equity us  billion  number of employees  december  website wwwbiogencom biogen inc previously known as biogen idec is an american multinational biotechnology company based in cambridge massachusetts specializing in the discovery development and delivery of therapies for the treatment of neurodegenerative hematologic and autoimmune diseases to patients worldwide contents  history  bioverativ  acquisition history  leadership  products  pipeline  references  external links historyedit biogen was founded in  in geneva by several prominent biologists including kenneth murray of the university of edinburgh phillip allen sharp of the massachusetts institute of technology walter gilbert of harvard who served as ceo during the startup phase heinz schaller university of heidelberg and charles weissmann university of zurich who contributed the first product interferon alpha gilbert and sharp were subsequently honored with nobel prizes gilbert was recognized in  with the nobel prize in chemistry for his work in understanding dna sequencing while sharp received the nobel prize in physiology or medicine in  for his discovery of split genes in  biogen merged with san diego californiabased idec pharmaceuticals formed in  by biotech pioneers ivor royston and howard birndorf and adopted the name biogen idec after the merger biogen idec became the rd largest biotechnology company in the world following shifts in research core areas the company has since shortened its name reverting to simply biogen biogen stock is a component of several stock indices such as the sp  sp  sp  and nasdaq and the company is listed on the nasdaq stock exchange under the ticker symbol biib in may  the company announced it would acquire cancer specialist conforma therapeutics for  million later in the same month the company announced its intention to acquire fumapharm ag consolidating ownership of fumaderm and bg an oral fumarate which is being studied for the treatment of multiple sclerosis and psoriasis in january  the company announced it would acquire syntonix pharmaceuticals for up to  million gaining syntonixs lead product for hemophilia b as well as the technology for developing inhalable treatments in february  bloomberg broke the news that biogen was planning the pay elan  billion for the full rights to tysabri used to treat multiple sclerosis in january  the company announced it will acquire convergence pharmaceuticals for up to  million with the acquisition aiming to accelerate the development of convergences pipeline inparticular cnv – a phase ii small molecule sodium channel blocking candidate in october  the company announced it will lay off  of its workforce effective immediately bioverativedit in may  the company announced that it will spin off its hemophilia drug business eloctate and alprolix into a public company in august the company announced that the spun off company would be called bioverativ in order to show heritage with biogen the company will trade on the nasdaq exchange under the ticker symbol bivv and will look to be spun off in early  acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list biogen biogen idec biogen founded  idec pharmaceuticals conforma therapeutics acq  fumapharm ag acq  syntonix pharmaceuticals acq  convergence pharmaceuticals acq  leadershipedit biogen is managed by an executive group composed of ten officers michel vounatsos chief executive officer and member board of directors susan h alexander executive vice president chief legal officer and corporate secretary spyros artavanistsakonas phd chief scientific officer paul j clancy executive vice president and chief financial officer paul mckenzie phd executive vice president of pharmaceutical operations  technology kenneth dipietro executive vice president of human resources alfred w sandrock jr md phdexecutive vice president head of development and worldwide medical and chief medical officer michael ehlers md phd executive vice president head of rd as is customary for a publicly traded company biogen is also overseen by a board of directors the executive chairman and chief executive officer both hold positions on the board of directors the directors are stelios papadopoulos chairman michel vounatsos ceo alexander j denner phd caroline dorsa nancy l leaming richard c mulligan robert w pangia brian s posner eric k rowinsky md the honorable lynn schenk and stephen a sherwin md productsedit therapy indication in united states unless otherwise noted year approved us year approved eu additional information alprolix™ coagulation factor ix recombinant fc fusion protein control and prevention of bleeding episodes perioperative management and routine prophylaxis in adults and children with hemophilia b   also approved in canada and australia biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of alprolix  avonex® interferon betaa relapsing forms of multiple sclerosis   includes the avonex pen autoinjector and the avostartgrip titration kit approved in the us in  eloctate™ antihemophilic factor recombinant fc fusion protein control and prevention of bleeding episodes perioperative surgical management and routine prophylaxis in adults and children with hemophilia a   biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of eloctate fampyra® prolongedrelease fampridine tablets multiple sclerosis walking ability   marketed by biogen in markets outside of the united states commercialized in the united states as ampyra dalfampridine extended release tablets by acorda therapeutics fumaderm™ fumaric acid esters psoriasis german use  germany only approved in germany acquired in acquisition of fumapharm ag in  gazyva® obinutuzumab chronic lymphocytic leukemia   the first medicine approved with the fda’s breakthrough therapy designation and is also currently in phase  trials for nhl and diffuse large bcell lymphoma currently commercialized in the united states by genentech a wholly owned subsidiary of roche spinraza™ nusinersen spinal muscular atrophy  — the first drug approved for the treatment of spinal muscular atrophy developed in collaboration with ionis pharmaceuticals eu approval process under way plegridy™ peginterferon betaa relapsing forms of multiple sclerosis   rituxan® rituximab nonhodgkins lymphoma nhl antitnf refractory rheumatoid arthritis ancaassociated vasculitis chronic lymphocytic leukemia     as mabthera the first monoclonal antibody for cancer developed by idec prior to merging with biogen currently commercialized by roche and its subsidiary genentech tecfidera® dimethyl fumarate relapsing forms of multiple sclerosis   tysabri® natalizumab relapsingremitting multiple sclerosis  reintroduced in   full rights purchased from partner elan in  pipelineedit biogen has focused its rd efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology hematology and immunology investigational ms medicines daclizumab highyield process dac hyp is being developed as a potential oncemonthly subcutaneous injection in the treatment of relapsingremitting multiple sclerosis rrms dac hyp is being developed in collaboration with abbvie inc in june  the companies announced positive topline results from the phase iii decide clinical trial where dac hyp demonstrated superiority over interferon betaa in annualized relapse rate antilingo biib opicinumab is the first candidate being investigated for its potential to remyelinate and repair neurons damaged by ms currently in phase  trials biogen has several candidates in phase  and  clinical trials in neurodegenerative and immunological diseases including ms alzheimer’s disease neuropathic pain spinal muscular atrophy and lupus nephritis phase a antilingo molecule opicinumab in acute optic neuritis phase b antitweak monoclonal antibody in lupus nephritis phase a stx in patients with idiopathic pulmonary fibrosis phase  neublastin for neuropathic pain in  phase  biib aducanumab biogen’s first clinical study in alzheimer’s disease phase  biib isissodrx for amyotrophic lateral sclerosis als in collaboration with ionis biogen also has several development agreements in place with ionis pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders in february  biogen formalized a joint venture with samsung creating samsung bioepis this joint venture brings biogen’s expertise and capabilities in protein engineering cell line development and recombinant biologics manufacturing to position the joint venture so biogen can participate in the emerging market for biosimilars in early  biogen entered into an agreement with eisai inc to jointly develop and commercialize two of their candidates for alzheimer’s disease which have the potential to reduce aβ plaques that form in the brains of patients as well as to slow the formation of new plaques potentially improving symptoms and suppressing disease progression referencesedit  a b biogen inc k report  securities and exchange commission retrieved november    biotechs comeback kid forbes retrieved    idec to merge with biogen in  billion deal new york times retrieved    biogen drops idec from name wall street journal retrieved    biogen idec inc stock quote  summary data nasdaq   httpwwwpharmatimescomnewsbiogenidecagreestobuyswisscompanyfumapharm  httpwwwbusinesswirecomnewshomeenbiogenidecacquirefumapharmagconsolidatesownership  httpwwwfiercebiotechcombiotechbiogentobuysyntonixmdeal  httpwwwbusinesswirecomnewshomeenbiogenidecacquiresyntonix  httpswwwbloombergcomnewsarticlesbiogentopayelanbillionforfulltysabrirights  biogen idec snaps up convergence for uptom  gen news highlights  gen   biogen is cutting  of its workforce   dsouza savio may   biogen to spin off hemophilia drug business into a public company reuters retrieved may     amid takeover chatter biogen introduces hemophilia spinoff bioverativ  fiercepharma   httpwwwbusinesswirecomnewsfinancialpostenbiogenannouncesbioverativhemophiliafocusedcompany  biogen unveils name for hemophilia drug spinoff bioverativ  the boston globe   biogen announces bioverativ as name of new hemophiliafocused company  biogen media   biogen idec inc biib top compensated officers business week retrieved    biogen announces departure of tony kingsley  business wire wwwbusinesswirecom retrieved    biogen idec biib chairman young to retire streetinsidercom retrieved    does biogen idec inc have a new blockbuster hemophilia therapy the motley fool retrieved    avonex national ms society   biogen idec’s eloctate gains fda approval the pharma letter retrieved    fampridine fampyra ms trust   biogen idec enters deal to acquire fumapharm first word pharma retrieved    fda approves gazyva for chronic lymphocytic leukemia fdagov retrieved    wadman meredith  december  updated fda approves drug that rescues babies with fatal neurodegenerative disease science   grant charley  surprise drug approval is holiday gift for biogen wall street journal issn  retrieved    biogen idec’s plegridy™peginterferon betaa approved in the us for the treatment of multiple sclerosis reuters   biogen idec’s plegridy approved in europe for relapsingremitting multiple sclerosis the pharma letter   fda approval for rituximab national cancer institute   update roche biogen end dispute over rituxan followons reuters retrieved    fda approves rituxan to treat two rare disorders fdagov retrieved    cell therapeutics buys zevalin from biogen idec for m with up to m extra plus milestones the pharma letter retrieved    tecifedra national ms society   tysabri national ms society   oncemonthly ms drug from biogen idec abbvie clears phase iii hurdle fierce biotech retrieved    lingo a promising remyelination target in ms multiple sclerosis research retrieved    aducanumab reduces amyloid plaques in early alzheimers prime   isis pharmaceuticals and biogen idec fierce biotech   biogen sees eloctate fda delay pushing marketing to mid businessweek retrieved    isis pharmaceuticals and biogen idec fierce biotech  external linksedit official website business data for biogen google finance yahoo finance reuters sec filings v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies companies portal coordinates °′″n °′″w﻿  ﻿°n °w﻿    retrieved from httpsenwikipediaorgwindexphptitlebiogenoldid categories companies in the nasdaq indexcompanies listed on nasdaqcompanies in the nasdaq biotechnology indexcompanies based in cambridge massachusettsbiotechnology companies of the united statesnational medal of technology recipientspharmaceutical companies of the united statespharmaceutical companies established in  establishments in massachusettsorphan drug companieslife sciences industry establishments in switzerlandbiotechnology companies established in spinal muscular atrophycompanies formed by mergerhealth care companies based in massachusettshidden categories pages using infobox company with unsupported parameterscoordinates not on wikidata navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdeutschفارسیfrançaisportuguêssuomi edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view biogen  wikipedia biogen from wikipedia the free encyclopedia   redirected from biogen idec jump to navigation search biogen type public traded as nasdaq biib nasdaq component sp  component sp  component industry biotechnology founded  from merger founders kenneth murray phillip allen sharp walter gilbert heinz schaller charles weissmann headquarters cambridge massachusetts us key people stelios papadopoulos chairman michel vounatsos ceo products alprolix avonex eloctate fampyra gazyva plegridy rituxan tecfidera tysabri spinraza revenue us  billion   operating income us  billion   net income us  billion  total assets us  billion  total equity us  billion  number of employees  december  website wwwbiogencom biogen inc previously known as biogen idec is an american multinational biotechnology company based in cambridge massachusetts specializing in the discovery development and delivery of therapies for the treatment of neurodegenerative hematologic and autoimmune diseases to patients worldwide contents  history  bioverativ  acquisition history  leadership  products  pipeline  references  external links historyedit biogen was founded in  in geneva by several prominent biologists including kenneth murray of the university of edinburgh phillip allen sharp of the massachusetts institute of technology walter gilbert of harvard who served as ceo during the startup phase heinz schaller university of heidelberg and charles weissmann university of zurich who contributed the first product interferon alpha gilbert and sharp were subsequently honored with nobel prizes gilbert was recognized in  with the nobel prize in chemistry for his work in understanding dna sequencing while sharp received the nobel prize in physiology or medicine in  for his discovery of split genes in  biogen merged with san diego californiabased idec pharmaceuticals formed in  by biotech pioneers ivor royston and howard birndorf and adopted the name biogen idec after the merger biogen idec became the rd largest biotechnology company in the world following shifts in research core areas the company has since shortened its name reverting to simply biogen biogen stock is a component of several stock indices such as the sp  sp  sp  and nasdaq and the company is listed on the nasdaq stock exchange under the ticker symbol biib in may  the company announced it would acquire cancer specialist conforma therapeutics for  million later in the same month the company announced its intention to acquire fumapharm ag consolidating ownership of fumaderm and bg an oral fumarate which is being studied for the treatment of multiple sclerosis and psoriasis in january  the company announced it would acquire syntonix pharmaceuticals for up to  million gaining syntonixs lead product for hemophilia b as well as the technology for developing inhalable treatments in february  bloomberg broke the news that biogen was planning the pay elan  billion for the full rights to tysabri used to treat multiple sclerosis in january  the company announced it will acquire convergence pharmaceuticals for up to  million with the acquisition aiming to accelerate the development of convergences pipeline inparticular cnv – a phase ii small molecule sodium channel blocking candidate in october  the company announced it will lay off  of its workforce effective immediately bioverativedit in may  the company announced that it will spin off its hemophilia drug business eloctate and alprolix into a public company in august the company announced that the spun off company would be called bioverativ in order to show heritage with biogen the company will trade on the nasdaq exchange under the ticker symbol bivv and will look to be spun off in early  acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list biogen biogen idec biogen founded  idec pharmaceuticals conforma therapeutics acq  fumapharm ag acq  syntonix pharmaceuticals acq  convergence pharmaceuticals acq  leadershipedit biogen is managed by an executive group composed of ten officers michel vounatsos chief executive officer and member board of directors susan h alexander executive vice president chief legal officer and corporate secretary spyros artavanistsakonas phd chief scientific officer paul j clancy executive vice president and chief financial officer paul mckenzie phd executive vice president of pharmaceutical operations  technology kenneth dipietro executive vice president of human resources alfred w sandrock jr md phdexecutive vice president head of development and worldwide medical and chief medical officer michael ehlers md phd executive vice president head of rd as is customary for a publicly traded company biogen is also overseen by a board of directors the executive chairman and chief executive officer both hold positions on the board of directors the directors are stelios papadopoulos chairman michel vounatsos ceo alexander j denner phd caroline dorsa nancy l leaming richard c mulligan robert w pangia brian s posner eric k rowinsky md the honorable lynn schenk and stephen a sherwin md productsedit therapy indication in united states unless otherwise noted year approved us year approved eu additional information alprolix™ coagulation factor ix recombinant fc fusion protein control and prevention of bleeding episodes perioperative management and routine prophylaxis in adults and children with hemophilia b   also approved in canada and australia biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of alprolix  avonex® interferon betaa relapsing forms of multiple sclerosis   includes the avonex pen autoinjector and the avostartgrip titration kit approved in the us in  eloctate™ antihemophilic factor recombinant fc fusion protein control and prevention of bleeding episodes perioperative surgical management and routine prophylaxis in adults and children with hemophilia a   biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of eloctate fampyra® prolongedrelease fampridine tablets multiple sclerosis walking ability   marketed by biogen in markets outside of the united states commercialized in the united states as ampyra dalfampridine extended release tablets by acorda therapeutics fumaderm™ fumaric acid esters psoriasis german use  germany only approved in germany acquired in acquisition of fumapharm ag in  gazyva® obinutuzumab chronic lymphocytic leukemia   the first medicine approved with the fda’s breakthrough therapy designation and is also currently in phase  trials for nhl and diffuse large bcell lymphoma currently commercialized in the united states by genentech a wholly owned subsidiary of roche spinraza™ nusinersen spinal muscular atrophy  — the first drug approved for the treatment of spinal muscular atrophy developed in collaboration with ionis pharmaceuticals eu approval process under way plegridy™ peginterferon betaa relapsing forms of multiple sclerosis   rituxan® rituximab nonhodgkins lymphoma nhl antitnf refractory rheumatoid arthritis ancaassociated vasculitis chronic lymphocytic leukemia     as mabthera the first monoclonal antibody for cancer developed by idec prior to merging with biogen currently commercialized by roche and its subsidiary genentech tecfidera® dimethyl fumarate relapsing forms of multiple sclerosis   tysabri® natalizumab relapsingremitting multiple sclerosis  reintroduced in   full rights purchased from partner elan in  pipelineedit biogen has focused its rd efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology hematology and immunology investigational ms medicines daclizumab highyield process dac hyp is being developed as a potential oncemonthly subcutaneous injection in the treatment of relapsingremitting multiple sclerosis rrms dac hyp is being developed in collaboration with abbvie inc in june  the companies announced positive topline results from the phase iii decide clinical trial where dac hyp demonstrated superiority over interferon betaa in annualized relapse rate antilingo biib opicinumab is the first candidate being investigated for its potential to remyelinate and repair neurons damaged by ms currently in phase  trials biogen has several candidates in phase  and  clinical trials in neurodegenerative and immunological diseases including ms alzheimer’s disease neuropathic pain spinal muscular atrophy and lupus nephritis phase a antilingo molecule opicinumab in acute optic neuritis phase b antitweak monoclonal antibody in lupus nephritis phase a stx in patients with idiopathic pulmonary fibrosis phase  neublastin for neuropathic pain in  phase  biib aducanumab biogen’s first clinical study in alzheimer’s disease phase  biib isissodrx for amyotrophic lateral sclerosis als in collaboration with ionis biogen also has several development agreements in place with ionis pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders in february  biogen formalized a joint venture with samsung creating samsung bioepis this joint venture brings biogen’s expertise and capabilities in protein engineering cell line development and recombinant biologics manufacturing to position the joint venture so biogen can participate in the emerging market for biosimilars in early  biogen entered into an agreement with eisai inc to jointly develop and commercialize two of their candidates for alzheimer’s disease which have the potential to reduce aβ plaques that form in the brains of patients as well as to slow the formation of new plaques potentially improving symptoms and suppressing disease progression referencesedit  a b biogen inc k report  securities and exchange commission retrieved november    biotechs comeback kid forbes retrieved    idec to merge with biogen in  billion deal new york times retrieved    biogen drops idec from name wall street journal retrieved    biogen idec inc stock quote  summary data nasdaq   httpwwwpharmatimescomnewsbiogenidecagreestobuyswisscompanyfumapharm  httpwwwbusinesswirecomnewshomeenbiogenidecacquirefumapharmagconsolidatesownership  httpwwwfiercebiotechcombiotechbiogentobuysyntonixmdeal  httpwwwbusinesswirecomnewshomeenbiogenidecacquiresyntonix  httpswwwbloombergcomnewsarticlesbiogentopayelanbillionforfulltysabrirights  biogen idec snaps up convergence for uptom  gen news highlights  gen   biogen is cutting  of its workforce   dsouza savio may   biogen to spin off hemophilia drug business into a public company reuters retrieved may     amid takeover chatter biogen introduces hemophilia spinoff bioverativ  fiercepharma   httpwwwbusinesswirecomnewsfinancialpostenbiogenannouncesbioverativhemophiliafocusedcompany  biogen unveils name for hemophilia drug spinoff bioverativ  the boston globe   biogen announces bioverativ as name of new hemophiliafocused company  biogen media   biogen idec inc biib top compensated officers business week retrieved    biogen announces departure of tony kingsley  business wire wwwbusinesswirecom retrieved    biogen idec biib chairman young to retire streetinsidercom retrieved    does biogen idec inc have a new blockbuster hemophilia therapy the motley fool retrieved    avonex national ms society   biogen idec’s eloctate gains fda approval the pharma letter retrieved    fampridine fampyra ms trust   biogen idec enters deal to acquire fumapharm first word pharma retrieved    fda approves gazyva for chronic lymphocytic leukemia fdagov retrieved    wadman meredith  december  updated fda approves drug that rescues babies with fatal neurodegenerative disease science   grant charley  surprise drug approval is holiday gift for biogen wall street journal issn  retrieved    biogen idec’s plegridy™peginterferon betaa approved in the us for the treatment of multiple sclerosis reuters   biogen idec’s plegridy approved in europe for relapsingremitting multiple sclerosis the pharma letter   fda approval for rituximab national cancer institute   update roche biogen end dispute over rituxan followons reuters retrieved    fda approves rituxan to treat two rare disorders fdagov retrieved    cell therapeutics buys zevalin from biogen idec for m with up to m extra plus milestones the pharma letter retrieved    tecifedra national ms society   tysabri national ms society   oncemonthly ms drug from biogen idec abbvie clears phase iii hurdle fierce biotech retrieved    lingo a promising remyelination target in ms multiple sclerosis research retrieved    aducanumab reduces amyloid plaques in early alzheimers prime   isis pharmaceuticals and biogen idec fierce biotech   biogen sees eloctate fda delay pushing marketing to mid businessweek retrieved    isis pharmaceuticals and biogen idec fierce biotech  external linksedit official website business data for biogen google finance yahoo finance reuters sec filings v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies companies portal coordinates °′″n °′″w﻿  ﻿°n °w﻿    retrieved from httpsenwikipediaorgwindexphptitlebiogenoldid categories companies in the nasdaq indexcompanies listed on nasdaqcompanies in the nasdaq biotechnology indexcompanies based in cambridge massachusettsbiotechnology companies of the united statesnational medal of technology recipientspharmaceutical companies of the united statespharmaceutical companies established in  establishments in massachusettsorphan drug companieslife sciences industry establishments in switzerlandbiotechnology companies established in spinal muscular atrophycompanies formed by mergerhealth care companies based in massachusettshidden categories pages using infobox company with unsupported parameterscoordinates not on wikidata navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdeutschفارسیfrançaisportuguêssuomi edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view research  pipeline avonex®  interferon betaa fampyra® prolongedrelease fampridine tablets plegridy® peginterferon betaa tecfidera® dimethyl fumarate tysabri® natalizumab zinbryta® daclizumab spinraza® nusinersen benepali®  etanercept flixabi® infliximab gazyva® obinutuzumab rituxan® rituximab x corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom x menu close about us about us overview about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance research  pipeline research  pipeline overview pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal therapies therapies overview multiple sclerosis spinal muscular atrophy biosimilars partnered global impact global impact overview science that matters biogen foundation community lab supplier diversity grants office newsroom newsroom newsroom latest press releases events and webcasts patients medical professionals careers investors therapy sites therapy sites avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinraza® benepali®  flixabi® gazyva® rituxan® global sites global sites corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom about us research  pipeline therapies global impact newsroom home through cuttingedge science and medicine biogen discovers develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases x about us at biogen we develop market and manufacture therapies for people living with serious neurological autoimmune and rare diseases explore about us about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance x research  pipeline we aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry to us that means creating novel medicines that benefit individuals and society and bringing new scientific understanding to diseases for which there are no adequate treatments explore research  pipeline pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal x therapies we develop and provide therapies to people living with serious diseases like multiple sclerosis explore therapies multiple sclerosis avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinal muscular atrophy spinraza® biosimilars benepali®  flixabi® partnered gazyva® rituxan® x global impact working to make a positive impact for our patients the communities where we work and live and for society explore global impact science that matters biogen foundation community lab supplier diversity grants office x newsroom explore biogen’s latest news releases and media resources explore newsroom latest press releases events and webcasts x patients we work to transform the lives of the patients we serve meeting their individual needs is what drives our science and provides our focus supporting patients supporting patients x medical professionals at biogen we work with healthcare professionals to ensure the therapies we create can reach those that need them disclosure x careers everyone at biogen plays a vital role in the discovery and delivery of breakthrough therapies explore career opportunities at biogen internship  coop disclosure disclaimer fraudulent job postings x investors find current and historical stock information financial statements and reports or view upcoming events and latest webcasts read more annual report  annual report  annual report  x privacy policy our privacy policy outlines the policies and practices in place to safeguard personal information x terms  conditions these terms and conditions of use describe the terms and conditions applicable to your use of biogen inc’s “biogen” website x forwardlooking statements x community guidelines we use social media as part of our commitment to transparency and to provide information to our customers and stakeholders x sitemap x search x  x leadership hub vounatsos michel alexander susan ehlers michael kress jeanpaul mckenzie paul sandrock alfred papadopoulos stelios denner alexander dorsa caroline leaming nancy mulligan richard pangia robert posner brian rowinsky eric schenk lynn sherwin stephen vounatsos michel gregory ginger x scientist hub huang ron xiao guangqing dunah anthone peters rob oterogutierrez karel mikulskis alvydas goyal jaya silvian laura cosentino mark burkly linda wang qin mingueneau michaël arnold moore gardet agnès staropoli john juhasz peter bussiere thierry pepinsky robert blake wei dong weinreb paul coomaraswamy janaky stevenson lauren rabah dania mi sha wipke brian sun chao shen chase lin edward gianni davide thankamony sai hamann stefan lalioti maria kankel mark sen anindya donelson nathan enyedy istvan trinh kien ryan sarah xin zhili arndt joe ren shuyu cahirmcfarland ellen li kejie subramanyam meena stebbins christopher carulli john weihofen andreas larigan doug mccampbell alexander cameron thomas narayanan sarav lydeard john hronowski xiaoping wei ru martin jeffrey smith benjamin ehrenfels chris valencia antonio mccurley amy rushe mia preyer martin bajrami bekim henderson chris ransohoff richard danos olivier x therapies pmultiple sclerosisp pspinal muscular atrophyp pbiosimilarsp ppartneredp x story hub craig melanie michelle richard daniel kate rosemarie x our people hub bob k judann a cherie b pinky p mike g amanda m vinay b ehs award x bioverativ privacy policy x pipeline filter by all disease areas all disease areas alzheimers disease amyotrophic lateral sclerosis als fibrosis lupus lymphoma multiple sclerosis ms myotonic dystrophy ophthalmology parkinsons disease progressive supranuclear palsy psp spinal muscular atrophy sma stroke trigeminal neuralgia all phases all phases filed phase  phase  phase  phase phase   phase  phase  filed aducanumab aβ mab alzheimer’s disease developed in collaboration with neurimmune alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in  the brain aducanumab is an antibody that binds to and may reduce amyloid plaques from the brain potentially slowing the progress of the disease more information about our aducanumab clinical trials  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  e bace inhibitor alzheimers disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain e is a smallmolecule inhibitor of betasecretase a protein that cleaves enzyme  bace by inhibiting bace e blocks amyloid production potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  ban aβ mab alzheimer’s disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain ban is an antibody that binds to amyloid which could reduce its presence in the brain and potentially slow the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  bg stx idiopathic pulmonary fibrosis ipf pulmonary fibrosis is a disease in which lung tissue becomes thickened and stiff due to scarring the formation of scar tissue is called fibrosis as the disease progresses it becomes harder for the lungs to work properly and the body cannot get the oxygen it needs this debilitating disease is almost always fatal how this therapy could help the tgfbeta brain cell pathway is involved in several fibrotic diseases the bg stx antibody may selectively block the tgfbeta pathway and may slow the development of fibrosis in ipf patients biib antibdca lupus this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help bdca is a protein present in specific cells within the immune system an antibody against bdca can potentially interrupt production of interferons inflammatory molecules that are increased in patients with lupus and contribute to disease activity  biib nav inhibitor trigeminal neuralgia tgn acquired in acquisition of convergence pharmaceuticals trigeminal neuralgia is an extremely painful condition usually involving one side of the face trigeminal neuralgia is characterized by sudden brief stabbing recurrent episodes of pain which frequently occurs spontaneously but is also commonly evoked by trivial stimuli including washing shaving smoking talking andor brushing the teeth trigger factors the pain follows one or more branches of the trigeminal nerve which provides nerve sensation from the mouth face and the front of the scalp the intensity of the pain and its unpredictability results in profound effects on the quality of life of patients how this therapy could help biib nav inhibitor is a novel state dependent small molecule sodium channel blocker that preferentially inhibits the nav  ion channel a therapeutic target implicated by genetics in human pain conditions biib is thought to penetrate the central nervous system and block nav channels in a novel manner and has the potential to provide a new and effective option for the treatment of trigeminal neuralgia biib progressive supranuclear palsy psp licensed from bristolmyers squibb progressive supranuclear palsy psp is a rare neurodegenerative disease that affects adults this devastating disease typically advances quickly and affects movement speech vision and cognitive function currently there are no effective therapies for psp how this therapy could help in psp deposits of abnormal tau socalled neurofibrillary tangles form within neurons and are linked to increasing impairment and loss of brain cells biib is an antibody targeting tau which may reduce the spreading of the abnormal form of this molecule from one nerve cell to the next potentially slowing the progression of the disease biib glibencamide iv stroke it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke the target indication for biib glibencamide iv is large hemispheric infarction lhi a severe form of ischemic stroke where brain swelling cerebral edema often leads to a disproportionately large share of strokerelated morbidity and mortality how this therapy could help in preclinical studies biib glibencamide iv has been shown to block surtrpm channels that mediate stroke related brain swelling clinical proofofconcept studies have demonstrated the potential of biib to reduce brain swelling disability and the risk of death in patients with lhi dapirolizumab pegol anticdl lupus developed in collaboration with ucb inc this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help cdl is a protein in b and t cells which helps regulate the immune system dapirolizumab pegol anticdl is an antibody that blocks cdl potentially lessening disease activity in lupus patients natalizumab αintegrin inhibitor acute ischemic stroke currently approved as tysabri® for relapsingremitting multiple sclerosis and crohn’s disease please visit tysabricom for prescribing and safety information it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke  how this therapy could help natalizumab is thought to reduce the inflammatory cells in the brain by blocking the lymphocytic infiltration known to occur in the brain following stroke which may reduce the extent of injury opicinumab antilingo multiple sclerosis ms this disease causes the body’s immune system to attack myelin a protective sheath covering nerve fibers damage to myelin “short circuits” communication between the brain spinal cord and other areas of the body severely impairing such neurological functions as mobility vision and thinking over time the nerves themselves can become damaged permanently how this therapy could help lingo is a cns specificprotein that is involved in the development of myelin in patients with ms lingo may inhibit myelin growth when it binds with its receptor data suggest that the antibody antilingo could block this process potentially allowing for the remyelination and restoration of nerve communication in ms patients xlrs gene therapy xlinked retinoschisis xlrs developed in collaboration with agtc xlrs is a disease that affects young males beginning in their teenage years it can lead to loss of vision and serious complications such as vitreous hemorrhage or retinal detachment during adulthood how this therapy could help the xlrs gene therapy is a recombinant adenoassociated virus vector raav delivering a transgene rs that expresses retinoschisin protein normal expression of retinoschisin could potentially improve longterm retinal function and preserve structural integrity biib antiαsynuclein parkinsons disease acquired from neurimmune parkinsons disease is a disorder of the central nervous system people who have this disease experience tremors slow movement muscle stiffness and impaired balance  as these symptoms become progressively worse patients have difficulty walking talking or completing other simple tasks how this therapy could help biib targets abnormal alphasynuclein protein that is associated with the destruction of nerve cells this progressive degeneration is the cause of parkinsons disease biib ionissodrx sodamyotrophic lateral sclerosis als developed in collaboration with ionis pharmaceuticals als is a progressive neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord motor neurons provide the ability to move speak swallow and breathe as the disease progresses als patients gradually lose these abilities how this therapy could help in a rare form of als a mutated protein called superoxide dismutase sod has been associated with the degeneration of motor neurons  sodals is the second most common form of inherited or familial als accounting for up to  percent of familial als and  percent of all als cases  biib ionissodrx is thought to reduce the production of sod protein and is being evaluated to see if it can potentially slow the fatal progression of sodals biib alzheimers disease alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting tau the protein that forms the deposits or tangles in the brain  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  biib alzheimers disease licensed from bristolmyers squibb alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting tau and may reduce the spreading of tau from one cell to the next potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  currently no results for this search × important notice you are now leaving biogen’s corporate website we encourage you to read and evaluate terms of use privacy security and other similar policies of the destination site as they may differ from biogen’s standards third party sites biogen assumes no responsibility nor does it control endorse or guarantee any aspect of your use of any third party sites additionally the presence of this link does not imply the third party sites endorsement of biogen or this website thank you for visiting our site   cancel continue biogen inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report biogen inc  product pipeline review   published by global markets direct product code  published february   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license biogen inc  product pipeline review   published february   content info  pages description summary global markets directs biogen inc  product pipeline review   provides an overview of the biogen incs pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by biogen inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope the report provides a snapshot of the pipeline therapeutic landscape of biogen inc the report provides overview of biogen inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses biogen incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features biogen incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy evaluate biogen incs strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for biogen inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding biogen incs pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures biogen inc snapshot biogen inc overview key information key facts biogen inc  research and development overview key therapeutic areas biogen inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities pipeline products  outlicensed products outlicensed productscombination treatment modalities biogen inc  pipeline products glance biogen inc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities biogen inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities biogen inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities biogen inc  drug profiles coagulation factor ix recombinant fc fusion protein product description mechanism of action rd progress rituximab product description mechanism of action rd progress aducanumab product description mechanism of action rd progress amiselimod hydrochloride product description mechanism of action rd progress bg product description mechanism of action rd progress natalizumab product description mechanism of action rd progress opicinumab product description mechanism of action rd progress raxatrigine hydrochloride product description mechanism of action rd progress bg product description mechanism of action rd progress biib product description mechanism of action rd progress biib product description mechanism of action rd progress biib product description mechanism of action rd progress biib product description mechanism of action rd progress dapirolizumab pegol product description mechanism of action rd progress d product description mechanism of action rd progress cnv product description mechanism of action rd progress cnv product description mechanism of action rd progress cnv product description mechanism of action rd progress gene therapy for hemophilia b product description mechanism of action rd progress ni product description mechanism of action rd progress ni product description mechanism of action rd progress prt product description mechanism of action rd progress recombinant interleukin to agonize gmcsfr for alzheimers disease and brain injury product description mechanism of action rd progress recombinant protein to agonize gmcsfr for alzheimers disease and brain injury product description mechanism of action rd progress recombinant protein to replace factor viii for hemophilia a product description mechanism of action rd progress small molecule to antagonize gpr for chronic pain product description mechanism of action rd progress small molecule to antagonize py for osteoarthritic pain product description mechanism of action rd progress small molecule to inhibit mpges for chronic pain product description mechanism of action rd progress small molecules to agonize rorgamma for autoimmune disease product description mechanism of action rd progress biogen inc  pipeline analysis biogen inc  pipeline products by target biogen inc  pipeline products by route of administration biogen inc  pipeline products by molecule type biogen inc  pipeline products by mechanism of action biogen inc  recent pipeline updates biogen inc  dormant projects biogen inc  discontinued pipeline products discontinued pipeline product profiles baminercept alfa bg biib clenoliximab cnf dexpramipexole dihydrochloride naxifylline biogen inc  company statement biogen inc  locations and subsidiaries head office other locations  subsidiaries biogen inc  key manufacturing facilities appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables biogen inc key information biogen inc key facts biogen inc  pipeline by indication  biogen inc  pipeline by stage of development  biogen inc  monotherapy products in pipeline  biogen inc  partnered products in pipeline  biogen inc  partnered products combination treatment modalities  biogen inc  outlicensed products in pipeline  biogen inc  outlicensed products combination treatment modalities  biogen inc  preregistration  biogen inc  phase iii  biogen inc  phase ii  biogen inc  phase i  biogen inc  preclinical  biogen inc  discovery  biogen inc  pipeline by target  biogen inc  pipeline by route of administration  biogen inc  pipeline by molecule type  biogen inc  pipeline products by mechanism of action  biogen inc  recent pipeline updates  biogen inc  dormant developmental projects biogen inc  discontinued pipeline products  biogen inc other locations biogen inc subsidiaries biogen inc key manufacturing facilities list of figures biogen inc  pipeline by top  indication  biogen inc  pipeline by stage of development  biogen inc  monotherapy products in pipeline  biogen inc  partnered products in pipeline  biogen inc  outlicensed products in pipeline  biogen inc  pipeline by top  target  biogen inc  pipeline by route of administration  biogen inc  pipeline by molecule type  biogen inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved biogen inc  company profile from hoover’s  db hoovers menu buy reports  lists how it works united states united kingdom   login company people industry search db hoovers company  people  industry login avention onesource is now db hoovers login here for access to db hoovers db datavision db business browser and isell login for customers of hoovers prior to march   login call   chat software by boldchat start free trial call   chat software by boldchat start free trial search the db hoovers database company company people industry home company information company search company overview  profile company profile information for sales preparation marketing contacts competition revenue  financial available products company report biotechnology product manufacturing industry report pharmaceutical manufacturing industry report competitive reports technology report biogen inccompany information  binney stcambridge ma  united states  † httpwwwbiogencom biogen inc rankings  in fortune  june  sp   in fortunes fastestgrowing companies september   in fortune  june  top  competitors abbott laboratories pfizer inc bayer pharma ag unlock more access to hoover’s build customized email lists  based on your best customer profile learn more about the companies you want to sell to hoover’s has reports on  million companies and  industries  data points are updated each day get real insight written by real people – exclusive research and reviews by our inhouse editorial staff we can deliver our data to your desktop to excel direct to your crm into your custom app or via mobile request your free trial call   today to get started with a free trial   biogen inc company profile with its pipeline full of biotech drugs biogen formerly biogen idec aims to meet the unmet needs of patients around the world the biotech giant is focused on developing treatments in the areas of immunology and neurology its product roster includes bestselling drugs tecfidera and avonex interferon for the treatment of relapsing multiple sclerosis ms tysabri a drug treatment for ms and crohns disease and fampyra which improves walking in adults with ms other products include plegridy for ms founded in  biogen serves customers in more than  countries † some telephone numbers on the hoover’s site may be on a country’s do not call or do not contact list including but not limited to the united kingdom’s ctps or tps registers it is a legal requirement that companies do not make sales or marketing calls to registered numbers these are central opt out registers whereby corporate subscribers and individuals can register their preference not to receive unsolicited sales and marketing telephone calls by using the information provided on the hoover’s sites as the direct marketer you represent and warrant that you will use such information in compliance with all applicable local state national or international laws and regulations including any local do not call registers or marketing regulations and agree to defend indemnify and hold harmless dun  bradstreet and each of its affiliates in the event your use violates such laws and regulations additional biogen inc information sales preparation get relevant industry context to prepare for your next sales call – trends competitors news call prep questions and more marketing campaigns find prospect companies that meet the profile of your best customers to maximize campaign roi strategy  planning identify new market opportunities and new strategies for existing markets credit management  finance determine and track a company’s financial condition related tags cambridge ma united states pharmaceutical manufacturing biotechnology product manufacturing free alerts to changes in your db® credit scores sign up get creditsignal® for free try db credit free for  days get started try db credit free for  days biogen inc  revenue and financial reports  db hoovers menu buy reports  lists how it works united states united kingdom   login company people industry search db hoovers company  people  industry login avention onesource is now db hoovers login here for access to db hoovers db datavision db business browser and isell login for customers of hoovers prior to march   login call   chat software by boldchat start free trial call   chat software by boldchat start free trial search the db hoovers database company company people industry home company information company search company overview  revenue  financial data company profile information for sales preparation marketing contacts competition revenue  financial available products company report biotechnology product manufacturing industry report pharmaceutical manufacturing industry report competitive reports technology report biogen inc revenue and financial data with its pipeline full of biotech drugs biogen formerly biogen idec aims to meet the unmet needs of patients around the world the biotech giant is focused on developing treatments in the areas of immunology and neurology its product roster includes bestselling drugs tecfidera and avonex interferon for the treatment of relapsing multiple sclerosis ms tysabri a drug treatment for ms and crohns disease and fampyra which improves walking in adults with ms other products include plegridy for ms founded in  biogen serves customers in more than  countries financials information for biogen inc track this company’s financial condition view company report request your free trial income statement cash flowbalance sheetcredit rating income statement mil      revenue      gross profit      operating income      net income      diluted eps      cash flow mil    cash at the beginning of the year    net operating cash    net investing cash    net financing cash    net change in cash    cash at end of the year    capital expenditure    assets mil    current assets cash    net receivables    inventories    other income assets    asset summary total current assets    net fixed assets    other noncurrent assets    total assets    liabilities mil    current liabilities accounts payable    short term debt    other current liabilities    liability summary total current liabilities    long term debt    other noncurrent liabilities    total liabilities    stakeholders equity mil    equity preferred stock equity    common stock equity    equity summary total equity    shares outstanding    credit rating medium these businesses have a moderate projected risk of delinquency and a moderate to low risk of failure need to go deeper no problem save time with complex financial data at your fingertips access financial statements sec filings earnings estimates and more call   to talk to a business information consultant request your free trial   free alerts to changes in your db® credit scores sign up get creditsignal® for free try db credit free for  days get started try db credit free for  days biogen inc  product pipeline review   trends share size research report uscanada toll free home global markets direct pharmaceutical biogen inc  product pipeline review   biogen inc  product pipeline review   published by  global markets direct published date  feb  category  pharmaceutical no of pages   pages description table of content check discount biogen inc  product pipeline review  summaryglobal markets directs biogen inc  product pipeline review   provides an overview of the biogen incs pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by biogen inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basisthe report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantagenote certain sections in the report may be removed or altered based on the availability and relevance of datascope the report provides a snapshot of the pipeline therapeutic landscape of biogen inc the report provides overview of biogen inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities  the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages  the report assesses biogen incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type  the report features biogen incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projectsreasons to buy evaluate biogen incs strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  identify and understand important and diverse types of therapeutics under development for biogen inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding biogen incs pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contentstable of contents list of tables list of figures biogen inc snapshot biogen inc overview key information key facts biogen inc  research and development overview key therapeutic areas biogen inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities pipeline products  outlicensed products outlicensed productscombination treatment modalities biogen inc  pipeline products glance biogen inc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities biogen inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities biogen inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities biogen inc  drug profiles coagulation factor ix recombinant fc fusion protein product description mechanism of action rd progress rituximab product description mechanism of action rd progress aducanumab product description mechanism of action rd progress amiselimod hydrochloride product description mechanism of action rd progress bg product description mechanism of action rd progress natalizumab product description mechanism of action rd progress opicinumab product description mechanism of action rd progress raxatrigine hydrochloride product description mechanism of action rd progress bg product description mechanism of action rd progress biib product description mechanism of action rd progress biib product description mechanism of action rd progress biib product description mechanism of action rd progress biib product description mechanism of action rd progress dapirolizumab pegol product description mechanism of action rd progress d product description mechanism of action rd progress cnv product description mechanism of action rd progress cnv product description mechanism of action rd progress cnv product description mechanism of action rd progress gene therapy for hemophilia b product description mechanism of action rd progress ni product description mechanism of action rd progress ni product description mechanism of action rd progress prt product description mechanism of action rd progress recombinant interleukin to agonize gmcsfr for alzheimers disease and brain injury product description mechanism of action rd progress recombinant protein to agonize gmcsfr for alzheimers disease and brain injury product description mechanism of action rd progress recombinant protein to replace factor viii for hemophilia a product description mechanism of action rd progress small molecule to antagonize gpr for chronic pain product description mechanism of action rd progress small molecule to antagonize py for osteoarthritic pain product description mechanism of action rd progress small molecule to inhibit mpges for chronic pain product description mechanism of action rd progress small molecules to agonize rorgamma for autoimmune disease product description mechanism of action rd progress biogen inc  pipeline analysis biogen inc  pipeline products by target biogen inc  pipeline products by route of administration biogen inc  pipeline products by molecule type biogen inc  pipeline products by mechanism of action biogen inc  recent pipeline updates biogen inc  dormant projects biogen inc  discontinued pipeline products discontinued pipeline product profiles baminercept alfa bg biib clenoliximab cnf dexpramipexole dihydrochloride naxifylline biogen inc  company statement biogen inc  locations and subsidiaries head office other locations  subsidiaries biogen inc  key manufacturing facilities appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesbiogen inc key information biogen inc key facts biogen inc  pipeline by indication  biogen inc  pipeline by stage of development  biogen inc  monotherapy products in pipeline  biogen inc  partnered products in pipeline  biogen inc  partnered products combination treatment modalities  biogen inc  outlicensed products in pipeline  biogen inc  outlicensed products combination treatment modalities  biogen inc  preregistration  biogen inc  phase iii  biogen inc  phase ii  biogen inc  phase i  biogen inc  preclinical  biogen inc  discovery  biogen inc  pipeline by target  biogen inc  pipeline by route of administration  biogen inc  pipeline by molecule type  biogen inc  pipeline products by mechanism of action  biogen inc  recent pipeline updates  biogen inc  dormant developmental projects biogen inc  discontinued pipeline products  biogen inc other locations biogen inc subsidiaries biogen inc key manufacturing facilities list of figuresbiogen inc  pipeline by top  indication  biogen inc  pipeline by stage of development  biogen inc  monotherapy products in pipeline  biogen inc  partnered products in pipeline  biogen inc  outlicensed products in pipeline  biogen inc  pipeline by top  target  biogen inc  pipeline by route of administration  biogen inc  pipeline by molecule type  biogen inc  pipeline products by top  mechanism of action   make an enquiry before buying this report please fill the enquiry form below full name  your email  job title  company  phone no  pls affix country code message security code   choose license type  select user license single license user  multiple license user  do you wish to check sample of this report order a sample report have query on this report related news tetraphases antibiotic eravacycline succeeds stage clinical trial sperm count in men across developed countries declining sharply study greenland darkens with fear of rising sea level intensifying microsoft paint moving towards retirement declares microsoft grab gets us bn funding from didi and softbank research assistance we will be happy to help you find what you need please call us or write to us  uscanada toll free tel   email  salesresearchmozus biogen company information  drugscom skip to content search all allconsumerprofessionalpill idinteractionsnewsfda alertsapprovalspipelineclinical trialscare notesencyclopediadictionarynatural products browse all medications a b c d e f g h i j k l m n o p q r s t u v w x y z advanced search topics  tools facebook twitter google plus sign in sign in register menu home › pharmaceutical companies › biogen print share biogen address biogen  binney street cambridge ma contact detailsphone  website httpswwwbiogencomcareers httpswwwbiogencomenuscareershtml drugs associated with biogenbiogen manufactures markets andor distributes more than  drugs in the united states medications listed here may also be marketed under different names in different countries nonus country and region specific information is not available on this page brandgeneric name average user rating alprolix generic name coagulation factor ix class miscellaneous coagulation modifiers na avonex generic name interferon betaa class interferons      eloctate generic name antihemophilic factor class miscellaneous coagulation modifiers      gazyva generic name obinutuzumab class cd monoclonal antibodies na plegridy generic name peginterferon betaa class interferons      rituxan generic name rituximab class antirheumatics cd monoclonal antibodies      spinraza generic name nusinersen class miscellaneous uncategorized agents na tecfidera generic name dimethyl fumarate class selective immunosuppressants      tysabri generic name natalizumab class selective immunosuppressants      zinbryta generic name daclizumab class interleukin inhibitors na latest drug information updates vosevi vosevi sofosbuvir  velpatasvir  voxilaprevir is a singletablet regimen for the treatment of adults withnerlynx nerlynx neratinib is a tyrosine kinase inhibitor for the extended adjuvant treatment of patients with earlytremfya tremfya guselkumab is an interleukin blocker indicated for the treatment of adult patients withbevyxxa bevyxxa betrixaban is an oral oncedaily factor xa inhibitor anticoagulant for the extendeddurationrituxan hycela rituxan hycela rituximab and hyaluronidase human is a subcutaneous monoclonal antibody and hyaluronidasebaxdela baxdela delafloxacin is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin more drug information updates drugscom mobile apps the easiest way to lookup drug information identify pills check interactions and set up your own personal medication records available for android and ios devices explore apps support help center frequent questions sitemap contact us about about drugscom advertising policy content submissions drugscom blog terms  privacy editorial policy privacy policy terms of use attribution  citations facebook twitter google plus youtube rss feed subscribe to receive email notifications whenever new articles are published drugscom provides accurate and independent information on more than  prescription drugs overthecounter medicines and natural products this material is provided for educational purposes only and is not intended for medical advice diagnosis or treatment data sources include micromedex® updated july th  cerner multum™ updated july th  wolters kluwer™ updated july th  and others to view content sources and attributions please refer to our editorial policy third party advertising we comply with the honcode standard for trustworthy health information  verify here copyright   drugscom all rights reserved share on facebook share on twitter share on googleplus email to a friend hide biogen inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports biogen inc  product pipeline review   biogen inc  product pipeline review   wgr  february  global  pages global markets direct description table of content sample report enquiry before buy related reports biogen inc  product pipeline review   summary global markets direct’s ‘biogen inc  product pipeline review  ’ provides an overview of the biogen inc’s pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by biogen inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope  the report provides a snapshot of the pipeline therapeutic landscape of biogen inc  the report provides overview of biogen inc including its business description key facts and locations and subsidiaries  the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities  the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages  the report assesses biogen inc’s pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type  the report features biogen inc’s outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy  evaluate biogen inc’s strategic position with total access to detailed information on its product pipeline  gain strategically significant competitor information analysis and insights to formulate effective rd strategies  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  identify and understand important and diverse types of therapeutics under development for biogen inc  identify potential new clients or partners in the target demographic  plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics  devise corrective measures for pipeline projects by understanding biogen inc’s pipeline depth and focus of pipeline therapeutics  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents table of contents  list of tables  list of figures  biogen inc snapshot  biogen inc overview  key information  key facts  biogen inc  research and development overview  key therapeutic areas  biogen inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  pipeline products  outlicensed products  outlicensed productscombination treatment modalities  biogen inc  pipeline products glance  biogen inc  late stage pipeline products  preregistration productscombination treatment modalities  phase iii productscombination treatment modalities  biogen inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  biogen inc  early stage pipeline products  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  biogen inc  drug profiles  coagulation factor ix recombinant fc fusion protein  product description  mechanism of action  rd progress  rituximab  product description  mechanism of action  rd progress  aducanumab  product description  mechanism of action  rd progress  amiselimod hydrochloride  product description  mechanism of action  rd progress  bg  product description  mechanism of action  rd progress  natalizumab  product description  mechanism of action  rd progress  opicinumab  product description  mechanism of action  rd progress  raxatrigine hydrochloride  product description  mechanism of action  rd progress  bg  product description  mechanism of action  rd progress  biib  product description  mechanism of action  rd progress  biib  product description  mechanism of action  rd progress  biib  product description  mechanism of action  rd progress  biib  product description  mechanism of action  rd progress  dapirolizumab pegol  product description  mechanism of action  rd progress  d  product description  mechanism of action  rd progress  cnv  product description  mechanism of action  rd progress  cnv  product description  mechanism of action  rd progress  cnv  product description  mechanism of action  rd progress  gene therapy for hemophilia b  product description  mechanism of action  rd progress  ni  product description  mechanism of action  rd progress  ni  product description  mechanism of action  rd progress  prt  product description  mechanism of action  rd progress  recombinant interleukin to agonize gmcsfr for alzheimers disease and brain injury  product description  mechanism of action  rd progress  recombinant protein to agonize gmcsfr for alzheimers disease and brain injury  product description  mechanism of action  rd progress  recombinant protein to replace factor viii for hemophilia a  product description  mechanism of action  rd progress  small molecule to antagonize gpr for chronic pain  product description  mechanism of action  rd progress  small molecule to antagonize py for osteoarthritic pain  product description  mechanism of action  rd progress  small molecule to inhibit mpges for chronic pain  product description  mechanism of action  rd progress  small molecules to agonize rorgamma for autoimmune disease  product description  mechanism of action  rd progress  biogen inc  pipeline analysis  biogen inc  pipeline products by target  biogen inc  pipeline products by route of administration  biogen inc  pipeline products by molecule type  biogen inc  pipeline products by mechanism of action  biogen inc  recent pipeline updates  biogen inc  dormant projects  biogen inc  discontinued pipeline products  discontinued pipeline product profiles  baminercept alfa  bg  biib  clenoliximab  cnf  dexpramipexole dihydrochloride  naxifylline  biogen inc  company statement  biogen inc  locations and subsidiaries  head office  other locations  subsidiaries  biogen inc  key manufacturing facilities  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables biogen inc key information  biogen inc key facts  biogen inc  pipeline by indication   biogen inc  pipeline by stage of development   biogen inc  monotherapy products in pipeline   biogen inc  partnered products in pipeline   biogen inc  partnered products combination treatment modalities   biogen inc  outlicensed products in pipeline   biogen inc  outlicensed products combination treatment modalities   biogen inc  preregistration   biogen inc  phase iii   biogen inc  phase ii   biogen inc  phase i   biogen inc  preclinical   biogen inc  discovery   biogen inc  pipeline by target   biogen inc  pipeline by route of administration   biogen inc  pipeline by molecule type   biogen inc  pipeline products by mechanism of action   biogen inc  recent pipeline updates   biogen inc  dormant developmental projects  biogen inc  discontinued pipeline products   biogen inc other locations  biogen inc subsidiaries  biogen inc key manufacturing facilities  list of figures biogen inc  pipeline by top  indication   biogen inc  pipeline by stage of development   biogen inc  monotherapy products in pipeline   biogen inc  partnered products in pipeline   biogen inc  outlicensed products in pipeline   biogen inc  pipeline by top  target   biogen inc  pipeline by route of administration   biogen inc  pipeline by molecule type   biogen inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send biogen  neurological autoimmune and rare diseases cookies this website intends to use cookies to improve the site and your experience by continuing to browse the site you are agreeing to accept our use of cookies  if you require further information andor do not wish to have cookies placed when using the site you can modify your browser settings appropriately or you may visit our internet privacy page  accept x corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom x menu close about us about us overview the company biogen international contact us research  pipeline research  pipeline overview our pipeline clinical trials collaborations medical research portal therapies therapies overview multiple sclerosis spinal muscular atrophy biosimilars partnered therapies responsibility responsibility overview global impact supporting patients community  foundation acting responsibly grants office newsroom newsroom overview corporate press releases corporate perspectives patients medical professionals investors careers global sites global sites corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom about us research  pipeline therapies responsibility newsroom home biogen develops manufactures and markets innovative therapies for patients living with serious neurological autoimmune and rare diseases x about us at biogen we develop market and manufacture therapies for people living with serious neurological autoimmune and rare diseases learn more about biogen the company about biogen leadership history manufacturing biosimilars public policy biogen international international headquarters management biologics manufacturing facility contact us x research  pipeline we aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry to us that means creating novel medicines that benefit individuals and society and bringing new scientific understanding to diseases for which there are no adequate treatments see what we are working on our pipeline clinical trials collaborations medical research portal x therapies we develop medicines for serious medical conditions with few or no treatment options every day we work to bring patients better outcomes and advance their standard of care explore our therapeutic areas multiple sclerosis spinal muscular atrophy biosimilars partnered therapies x responsibility working to make a positive impact for our patients the communities where we work and live and for society read more global impact supporting patients community  foundation acting responsibly grants office x newsroom explore the latest biogen news and insights see the latest corporate press releases corporate perspectives x careers explore career opportunities at biogen and experience the fulfillment that comes from helping to discover manufacture and market new treatments for patients read more working at biogen international biologics manufacturing facility local rewards and benefits find job listings growing your career x patients we work to transform the lives of the patients we serve meeting their individual needs is what drives our science and provides our focus read more patient stories x medical professionals at biogen we work with healthcare professionals to ensure the therapies we create can reach those that need them read more disclosure doccheck login page x investors find current and historical stock information financial statements and reports or view upcoming events and latest webcasts read more annual report  annual report  x privacy policy cookies x terms  conditions these terms and conditions of use describe the terms and conditions applicable to your use of biogen inc’s “biogen” website find out more x sitemap x search x  x story hub craig melanie michelle richard daniel kate rosemarie x localcards x card design catalogue x biogencardrepository x doccheck login page x regional policies x our commitment to sma  working to improve the lives of people with sma learn more a transformative age of neurology as a leading company in the fight against multiple sclerosis biogen is applying its expertise to help address some of most challenging and complex diseases of the brain learn more caring deeply changing livestm the same passion that drives our science is reflected in our corporate citizenship environmental sustainability and commitment to diversity learn more impact for patients we aspire to have the greatest impact on patients of any biotechnology company in the history of our industry learn more our commitment to sma  working to improve the lives of people with sma learn more a transformative age of neurology as a leading company in the fight against multiple sclerosis biogen is applying its expertise to help address some of most challenging and complex diseases of the brain learn more caring deeply changing livestm the same passion that drives our science is reflected in our corporate citizenship environmental sustainability and commitment to diversity learn more impact for patients we aspire to have the greatest impact on patients of any biotechnology company in the history of our industry learn more innovative therapies we develop medicines for debilitating medical conditions with the goal of making a meaningful difference in patients’ lives more about our therapies dedicated to new discoveries our pipeline is more than a list of medicines in development it reflects the work we do here every day to break new ground with science that makes a difference in the lives of patients see full pipeline caring deeply about those around us we understand that what we do matters – to our patients our employees and the communities in which we live and work see how contact us headquarters the americas corporate hq cambridge ma weston ma research triangle park rtp nc washington dc argentina brazil canada chile europe international hq zug switzerland austria belgium czech republic denmark manufacturing denmark finland france germany hungary ireland italy norway poland portugal slovak republic slovenia spain sweden switzerland the netherlands the united kingdom asiaaustralia australia japan new zealand reaching patients with locations worldwide biogen has employees and facilities around the world contact us × important notice you are now leaving biogen internationals website we encourage you to read and evaluate terms of use privacy security and other similar policies of the destination site as they may differ from biogen’s standards third party sites biogen assumes no responsibility nor does it control endorse or guarantee any aspect of your use of any third party sites additionally the presence of this link does not imply the third party sites endorsement of biogen or this website thank you for visiting our site   cancel continue microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft homepage hidechilds  false systemname  homepage   about us our purpose our background our leadership therapies hemophilia a hemophilia b manufacturing research  pipeline our pipeline clinical trials scientific  medical research community support humanitarian aid my life our future patient support sickle cell disease global sites corporate canada japan bioverativ – science matters because patients matter science matters because patients matter learn more   science that redefines whats possible our scientists brought the first major advances in hemophilia treatment in nearly two decades and we’re committed to developing new lifechanging medicines for people with rare blood disorders learn more   expanding access around the world we committed with sobi to donate up to  billion ius of factor therapy to the developing world already more than  people with hemophilia have been treated learn more   bioverativ in the news friday july    am bioverativ to report second quarter  financial results on august   read more our purpose  about us hidechilds  false systemname    about us our purpose our background our leadership therapies hemophilia a hemophilia b manufacturing research  pipeline our pipeline clinical trials scientific  medical research community support humanitarian aid my life our future patient support sickle cell disease global sites corporate canada japan bioverativ is a global biotechnology company dedicated to transforming the lives of people living with hemophilia and other blood disorders creating meaningful progress for patients our purpose at bioverativ we are dedicated to transforming the lives of people with hemophilia cold agglutinin disease and other rare blood disorders as an independent biotechnology company spun out of biogen’s hemophilia business we bring a strong legacy of innovation worldclass science and commitment to the rare blood disorders community we are united by a singular purpose to create progress where patients need it most we believe that great science conquers the toughest medical obstacles and we are inspired to push scientific boundaries to make a meaningful impact in the lives of people with rare blood disorders beginning with hemophilia we will lead by doing what’s right for patients and those who care for them and by actively working with the blood disorders community to accelerate innovation and develop lifechanging treatments   john g cox ceo our hemophilia therapies were the first major advancements in the treatment of hemophilia a and b in nearly two decades and are the first extended halflife clotting factors introduced to patients we will continue to explore the potential benefits and better understand the science of these therapies in areas of serious need including immune tolerance induction in hemophilia patients who develop inhibitors longterm joint health and women with bleeding disorders in the same spirit as in hemophilia we will carry forward a commitment to significantly impact the lives of people with other rare blood disorders including cold agglutinin disease sickle cell disease and beta thalassemia press releases watch creating progress together together we are committed to making a significant positive impact for patients and society through innovative programs that aim to improve access to treatment advance disease understanding and create true partnership with the community our commitment to that purpose is reflected in our name “bio” refers to our legacy of scientific innovation which we will build upon and “ver” refers to the latin word veritas meaning truth “ativ” is based on the word active —we will actively work with the community build trust and create change for patients × therapies hidechilds  false systemname    about us our purpose our background our leadership therapies hemophilia a hemophilia b manufacturing research  pipeline our pipeline clinical trials scientific  medical research community support humanitarian aid my life our future patient support sickle cell disease global sites corporate canada japan building on a legacy of innovation we’re dedicated to creating meaningful progress for people with hemophilia and other blood disorders delivering innovative therapies therapies hemophilia a eloctate®  read more  hemophilia b alprolix®  read more  manufacturing delivering quality medicine read more   bioverativ was formed by a spinoff of biogen’s hemophilia business biogen has initiated the transfer of various licenses including the biologics license applications for eloctate® and alprolix® until the transfers are completed bioverativ and biogen will have a relationship to the products contact us with any questions   our pipeline  research  pipeline hidechilds  false systemname    about us our purpose our background our leadership therapies hemophilia a hemophilia b manufacturing research  pipeline our pipeline clinical trials scientific  medical research community support humanitarian aid my life our future patient support sickle cell disease global sites corporate canada japan bioverativ’s research pipeline shows our scientists’ commitment to the discovery and development of new medicines to address areas of serious need for patients including hemophilia sickle cell disorders moving science forward to benefit patients our pipeline leaders in their fields our scientists are deeply committed to the discovery and development of new medicines to address areas of serious need for patients leveraging our deep understanding of the biology of hemostasis gained over  years of research we plan to accelerate the development of our innovative pipeline of programs in hemophilia cold agglutinin disease sickle cell disease beta thalassemia and other blood disorders our pipeline includes hemophilia programs that have been designed to provide lessfrequent prophylactic dosing for hemophilia a and subcutaneous dosing for hemophilia b and gene therapy programs for hemophilia a and b  it also includes programs to address cold agglutinin disease a rare and chronic autoimmune hemolytic condition for which there are no approved therapies bivv formerly tnt is the only therapy in development that is designed to selectively inhibit the classical complement pathway of the immune system bivv targets cs thereby impacting the central mechanism of this disease we are also pursuing several approaches that seek to target the root cause of sickle cell disease a profoundly debilitating disease that is linked to a shorter life expectancy and has few treatment options just as we have done in hemophilia we hope to bring forward new medicines that meaningfully advance the treatment of people with sickle cell disease   drug indication modality discovery preclinical clinical marketed bivv formerly tnt   bivv is a monoclonal antibody in development to treat cold agglutinin disease cagd there are no approved therapies for cagd which occurs in approximately  people per million globally bivv has been granted breakthrough therapy designation by the us fda for the treatment of hemolysis in patients with primary cagd and has also been granted orphan drug designation from the fda and the european medicines agency bivv formerly tnt indication cold agglutinin disease modality biologic   clinical   bivv is a monoclonal antibody in development to treat cold agglutinin disease cagd there are no approved therapies for cagd which occurs in approximately  people per million globally bivv has been granted breakthrough therapy designation by the us fda for the treatment of hemolysis in patients with primary cagd and has also been granted orphan drug designation from the fda and the european medicines agency bivv   bivv also known as rfviiifcvwfxten is a uniquely engineered factor viii molecule with a region of fc dimer von willebrand factor and xten a halflife extension technology licensed from amunix  bivv has been designed to provide onceweekly or less frequent prophylactic dosing intervals for hemophilia a  bivv indication hemophilia a modality biologic   preclinical   bivv also known as rfviiifcvwfxten is a uniquely engineered factor viii molecule with a region of fc dimer von willebrand factor and xten a halflife extension technology licensed from amunix  bivv has been designed to provide onceweekly or less frequent prophylactic dosing intervals for hemophilia a  collaboration with sangamo therapeutics   collaboration with sangamo therapeutics genome editing technology for beta thalassemia and sickle cell disease bioverativ has a worldwide collaboration with sangamo therapeutics for the treatment of inherited conditions that result from the abnormal structure or underproduction of hemoglobin the collaboration combines the extensive expertise of sangamo in developing their genome editing technology with bioverativs deep understanding of hematology our collaboration is focused on the goal of providing a singledose lasting treatment for both sickle cell disease and beta thalassemia collaboration with sangamo therapeutics indication beta thalassemia modality genome editing   preclinical indication sickle cell disease modality genome editing   preclinical   collaboration with sangamo therapeutics genome editing technology for beta thalassemia and sickle cell disease bioverativ has a worldwide collaboration with sangamo therapeutics for the treatment of inherited conditions that result from the abnormal structure or underproduction of hemoglobin the collaboration combines the extensive expertise of sangamo in developing their genome editing technology with bioverativs deep understanding of hematology our collaboration is focused on the goal of providing a singledose lasting treatment for both sickle cell disease and beta thalassemia bivv   bivv also known as rfixfcxten is a novel factor ix fusion protein that combines fc dimer and xten halflife extension technology licensed from amunix along with rl padua factor ix variant in the treatment of hemophilia b bivv has been designed to enable subcutaneous administration of factor ix with a goal of providing weekly or less frequent prophylactic dosing  bivv indication hemophilia b modality biologic   preclinical   bivv also known as rfixfcxten is a novel factor ix fusion protein that combines fc dimer and xten halflife extension technology licensed from amunix along with rl padua factor ix variant in the treatment of hemophilia b bivv has been designed to enable subcutaneous administration of factor ix with a goal of providing weekly or less frequent prophylactic dosing  bivv formerly tnt   bivv is a followon monoclonal antibody to treat cold agglutinin disease targeting activated cs with the potential for less frequent dosing and subcutaneous administration bivv formerly tnt indication cold agglutinin disease modality biologic   preclinical   bivv is a followon monoclonal antibody to treat cold agglutinin disease targeting activated cs with the potential for less frequent dosing and subcutaneous administration collaboration with san raffaeletiget   gene therapy collaboration with san raffaeletiget for the treatment of hemophilia a and b  bioverativ has a worldwide collaboration with the san raffaele telethon institute for gene therapy srtiget to jointly develop gene therapies for the treatment of both hemophilia a and b the collaboration combines the extensive expertise of srtiget in creating new gene therapy strategies and developing them from the bench to bedside with bioverativs deep understanding of hematology to potentially treat the underlying causes of hemophilia a and b  the collaboration centers on tiget’s advanced lentiviral gene transfer technology lentiviral vectors are engineered viruses designed to deliver working versions of defective genes responsible for causing certain diseases into the patients’ cells  the intent of this program is to provide a singledose lasting treatment for hemophilia a and b patients collaboration with san raffaeletiget indication hemophilia a modality gene therapy   discovery indication hemophilia b modality gene therapy   discovery   gene therapy collaboration with san raffaeletiget for the treatment of hemophilia a and b  bioverativ has a worldwide collaboration with the san raffaele telethon institute for gene therapy srtiget to jointly develop gene therapies for the treatment of both hemophilia a and b the collaboration combines the extensive expertise of srtiget in creating new gene therapy strategies and developing them from the bench to bedside with bioverativs deep understanding of hematology to potentially treat the underlying causes of hemophilia a and b  the collaboration centers on tiget’s advanced lentiviral gene transfer technology lentiviral vectors are engineered viruses designed to deliver working versions of defective genes responsible for causing certain diseases into the patients’ cells  the intent of this program is to provide a singledose lasting treatment for hemophilia a and b patients fviiia mimetic bispecific antibody program   fviiia mimetic bispecific antibody program  the aim of this program is to generate a bispecific antibody that better mimics the function of factor viii potentially eliminating the need for fviii in the clotting cascade fviiia mimetic bispecific antibody program indication hemophilia a inhibitors modality biologic   discovery   fviiia mimetic bispecific antibody program  the aim of this program is to generate a bispecific antibody that better mimics the function of factor viii potentially eliminating the need for fviii in the clotting cascade multiple early stage programs   sickle cell disease bioverativ has several small molecule programs in research that target the root cause of sickle cell disease  multiple early stage programs indication sickle cell disease modality sm molecules   discovery   sickle cell disease bioverativ has several small molecule programs in research that target the root cause of sickle cell disease  biogen  neurological and neurodegenerative diseases avonex®  interferon betaa fampyra® prolongedrelease fampridine tablets plegridy® peginterferon betaa tecfidera® dimethyl fumarate tysabri® natalizumab zinbryta® daclizumab spinraza® nusinersen benepali®  etanercept flixabi® infliximab gazyva® obinutuzumab rituxan® rituximab x corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom x menu close about us about us overview about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance research  pipeline research  pipeline overview pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal therapies therapies overview multiple sclerosis spinal muscular atrophy biosimilars partnered global impact global impact overview science that matters biogen foundation community lab supplier diversity grants office newsroom newsroom newsroom latest press releases events and webcasts patients medical professionals careers investors therapy sites therapy sites avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinraza® benepali®  flixabi® gazyva® rituxan® global sites global sites corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom about us research  pipeline therapies global impact newsroom home through cuttingedge science and medicine biogen discovers develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases x about us at biogen we develop market and manufacture therapies for people living with serious neurological autoimmune and rare diseases explore about us about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance x research  pipeline we aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry to us that means creating novel medicines that benefit individuals and society and bringing new scientific understanding to diseases for which there are no adequate treatments explore research  pipeline pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal x therapies we develop and provide therapies to people living with serious diseases like multiple sclerosis explore therapies multiple sclerosis avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinal muscular atrophy spinraza® biosimilars benepali®  flixabi® partnered gazyva® rituxan® x global impact working to make a positive impact for our patients the communities where we work and live and for society explore global impact science that matters biogen foundation community lab supplier diversity grants office x newsroom explore biogen’s latest news releases and media resources explore newsroom latest press releases events and webcasts x patients we work to transform the lives of the patients we serve meeting their individual needs is what drives our science and provides our focus supporting patients supporting patients x medical professionals at biogen we work with healthcare professionals to ensure the therapies we create can reach those that need them disclosure x careers everyone at biogen plays a vital role in the discovery and delivery of breakthrough therapies explore career opportunities at biogen internship  coop disclosure disclaimer fraudulent job postings x investors find current and historical stock information financial statements and reports or view upcoming events and latest webcasts read more annual report  annual report  annual report  x privacy policy our privacy policy outlines the policies and practices in place to safeguard personal information x terms  conditions these terms and conditions of use describe the terms and conditions applicable to your use of biogen inc’s “biogen” website x forwardlooking statements x community guidelines we use social media as part of our commitment to transparency and to provide information to our customers and stakeholders x sitemap x search x  x leadership hub vounatsos michel alexander susan ehlers michael kress jeanpaul mckenzie paul sandrock alfred papadopoulos stelios denner alexander dorsa caroline leaming nancy mulligan richard pangia robert posner brian rowinsky eric schenk lynn sherwin stephen vounatsos michel gregory ginger x scientist hub huang ron xiao guangqing dunah anthone peters rob oterogutierrez karel mikulskis alvydas goyal jaya silvian laura cosentino mark burkly linda wang qin mingueneau michaël arnold moore gardet agnès staropoli john juhasz peter bussiere thierry pepinsky robert blake wei dong weinreb paul coomaraswamy janaky stevenson lauren rabah dania mi sha wipke brian sun chao shen chase lin edward gianni davide thankamony sai hamann stefan lalioti maria kankel mark sen anindya donelson nathan enyedy istvan trinh kien ryan sarah xin zhili arndt joe ren shuyu cahirmcfarland ellen li kejie subramanyam meena stebbins christopher carulli john weihofen andreas larigan doug mccampbell alexander cameron thomas narayanan sarav lydeard john hronowski xiaoping wei ru martin jeffrey smith benjamin ehrenfels chris valencia antonio mccurley amy rushe mia preyer martin bajrami bekim henderson chris ransohoff richard danos olivier x therapies pmultiple sclerosisp pspinal muscular atrophyp pbiosimilarsp ppartneredp x story hub craig melanie michelle richard daniel kate rosemarie x our people hub bob k judann a cherie b pinky p mike g amanda m vinay b ehs award x bioverativ privacy policy x a transformative age of neurology as a leading company in the fight against multiple sclerosis biogen is applying its expertise to help address some of the most challenging and complex diseases of the brain learn more global impact working to make a positive impact for our patients the communities where we work and live and for society learn more watch video a transformative age of neurology as a leading company in the fight against multiple sclerosis biogen is applying its expertise to help address some of the most challenging and complex diseases of the brain learn more global impact working to make a positive impact for our patients the communities where we work and live and for society learn more watch video innovative therapies we develop medicines for debilitating medical conditions with the goal of making a meaningful difference in patients’ lives multiple sclerosis spinal muscular atrophy biosimilars partnered more about our therapies filter by all approved therapies multiple sclerosis spinal muscular atrophy biosimilars partnered multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis spinal muscular atrophy biosimilars biosimilars partnered partnered dedicated to new discoveries our pipeline is more than a list of medicines in development it reflects the work we do here every day to break new ground with science that makes a difference in the lives of patients filter by all disease areas all disease areas alzheimers disease fibrosis inflammatory bowel disease ibd lupus lymphoma multiple sclerosis ms myotonic dystrophy ophthalmology parkinsons disease sjögrens syndrome spinal muscular atrophy sma stroke trigeminal neuralgia all phases all phases filed phase  phase  phase  phase phase   phase  phase  filed aducanumab aβ mab alzheimer’s disease developed in collaboration with neurimmune alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in  the brain aducanumab is an antibody that binds to and may reduce amyloid plaques from the brain potentially slowing the progress of the disease more information about our aducanumab clinical trials  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  e bace inhibitor alzheimers disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain e is a smallmolecule inhibitor of betasecretase a protein that cleaves enzyme  bace by inhibiting bace e blocks amyloid production potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  ban aβ mab alzheimer’s disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain ban is an antibody that binds to amyloid which could reduce its presence in the brain and potentially slow the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  bg stx idiopathic pulmonary fibrosis ipf pulmonary fibrosis is a disease in which lung tissue becomes thickened and stiff due to scarring the formation of scar tissue is called fibrosis as the disease progresses it becomes harder for the lungs to work properly and the body cannot get the oxygen it needs this debilitating disease is almost always fatal how this therapy could help the tgfbeta brain cell pathway is involved in several fibrotic diseases the bg stx antibody may selectively block the tgfbeta pathway and may slow the development of fibrosis in ipf patients biib antibdca lupus this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help bdca is a protein present in specific cells within the immune system an antibody against bdca can potentially interrupt production of interferons inflammatory molecules that are increased in patients with lupus and contribute to disease activity  biib nav inhibitor trigeminal neuralgia tgn acquired in acquisition of convergence pharmaceuticals trigeminal neuralgia is an extremely painful condition usually involving one side of the face trigeminal neuralgia is characterized by sudden brief stabbing recurrent episodes of pain which frequently occurs spontaneously but is also commonly evoked by trivial stimuli including washing shaving smoking talking andor brushing the teeth trigger factors the pain follows one or more branches of the trigeminal nerve which provides nerve sensation from the mouth face and the front of the scalp the intensity of the pain and its unpredictability results in profound effects on the quality of life of patients how this therapy could help biib nav inhibitor is a novel state dependent small molecule sodium channel blocker that preferentially inhibits the nav  ion channel a therapeutic target implicated by genetics in human pain conditions biib is thought to penetrate the central nervous system and block nav channels in a novel manner and has the potential to provide a new and effective option for the treatment of trigeminal neuralgia biib glibenclamide iv stroke it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke the target indication for biib glibenclamide iv is large hemispheric infarction lhi a severe form of ischemic stroke where brain swelling cerebral edema often leads to a disproportionately large share of strokerelated morbidity and mortality how this therapy could help in preclinical studies biib glibenclamide iv has been shown to block surtrpm channels that mediate stroke related brain swelling clinical proofofconcept studies have demonstrated the potential of biib to reduce brain swelling disability and the risk of death in patients with lhi dapirolizumab pegol anticdl lupus developed in collaboration with ucb inc this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help cdl is a protein in b and t cells which helps regulate the immune system dapirolizumab pegol anticdl is an antibody that blocks cdl potentially lessening disease activity in lupus patients natalizumab αintegrin inhibitor acute ischemic stroke currently approved as tysabri® for relapsingremitting multiple sclerosis and crohn’s disease please visit tysabricom for prescribing and safety information it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke  how this therapy could help natalizumab is thought to reduce the inflammatory cells in the brain by blocking the lymphocytic infiltration known to occur in the brain following stroke which may reduce the extent of injury opicinumab antilingo multiple sclerosis ms this disease causes the body’s immune system to attack myelin a protective sheath covering nerve fibers damage to myelin “short circuits” communication between the brain spinal cord and other areas of the body severely impairing such neurological functions as mobility vision and thinking over time the nerves themselves can become damaged permanently how this therapy could help lingo is a cns specificprotein that is involved in the development of myelin in patients with ms lingo may inhibit myelin growth when it binds with its receptor data suggest that the antibody antilingo could block this process potentially allowing for the remyelination and restoration of nerve communication in ms patients xlrs gene therapy xlinked retinoschisis xlrs developed in collaboration with agtc xlrs is a disease that affects young males beginning in their teenage years it can lead to loss of vision and serious complications such as vitreous hemorrhage or retinal detachment during adulthood how this therapy could help the xlrs gene therapy is a recombinant adenoassociated virus vector raav delivering a transgene rs that expresses retinoschisin protein normal expression of retinoschisin could potentially improve longterm retinal function and preserve structural integrity biib antiαsynuclein parkinsons disease acquired from neurimmune parkinsons disease is a disorder of the central nervous system people who have this disease experience tremors slow movement muscle stiffness and impaired balance  as these symptoms become progressively worse patients have difficulty walking talking or completing other simple tasks how this therapy could help biib targets abnormal alphasynuclein protein that is associated with the destruction of nerve cells this progressive degeneration is the cause of parkinsons disease biib alzheimers disease alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting tau the protein that forms the deposits or tangles in the brain  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  biib alzheimers disease licensed from bristolmyers squibb alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting extracellular tau and may reduce the spreading of tau from one cell to the next potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  currently no results for this search see full pipeline our perspectives july   teaming up for als see all perspectives × important notice you are now leaving biogen’s corporate website we encourage you to read and evaluate terms of use privacy security and other similar policies of the destination site as they may differ from biogen’s standards third party sites biogen assumes no responsibility nor does it control endorse or guarantee any aspect of your use of any third party sites additionally the presence of this link does not imply the third party sites endorsement of biogen or this website thank you for visiting our site   cancel continue biogen  neurological and neurodegenerative diseases avonex®  interferon betaa fampyra® prolongedrelease fampridine tablets plegridy® peginterferon betaa tecfidera® dimethyl fumarate tysabri® natalizumab zinbryta® daclizumab spinraza® nusinersen benepali®  etanercept flixabi® infliximab gazyva® obinutuzumab rituxan® rituximab x corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom x menu close about us about us overview about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance research  pipeline research  pipeline overview pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal therapies therapies overview multiple sclerosis spinal muscular atrophy biosimilars partnered global impact global impact overview science that matters biogen foundation community lab supplier diversity grants office newsroom newsroom newsroom latest press releases events and webcasts patients medical professionals careers investors therapy sites therapy sites avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinraza® benepali®  flixabi® gazyva® rituxan® global sites global sites corporate hq international hq argentina australia austria belgium brazil canada chile czech republic denmark finland france germany hungary ireland italy japan the netherlands new zealand norway poland portugal slovak republic slovenia spain sweden switzerland united kingdom about us research  pipeline therapies global impact newsroom home through cuttingedge science and medicine biogen discovers develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases x about us at biogen we develop market and manufacture therapies for people living with serious neurological autoimmune and rare diseases explore about us about biogen a leader in multiple sclerosis executive leadership board of directors history manufacturing biosimilars positions  policy perspectives contact us governance x research  pipeline we aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry to us that means creating novel medicines that benefit individuals and society and bringing new scientific understanding to diseases for which there are no adequate treatments explore research  pipeline pipeline clinical trials access to investigational therapies biogenscience areas of research postdoc program collaborations medical research portal x therapies we develop and provide therapies to people living with serious diseases like multiple sclerosis explore therapies multiple sclerosis avonex®  fampyra® plegridy® tecfidera® tysabri® zinbryta® spinal muscular atrophy spinraza® biosimilars benepali®  flixabi® partnered gazyva® rituxan® x global impact working to make a positive impact for our patients the communities where we work and live and for society explore global impact science that matters biogen foundation community lab supplier diversity grants office x newsroom explore biogen’s latest news releases and media resources explore newsroom latest press releases events and webcasts x patients we work to transform the lives of the patients we serve meeting their individual needs is what drives our science and provides our focus supporting patients supporting patients x medical professionals at biogen we work with healthcare professionals to ensure the therapies we create can reach those that need them disclosure x careers everyone at biogen plays a vital role in the discovery and delivery of breakthrough therapies explore career opportunities at biogen internship  coop disclosure disclaimer fraudulent job postings x investors find current and historical stock information financial statements and reports or view upcoming events and latest webcasts read more annual report  annual report  annual report  x privacy policy our privacy policy outlines the policies and practices in place to safeguard personal information x terms  conditions these terms and conditions of use describe the terms and conditions applicable to your use of biogen inc’s “biogen” website x forwardlooking statements x community guidelines we use social media as part of our commitment to transparency and to provide information to our customers and stakeholders x sitemap x search x  x leadership hub vounatsos michel alexander susan ehlers michael kress jeanpaul mckenzie paul sandrock alfred papadopoulos stelios denner alexander dorsa caroline leaming nancy mulligan richard pangia robert posner brian rowinsky eric schenk lynn sherwin stephen vounatsos michel gregory ginger x scientist hub huang ron xiao guangqing dunah anthone peters rob oterogutierrez karel mikulskis alvydas goyal jaya silvian laura cosentino mark burkly linda wang qin mingueneau michaël arnold moore gardet agnès staropoli john juhasz peter bussiere thierry pepinsky robert blake wei dong weinreb paul coomaraswamy janaky stevenson lauren rabah dania mi sha wipke brian sun chao shen chase lin edward gianni davide thankamony sai hamann stefan lalioti maria kankel mark sen anindya donelson nathan enyedy istvan trinh kien ryan sarah xin zhili arndt joe ren shuyu cahirmcfarland ellen li kejie subramanyam meena stebbins christopher carulli john weihofen andreas larigan doug mccampbell alexander cameron thomas narayanan sarav lydeard john hronowski xiaoping wei ru martin jeffrey smith benjamin ehrenfels chris valencia antonio mccurley amy rushe mia preyer martin bajrami bekim henderson chris ransohoff richard danos olivier x therapies pmultiple sclerosisp pspinal muscular atrophyp pbiosimilarsp ppartneredp x story hub craig melanie michelle richard daniel kate rosemarie x our people hub bob k judann a cherie b pinky p mike g amanda m vinay b ehs award x bioverativ privacy policy x a transformative age of neurology as a leading company in the fight against multiple sclerosis biogen is applying its expertise to help address some of the most challenging and complex diseases of the brain learn more global impact working to make a positive impact for our patients the communities where we work and live and for society learn more watch video a transformative age of neurology as a leading company in the fight against multiple sclerosis biogen is applying its expertise to help address some of the most challenging and complex diseases of the brain learn more global impact working to make a positive impact for our patients the communities where we work and live and for society learn more watch video innovative therapies we develop medicines for debilitating medical conditions with the goal of making a meaningful difference in patients’ lives multiple sclerosis spinal muscular atrophy biosimilars partnered more about our therapies filter by all approved therapies multiple sclerosis spinal muscular atrophy biosimilars partnered multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis spinal muscular atrophy biosimilars biosimilars partnered partnered dedicated to new discoveries our pipeline is more than a list of medicines in development it reflects the work we do here every day to break new ground with science that makes a difference in the lives of patients filter by all disease areas all disease areas alzheimers disease fibrosis inflammatory bowel disease ibd lupus lymphoma multiple sclerosis ms myotonic dystrophy ophthalmology parkinsons disease sjögrens syndrome spinal muscular atrophy sma stroke trigeminal neuralgia all phases all phases filed phase  phase  phase  phase phase   phase  phase  filed aducanumab aβ mab alzheimer’s disease developed in collaboration with neurimmune alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in  the brain aducanumab is an antibody that binds to and may reduce amyloid plaques from the brain potentially slowing the progress of the disease more information about our aducanumab clinical trials  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  e bace inhibitor alzheimers disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain e is a smallmolecule inhibitor of betasecretase a protein that cleaves enzyme  bace by inhibiting bace e blocks amyloid production potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  ban aβ mab alzheimer’s disease developed in collaboration with eisai co ltd alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functionality decline of alzheimer’s disease have been linked to amyloid plaques abnormal protein deposits that build up in the brain ban is an antibody that binds to amyloid which could reduce its presence in the brain and potentially slow the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  bg stx idiopathic pulmonary fibrosis ipf pulmonary fibrosis is a disease in which lung tissue becomes thickened and stiff due to scarring the formation of scar tissue is called fibrosis as the disease progresses it becomes harder for the lungs to work properly and the body cannot get the oxygen it needs this debilitating disease is almost always fatal how this therapy could help the tgfbeta brain cell pathway is involved in several fibrotic diseases the bg stx antibody may selectively block the tgfbeta pathway and may slow the development of fibrosis in ipf patients biib antibdca lupus this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help bdca is a protein present in specific cells within the immune system an antibody against bdca can potentially interrupt production of interferons inflammatory molecules that are increased in patients with lupus and contribute to disease activity  biib nav inhibitor trigeminal neuralgia tgn acquired in acquisition of convergence pharmaceuticals trigeminal neuralgia is an extremely painful condition usually involving one side of the face trigeminal neuralgia is characterized by sudden brief stabbing recurrent episodes of pain which frequently occurs spontaneously but is also commonly evoked by trivial stimuli including washing shaving smoking talking andor brushing the teeth trigger factors the pain follows one or more branches of the trigeminal nerve which provides nerve sensation from the mouth face and the front of the scalp the intensity of the pain and its unpredictability results in profound effects on the quality of life of patients how this therapy could help biib nav inhibitor is a novel state dependent small molecule sodium channel blocker that preferentially inhibits the nav  ion channel a therapeutic target implicated by genetics in human pain conditions biib is thought to penetrate the central nervous system and block nav channels in a novel manner and has the potential to provide a new and effective option for the treatment of trigeminal neuralgia biib glibenclamide iv stroke it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke the target indication for biib glibenclamide iv is large hemispheric infarction lhi a severe form of ischemic stroke where brain swelling cerebral edema often leads to a disproportionately large share of strokerelated morbidity and mortality how this therapy could help in preclinical studies biib glibenclamide iv has been shown to block surtrpm channels that mediate stroke related brain swelling clinical proofofconcept studies have demonstrated the potential of biib to reduce brain swelling disability and the risk of death in patients with lhi dapirolizumab pegol anticdl lupus developed in collaboration with ucb inc this chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin joints kidneys the brain and other organs it is a difficult disease to diagnose because it resembles several other conditions how this therapy could help cdl is a protein in b and t cells which helps regulate the immune system dapirolizumab pegol anticdl is an antibody that blocks cdl potentially lessening disease activity in lupus patients natalizumab αintegrin inhibitor acute ischemic stroke currently approved as tysabri® for relapsingremitting multiple sclerosis and crohn’s disease please visit tysabricom for prescribing and safety information it is estimated that nearly two million people in the united states and the european union will have a stroke each year stroke is a leading cause of mortality and serious longterm disability there is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke  how this therapy could help natalizumab is thought to reduce the inflammatory cells in the brain by blocking the lymphocytic infiltration known to occur in the brain following stroke which may reduce the extent of injury opicinumab antilingo multiple sclerosis ms this disease causes the body’s immune system to attack myelin a protective sheath covering nerve fibers damage to myelin “short circuits” communication between the brain spinal cord and other areas of the body severely impairing such neurological functions as mobility vision and thinking over time the nerves themselves can become damaged permanently how this therapy could help lingo is a cns specificprotein that is involved in the development of myelin in patients with ms lingo may inhibit myelin growth when it binds with its receptor data suggest that the antibody antilingo could block this process potentially allowing for the remyelination and restoration of nerve communication in ms patients xlrs gene therapy xlinked retinoschisis xlrs developed in collaboration with agtc xlrs is a disease that affects young males beginning in their teenage years it can lead to loss of vision and serious complications such as vitreous hemorrhage or retinal detachment during adulthood how this therapy could help the xlrs gene therapy is a recombinant adenoassociated virus vector raav delivering a transgene rs that expresses retinoschisin protein normal expression of retinoschisin could potentially improve longterm retinal function and preserve structural integrity biib antiαsynuclein parkinsons disease acquired from neurimmune parkinsons disease is a disorder of the central nervous system people who have this disease experience tremors slow movement muscle stiffness and impaired balance  as these symptoms become progressively worse patients have difficulty walking talking or completing other simple tasks how this therapy could help biib targets abnormal alphasynuclein protein that is associated with the destruction of nerve cells this progressive degeneration is the cause of parkinsons disease biib alzheimers disease alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting tau the protein that forms the deposits or tangles in the brain  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  biib alzheimers disease licensed from bristolmyers squibb alzheimer’s disease ad is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability it is estimated that more than  million individuals are living with ad worldwide today we understand that ad is a continuum with a long silent phase that begins years before symptoms appear as ad progresses symptoms like memory loss personality and behavioral changes commonly associated with ad begin to manifest how this therapy could help the memory loss and functional decline of ad have been linked to abnormal protein deposits that build up in the brain among those proteins are amyloid and tau deposits of abnormal tau socalled neurofibrillary tangles form in the neurons and are linked to increasing impairment and loss of brain cells associated both with ad and with other neurodegenerative diseases known as tauopathies such as progressive supranuclear palsy and frontotemporal dementia biib is an antibody targeting extracellular tau and may reduce the spreading of tau from one cell to the next potentially slowing the progress of the disease  world health organization dementia a public health priority httpwwwwhointmentalhealthpublicationsdementiareporten accessed  may  currently no results for this search see full pipeline our perspectives july   teaming up for als see all perspectives × important notice you are now leaving biogen’s corporate website we encourage you to read and evaluate terms of use privacy security and other similar policies of the destination site as they may differ from biogen’s standards third party sites biogen assumes no responsibility nor does it control endorse or guarantee any aspect of your use of any third party sites additionally the presence of this link does not imply the third party sites endorsement of biogen or this website thank you for visiting our site   cancel continue biogen  wikipedia biogen from wikipedia the free encyclopedia jump to navigation search biogen type public traded as nasdaq biib nasdaq component sp  component sp  component industry biotechnology founded  from merger founders kenneth murray phillip allen sharp walter gilbert heinz schaller charles weissmann headquarters cambridge massachusetts us key people stelios papadopoulos chairman michel vounatsos ceo products alprolix avonex eloctate fampyra gazyva plegridy rituxan tecfidera tysabri spinraza revenue us  billion   operating income us  billion   net income us  billion  total assets us  billion  total equity us  billion  number of employees  december  website wwwbiogencom biogen inc previously known as biogen idec is an american multinational biotechnology company based in cambridge massachusetts specializing in the discovery development and delivery of therapies for the treatment of neurodegenerative hematologic and autoimmune diseases to patients worldwide contents  history  bioverativ  acquisition history  leadership  products  pipeline  references  external links historyedit biogen was founded in  in geneva by several prominent biologists including kenneth murray of the university of edinburgh phillip allen sharp of the massachusetts institute of technology walter gilbert of harvard who served as ceo during the startup phase heinz schaller university of heidelberg and charles weissmann university of zurich who contributed the first product interferon alpha gilbert and sharp were subsequently honored with nobel prizes gilbert was recognized in  with the nobel prize in chemistry for his work in understanding dna sequencing while sharp received the nobel prize in physiology or medicine in  for his discovery of split genes in  biogen merged with san diego californiabased idec pharmaceuticals formed in  by biotech pioneers ivor royston and howard birndorf and adopted the name biogen idec after the merger biogen idec became the rd largest biotechnology company in the world following shifts in research core areas the company has since shortened its name reverting to simply biogen biogen stock is a component of several stock indices such as the sp  sp  sp  and nasdaq and the company is listed on the nasdaq stock exchange under the ticker symbol biib in may  the company announced it would acquire cancer specialist conforma therapeutics for  million later in the same month the company announced its intention to acquire fumapharm ag consolidating ownership of fumaderm and bg an oral fumarate which is being studied for the treatment of multiple sclerosis and psoriasis in january  the company announced it would acquire syntonix pharmaceuticals for up to  million gaining syntonixs lead product for hemophilia b as well as the technology for developing inhalable treatments in february  bloomberg broke the news that biogen was planning the pay elan  billion for the full rights to tysabri used to treat multiple sclerosis in january  the company announced it will acquire convergence pharmaceuticals for up to  million with the acquisition aiming to accelerate the development of convergences pipeline inparticular cnv – a phase ii small molecule sodium channel blocking candidate in october  the company announced it will lay off  of its workforce effective immediately bioverativedit in may  the company announced that it will spin off its hemophilia drug business eloctate and alprolix into a public company in august the company announced that the spun off company would be called bioverativ in order to show heritage with biogen the company will trade on the nasdaq exchange under the ticker symbol bivv and will look to be spun off in early  acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list biogen biogen idec biogen founded  idec pharmaceuticals conforma therapeutics acq  fumapharm ag acq  syntonix pharmaceuticals acq  convergence pharmaceuticals acq  leadershipedit biogen is managed by an executive group composed of ten officers michel vounatsos chief executive officer and member board of directors susan h alexander executive vice president chief legal officer and corporate secretary spyros artavanistsakonas phd chief scientific officer paul j clancy executive vice president and chief financial officer paul mckenzie phd executive vice president of pharmaceutical operations  technology kenneth dipietro executive vice president of human resources alfred w sandrock jr md phdexecutive vice president head of development and worldwide medical and chief medical officer michael ehlers md phd executive vice president head of rd as is customary for a publicly traded company biogen is also overseen by a board of directors the executive chairman and chief executive officer both hold positions on the board of directors the directors are stelios papadopoulos chairman michel vounatsos ceo alexander j denner phd caroline dorsa nancy l leaming richard c mulligan robert w pangia brian s posner eric k rowinsky md the honorable lynn schenk and stephen a sherwin md productsedit therapy indication in united states unless otherwise noted year approved us year approved eu additional information alprolix™ coagulation factor ix recombinant fc fusion protein control and prevention of bleeding episodes perioperative management and routine prophylaxis in adults and children with hemophilia b   also approved in canada and australia biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of alprolix  avonex® interferon betaa relapsing forms of multiple sclerosis   includes the avonex pen autoinjector and the avostartgrip titration kit approved in the us in  eloctate™ antihemophilic factor recombinant fc fusion protein control and prevention of bleeding episodes perioperative surgical management and routine prophylaxis in adults and children with hemophilia a   biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of eloctate fampyra® prolongedrelease fampridine tablets multiple sclerosis walking ability   marketed by biogen in markets outside of the united states commercialized in the united states as ampyra dalfampridine extended release tablets by acorda therapeutics fumaderm™ fumaric acid esters psoriasis german use  germany only approved in germany acquired in acquisition of fumapharm ag in  gazyva® obinutuzumab chronic lymphocytic leukemia   the first medicine approved with the fda’s breakthrough therapy designation and is also currently in phase  trials for nhl and diffuse large bcell lymphoma currently commercialized in the united states by genentech a wholly owned subsidiary of roche spinraza™ nusinersen spinal muscular atrophy  — the first drug approved for the treatment of spinal muscular atrophy developed in collaboration with ionis pharmaceuticals eu approval process under way plegridy™ peginterferon betaa relapsing forms of multiple sclerosis   rituxan® rituximab nonhodgkins lymphoma nhl antitnf refractory rheumatoid arthritis ancaassociated vasculitis chronic lymphocytic leukemia     as mabthera the first monoclonal antibody for cancer developed by idec prior to merging with biogen currently commercialized by roche and its subsidiary genentech tecfidera® dimethyl fumarate relapsing forms of multiple sclerosis   tysabri® natalizumab relapsingremitting multiple sclerosis  reintroduced in   full rights purchased from partner elan in  pipelineedit biogen has focused its rd efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology hematology and immunology investigational ms medicines daclizumab highyield process dac hyp is being developed as a potential oncemonthly subcutaneous injection in the treatment of relapsingremitting multiple sclerosis rrms dac hyp is being developed in collaboration with abbvie inc in june  the companies announced positive topline results from the phase iii decide clinical trial where dac hyp demonstrated superiority over interferon betaa in annualized relapse rate antilingo biib opicinumab is the first candidate being investigated for its potential to remyelinate and repair neurons damaged by ms currently in phase  trials biogen has several candidates in phase  and  clinical trials in neurodegenerative and immunological diseases including ms alzheimer’s disease neuropathic pain spinal muscular atrophy and lupus nephritis phase a antilingo molecule opicinumab in acute optic neuritis phase b antitweak monoclonal antibody in lupus nephritis phase a stx in patients with idiopathic pulmonary fibrosis phase  neublastin for neuropathic pain in  phase  biib aducanumab biogen’s first clinical study in alzheimer’s disease phase  biib isissodrx for amyotrophic lateral sclerosis als in collaboration with ionis biogen also has several development agreements in place with ionis pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders in february  biogen formalized a joint venture with samsung creating samsung bioepis this joint venture brings biogen’s expertise and capabilities in protein engineering cell line development and recombinant biologics manufacturing to position the joint venture so biogen can participate in the emerging market for biosimilars in early  biogen entered into an agreement with eisai inc to jointly develop and commercialize two of their candidates for alzheimer’s disease which have the potential to reduce aβ plaques that form in the brains of patients as well as to slow the formation of new plaques potentially improving symptoms and suppressing disease progression referencesedit  a b biogen inc k report  securities and exchange commission retrieved november    biotechs comeback kid forbes retrieved    idec to merge with biogen in  billion deal new york times retrieved    biogen drops idec from name wall street journal retrieved    biogen idec inc stock quote  summary data nasdaq   httpwwwpharmatimescomnewsbiogenidecagreestobuyswisscompanyfumapharm  httpwwwbusinesswirecomnewshomeenbiogenidecacquirefumapharmagconsolidatesownership  httpwwwfiercebiotechcombiotechbiogentobuysyntonixmdeal  httpwwwbusinesswirecomnewshomeenbiogenidecacquiresyntonix  httpswwwbloombergcomnewsarticlesbiogentopayelanbillionforfulltysabrirights  biogen idec snaps up convergence for uptom  gen news highlights  gen   biogen is cutting  of its workforce   dsouza savio may   biogen to spin off hemophilia drug business into a public company reuters retrieved may     amid takeover chatter biogen introduces hemophilia spinoff bioverativ  fiercepharma   httpwwwbusinesswirecomnewsfinancialpostenbiogenannouncesbioverativhemophiliafocusedcompany  biogen unveils name for hemophilia drug spinoff bioverativ  the boston globe   biogen announces bioverativ as name of new hemophiliafocused company  biogen media   biogen idec inc biib top compensated officers business week retrieved    biogen announces departure of tony kingsley  business wire wwwbusinesswirecom retrieved    biogen idec biib chairman young to retire streetinsidercom retrieved    does biogen idec inc have a new blockbuster hemophilia therapy the motley fool retrieved    avonex national ms society   biogen idec’s eloctate gains fda approval the pharma letter retrieved    fampridine fampyra ms trust   biogen idec enters deal to acquire fumapharm first word pharma retrieved    fda approves gazyva for chronic lymphocytic leukemia fdagov retrieved    wadman meredith  december  updated fda approves drug that rescues babies with fatal neurodegenerative disease science   grant charley  surprise drug approval is holiday gift for biogen wall street journal issn  retrieved    biogen idec’s plegridy™peginterferon betaa approved in the us for the treatment of multiple sclerosis reuters   biogen idec’s plegridy approved in europe for relapsingremitting multiple sclerosis the pharma letter   fda approval for rituximab national cancer institute   update roche biogen end dispute over rituxan followons reuters retrieved    fda approves rituxan to treat two rare disorders fdagov retrieved    cell therapeutics buys zevalin from biogen idec for m with up to m extra plus milestones the pharma letter retrieved    tecifedra national ms society   tysabri national ms society   oncemonthly ms drug from biogen idec abbvie clears phase iii hurdle fierce biotech retrieved    lingo a promising remyelination target in ms multiple sclerosis research retrieved    aducanumab reduces amyloid plaques in early alzheimers prime   isis pharmaceuticals and biogen idec fierce biotech   biogen sees eloctate fda delay pushing marketing to mid businessweek retrieved    isis pharmaceuticals and biogen idec fierce biotech  external linksedit official website business data for biogen google finance yahoo finance reuters sec filings v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies companies portal coordinates °′″n °′″w﻿  ﻿°n °w﻿    retrieved from httpsenwikipediaorgwindexphptitlebiogenoldid categories companies in the nasdaq indexcompanies listed on nasdaqcompanies in the nasdaq biotechnology indexcompanies based in cambridge massachusettsbiotechnology companies of the united statesnational medal of technology recipientspharmaceutical companies of the united statespharmaceutical companies established in  establishments in massachusettsorphan drug companieslife sciences industry establishments in switzerlandbiotechnology companies established in spinal muscular atrophycompanies formed by mergerhealth care companies based in massachusettshidden categories pages using infobox company with unsupported parameterscoordinates not on wikidata navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdeutschفارسیfrançaisportuguêssuomi edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view biogen biogen  twitter skip to content home home home current page moments moments moments current page search query search twitter searches you follow follow following unfollow saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  language english bahasa indonesia bahasa melayu català čeština dansk deutsch english uk español filipino français hrvatski italiano magyar nederlands norsk polski português română slovenčina suomi svenska tiếng việt türkçe ελληνικά български език русский српски українська мова עִבְרִית العربية فارسی मराठी हिन्दी বাংলা ગુજરાતી தமிழ் ಕನ್ನಡ ภาษาไทย 한국어  简体 繁體 have an account log in have an account remember me · forgot password new to twitter sign up biogenverified account biogen tweets tweets current page  following following  followers followers k likes likes    more likes unmute biogen mute biogen follow following unfollow blocked unblock pending cancel biogenverified account biogen official twitter channel for biogen focused on cuttingedge science and medicine community guidelines httpbitlymzocks  cambridge ma biogencom joined june   photos and videos photos and videos tweets tweets tweets current page tweets  replies media you blocked biogen are you sure you want to view these tweets viewing tweets wont unblock biogen yes view profile close biogen followed biogen‏verified account biogen h hours ago more copy link to tweet embed tweet reading the earliest signs of alzheimers disease learn about our exploration of this topic via biogensciencehttpscardstwittercomcardscewghxgjii …  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet click here for our second quarter  financial results httpbitlyvfcuu   replies  retweets  likes reply  retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet today well be reporting our second quarter  financial results listen live from am et httpbitlyuitopo   replies  retweets  likes reply retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet at biogen our employees are dedicated and passionate see what inspires bob mystory httpbitlykegeej pictwittercomlpndobxiq employee stories bob shares his story  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet tomorrow well be reporting our second quarter  financial results listen live from am et httpbitlyuitopo   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen retweeted biogen‏verified account biogen jul  more copy link to tweet embed tweet our community lab is inspiring the next generation of scientists to us that is sciencethatmatterspictwittercomeexxoyqpw inspiring the next generation of scientists  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet see how we’re impacting lives through visionary science—for patients for society for communitieshttpscardstwittercomcardscewghxgguld …  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet thank you to alzassociation for organizing a successful conference aaic  replies  retweet  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet we are identifying realworld gaps in assessing early signs of alzheimers learn more via new biogenscience posthttpscardstwittercomcardscewghxgjii …  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet our community lab is inspiring the next generation of scientists to us that is sciencethatmatterspictwittercomeexxoyqpw inspiring the next generation of scientists  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet biogen remains committed to alzheimers research because by  as many as  million people could be living with alzheimers aaic  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet interested in clinical trials in alzheimers disease you can learn more about our trials here httpbitlyyheh  research aaic  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet our alzheimer’s disease data at aaic identify realworld gaps in assessing early signs of ad learn morehttpscardstwittercomcardscewghxgjii …  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet today we welcome new leadership ginger gregory phd catherine steele and amy chevalier efantis learn more httpmediabiogencom   replies  retweet  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet we are attending aaic to help advance the science for those affected by alzheimers  replies  retweet  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet our participation at aaic highlights our ongoing support  commitment to those with alzheimers diseasepictwittercomnhyvziwxc  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet alzheimers accounts for up to  of dementia cases worldwide biogen remains committed to advancing the science in this space aaic  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet sciencethatmatters extends beyond our therapies “biogen is helping patients saving lives and improving quality of life”pictwittercomtfzcwmrew protecting our patients from product counterfeits  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet on our way to london to participate in aaic looking forward to connecting with the alzheimers community httpswwwalzorgaaicaboutlondonasp …pictwittercomtwnxnlajl  replies  retweet  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen‏verified account biogen jul  more copy link to tweet embed tweet dissecting the genetics behind parkinsons disease learn about our new collaborative approach in biogensciencehttpscardstwittercomcardscewghxghzo …  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo biogen hasnt tweeted yet back to top ↑ loading seems to be taking a while twitter may be over capacity or experiencing a momentary hiccup try again or visit twitter status for more information new to twitter sign up now to get your own personalized timeline sign up you may also like · refresh false   twitter about help center terms privacy policy cookies ads info close choose a trend location dismiss close previous next close go to a persons profile searches you follow follow following unfollow saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  close promote this tweet close block cancel block add a location to your tweets when you tweet with a location twitter stores that location you can switch location onoff before each tweet and always have the option to delete your location history learn more turn location on not now close share location results from send close your lists close create a new list list name description under  characters optional privacy public · anyone can follow this list private · only you can access this list save list close close copy link to tweet heres the url for this tweet copy it to easily share with friends close embed this tweet embed this video add this tweet to your website by copying the code below learn more add this video to your website by copying the code below learn more hmm there was a problem reaching the server try again include parent tweet include media by embedding twitter content in your website or app you are agreeing to the twitter developer agreement and developer policy preview close why youre seeing this ad close log in to twitter remember me · forgot password dont have an account sign up » close sign up for twitter not on twitter sign up tune into the things you care about and get updates as they happen sign up have an account log in » close twoway sending and receiving short codes country code for customers of united states  any canada  any united kingdom  vodafone orange  o brazil  nextel tim haiti  digicel voila ireland  vodafone o india  bharti airtel videocon reliance indonesia  axis  telkomsel indosat xl axiata italy  wind  vodafone » see sms short codes for other countries close confirmation close   close skip all welcome home this timeline is where you’ll spend most of your time getting instant updates about what matters to you tweets not working for you hover over the profile pic and click the following button to unfollow any account say a lot with a little when you see a tweet you love tap the heart — it lets the person who wrote it know you shared the love spread the word the fastest way to share someone else’s tweet with your followers is with a retweet tap the icon to send it instantly join the conversation add your thoughts about any tweet with a reply find a topic you’re passionate about and jump right in learn the latest get instant insight into what people are talking about now get more of what you love follow more accounts to get instant updates about topics you care about find whats happening see the latest conversations about any topic instantly never miss a moment catch up instantly on the best stories happening as they unfold back next next tweet from user biogen  wikipedia biogen from wikipedia the free encyclopedia jump to navigation search biogen type public traded as nasdaq biib nasdaq component sp  component sp  component industry biotechnology founded  from merger founders kenneth murray phillip allen sharp walter gilbert heinz schaller charles weissmann headquarters cambridge massachusetts us key people stelios papadopoulos chairman michel vounatsos ceo products alprolix avonex eloctate fampyra gazyva plegridy rituxan tecfidera tysabri spinraza revenue us  billion   operating income us  billion   net income us  billion  total assets us  billion  total equity us  billion  number of employees  december  website wwwbiogencom biogen inc previously known as biogen idec is an american multinational biotechnology company based in cambridge massachusetts specializing in the discovery development and delivery of therapies for the treatment of neurodegenerative hematologic and autoimmune diseases to patients worldwide contents  history  bioverativ  acquisition history  leadership  products  pipeline  references  external links historyedit biogen was founded in  in geneva by several prominent biologists including kenneth murray of the university of edinburgh phillip allen sharp of the massachusetts institute of technology walter gilbert of harvard who served as ceo during the startup phase heinz schaller university of heidelberg and charles weissmann university of zurich who contributed the first product interferon alpha gilbert and sharp were subsequently honored with nobel prizes gilbert was recognized in  with the nobel prize in chemistry for his work in understanding dna sequencing while sharp received the nobel prize in physiology or medicine in  for his discovery of split genes in  biogen merged with san diego californiabased idec pharmaceuticals formed in  by biotech pioneers ivor royston and howard birndorf and adopted the name biogen idec after the merger biogen idec became the rd largest biotechnology company in the world following shifts in research core areas the company has since shortened its name reverting to simply biogen biogen stock is a component of several stock indices such as the sp  sp  sp  and nasdaq and the company is listed on the nasdaq stock exchange under the ticker symbol biib in may  the company announced it would acquire cancer specialist conforma therapeutics for  million later in the same month the company announced its intention to acquire fumapharm ag consolidating ownership of fumaderm and bg an oral fumarate which is being studied for the treatment of multiple sclerosis and psoriasis in january  the company announced it would acquire syntonix pharmaceuticals for up to  million gaining syntonixs lead product for hemophilia b as well as the technology for developing inhalable treatments in february  bloomberg broke the news that biogen was planning the pay elan  billion for the full rights to tysabri used to treat multiple sclerosis in january  the company announced it will acquire convergence pharmaceuticals for up to  million with the acquisition aiming to accelerate the development of convergences pipeline inparticular cnv – a phase ii small molecule sodium channel blocking candidate in october  the company announced it will lay off  of its workforce effective immediately bioverativedit in may  the company announced that it will spin off its hemophilia drug business eloctate and alprolix into a public company in august the company announced that the spun off company would be called bioverativ in order to show heritage with biogen the company will trade on the nasdaq exchange under the ticker symbol bivv and will look to be spun off in early  acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list biogen biogen idec biogen founded  idec pharmaceuticals conforma therapeutics acq  fumapharm ag acq  syntonix pharmaceuticals acq  convergence pharmaceuticals acq  leadershipedit biogen is managed by an executive group composed of ten officers michel vounatsos chief executive officer and member board of directors susan h alexander executive vice president chief legal officer and corporate secretary spyros artavanistsakonas phd chief scientific officer paul j clancy executive vice president and chief financial officer paul mckenzie phd executive vice president of pharmaceutical operations  technology kenneth dipietro executive vice president of human resources alfred w sandrock jr md phdexecutive vice president head of development and worldwide medical and chief medical officer michael ehlers md phd executive vice president head of rd as is customary for a publicly traded company biogen is also overseen by a board of directors the executive chairman and chief executive officer both hold positions on the board of directors the directors are stelios papadopoulos chairman michel vounatsos ceo alexander j denner phd caroline dorsa nancy l leaming richard c mulligan robert w pangia brian s posner eric k rowinsky md the honorable lynn schenk and stephen a sherwin md productsedit therapy indication in united states unless otherwise noted year approved us year approved eu additional information alprolix™ coagulation factor ix recombinant fc fusion protein control and prevention of bleeding episodes perioperative management and routine prophylaxis in adults and children with hemophilia b   also approved in canada and australia biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of alprolix  avonex® interferon betaa relapsing forms of multiple sclerosis   includes the avonex pen autoinjector and the avostartgrip titration kit approved in the us in  eloctate™ antihemophilic factor recombinant fc fusion protein control and prevention of bleeding episodes perioperative surgical management and routine prophylaxis in adults and children with hemophilia a   biogen and swedish orphan biovitrum sobi are collaborators in the development and commercialization of eloctate fampyra® prolongedrelease fampridine tablets multiple sclerosis walking ability   marketed by biogen in markets outside of the united states commercialized in the united states as ampyra dalfampridine extended release tablets by acorda therapeutics fumaderm™ fumaric acid esters psoriasis german use  germany only approved in germany acquired in acquisition of fumapharm ag in  gazyva® obinutuzumab chronic lymphocytic leukemia   the first medicine approved with the fda’s breakthrough therapy designation and is also currently in phase  trials for nhl and diffuse large bcell lymphoma currently commercialized in the united states by genentech a wholly owned subsidiary of roche spinraza™ nusinersen spinal muscular atrophy  — the first drug approved for the treatment of spinal muscular atrophy developed in collaboration with ionis pharmaceuticals eu approval process under way plegridy™ peginterferon betaa relapsing forms of multiple sclerosis   rituxan® rituximab nonhodgkins lymphoma nhl antitnf refractory rheumatoid arthritis ancaassociated vasculitis chronic lymphocytic leukemia     as mabthera the first monoclonal antibody for cancer developed by idec prior to merging with biogen currently commercialized by roche and its subsidiary genentech tecfidera® dimethyl fumarate relapsing forms of multiple sclerosis   tysabri® natalizumab relapsingremitting multiple sclerosis  reintroduced in   full rights purchased from partner elan in  pipelineedit biogen has focused its rd efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology hematology and immunology investigational ms medicines daclizumab highyield process dac hyp is being developed as a potential oncemonthly subcutaneous injection in the treatment of relapsingremitting multiple sclerosis rrms dac hyp is being developed in collaboration with abbvie inc in june  the companies announced positive topline results from the phase iii decide clinical trial where dac hyp demonstrated superiority over interferon betaa in annualized relapse rate antilingo biib opicinumab is the first candidate being investigated for its potential to remyelinate and repair neurons damaged by ms currently in phase  trials biogen has several candidates in phase  and  clinical trials in neurodegenerative and immunological diseases including ms alzheimer’s disease neuropathic pain spinal muscular atrophy and lupus nephritis phase a antilingo molecule opicinumab in acute optic neuritis phase b antitweak monoclonal antibody in lupus nephritis phase a stx in patients with idiopathic pulmonary fibrosis phase  neublastin for neuropathic pain in  phase  biib aducanumab biogen’s first clinical study in alzheimer’s disease phase  biib isissodrx for amyotrophic lateral sclerosis als in collaboration with ionis biogen also has several development agreements in place with ionis pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders in february  biogen formalized a joint venture with samsung creating samsung bioepis this joint venture brings biogen’s expertise and capabilities in protein engineering cell line development and recombinant biologics manufacturing to position the joint venture so biogen can participate in the emerging market for biosimilars in early  biogen entered into an agreement with eisai inc to jointly develop and commercialize two of their candidates for alzheimer’s disease which have the potential to reduce aβ plaques that form in the brains of patients as well as to slow the formation of new plaques potentially improving symptoms and suppressing disease progression referencesedit  a b biogen inc k report  securities and exchange commission retrieved november    biotechs comeback kid forbes retrieved    idec to merge with biogen in  billion deal new york times retrieved    biogen drops idec from name wall street journal retrieved    biogen idec inc stock quote  summary data nasdaq   httpwwwpharmatimescomnewsbiogenidecagreestobuyswisscompanyfumapharm  httpwwwbusinesswirecomnewshomeenbiogenidecacquirefumapharmagconsolidatesownership  httpwwwfiercebiotechcombiotechbiogentobuysyntonixmdeal  httpwwwbusinesswirecomnewshomeenbiogenidecacquiresyntonix  httpswwwbloombergcomnewsarticlesbiogentopayelanbillionforfulltysabrirights  biogen idec snaps up convergence for uptom  gen news highlights  gen   biogen is cutting  of its workforce   dsouza savio may   biogen to spin off hemophilia drug business into a public company reuters retrieved may     amid takeover chatter biogen introduces hemophilia spinoff bioverativ  fiercepharma   httpwwwbusinesswirecomnewsfinancialpostenbiogenannouncesbioverativhemophiliafocusedcompany  biogen unveils name for hemophilia drug spinoff bioverativ  the boston globe   biogen announces bioverativ as name of new hemophiliafocused company  biogen media   biogen idec inc biib top compensated officers business week retrieved    biogen announces departure of tony kingsley  business wire wwwbusinesswirecom retrieved    biogen idec biib chairman young to retire streetinsidercom retrieved    does biogen idec inc have a new blockbuster hemophilia therapy the motley fool retrieved    avonex national ms society   biogen idec’s eloctate gains fda approval the pharma letter retrieved    fampridine fampyra ms trust   biogen idec enters deal to acquire fumapharm first word pharma retrieved    fda approves gazyva for chronic lymphocytic leukemia fdagov retrieved    wadman meredith  december  updated fda approves drug that rescues babies with fatal neurodegenerative disease science   grant charley  surprise drug approval is holiday gift for biogen wall street journal issn  retrieved    biogen idec’s plegridy™peginterferon betaa approved in the us for the treatment of multiple sclerosis reuters   biogen idec’s plegridy approved in europe for relapsingremitting multiple sclerosis the pharma letter   fda approval for rituximab national cancer institute   update roche biogen end dispute over rituxan followons reuters retrieved    fda approves rituxan to treat two rare disorders fdagov retrieved    cell therapeutics buys zevalin from biogen idec for m with up to m extra plus milestones the pharma letter retrieved    tecifedra national ms society   tysabri national ms society   oncemonthly ms drug from biogen idec abbvie clears phase iii hurdle fierce biotech retrieved    lingo a promising remyelination target in ms multiple sclerosis research retrieved    aducanumab reduces amyloid plaques in early alzheimers prime   isis pharmaceuticals and biogen idec fierce biotech   biogen sees eloctate fda delay pushing marketing to mid businessweek retrieved    isis pharmaceuticals and biogen idec fierce biotech  external linksedit official website business data for biogen google finance yahoo finance reuters sec filings v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies companies portal coordinates °′″n °′″w﻿  ﻿°n °w﻿    retrieved from httpsenwikipediaorgwindexphptitlebiogenoldid categories companies in the nasdaq indexcompanies listed on nasdaqcompanies in the nasdaq biotechnology indexcompanies based in cambridge massachusettsbiotechnology companies of the united statesnational medal of technology recipientspharmaceutical companies of the united statespharmaceutical companies established in  establishments in massachusettsorphan drug companieslife sciences industry establishments in switzerlandbiotechnology companies established in spinal muscular atrophycompanies formed by mergerhealth care companies based in massachusettshidden categories pages using infobox company with unsupported parameterscoordinates not on wikidata navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdeutschفارسیfrançaisportuguêssuomi edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view data dumps    freebase api deprecated    google developers freebase api deprecated all products sign in send feedback hey there are you maybe looking for firebase instead data dumps the freebase api will be completely shutdown on aug   this page provides access to the last available data dump read more data dumps are a downloadable version of the data in freebase they constitute a snapshot of the data stored in freebase and the schema that structures it and are provided under the same ccby license the freebasewikidata mappings are provided under the cc license freebase triples freebase deleted triples freebasewikidata mappings license citing freebase triples this dataset contains every fact currently in freebase total triples  billion updated weekly data format ntriples rdf license ccby  gb gzip gb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagedate httpwwwworgxmlschemagyearmonth  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagesource httprdffreebasecomnsgxgfm  httprdffreebasecomnsgvjzynm httprdffreebasecomnstypeobjecttype httprdffreebasecomnsmeasurementunitdatedpercentage  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagerate   httprdffreebasecomnsgvjzynm httpwwwworgrdfsyntaxnstype httprdffreebasecomnsmeasurementunitdatedpercentage  if youre writing your own code to parse the rdf dumps its often more efficient to read directly from gzip file rather than extracting the data first and then processing the uncompressed data subject predicate object  note in freebase objects have mids that look like mrkqx in rdf those mids become mrkqx likewise freebase schema like commontopic are written as commontopic the subject is the id of a freebase object it can be a freebase mid ex mrkqx for topics and cvts or a humanreadable id ex commontopic for schema the predicate is always a humanreadable id for a freebase property or a property from a standard rdf vocabulary like rdfs freebase foreign key namespaces are also used as predicates to make it easier to look up keys by namespace the object field may contain a freebase mid for an object or a humanreadable id for schema from freebase or other rdf vocabularies it may also include literal values like strings booleans and numeric values topic descriptions often contain newlines in order to make each triple fit on one line we have escaped newlines with n freebase deleted triples we also provide a dump of triples that have been deleted from freebase over time this is a onetime dump through march  in the future we might consider providing periodic updates of recently deleted triples but at the moment we have no specific timeframe for doing so and are only providing this onetime dump the dump is distributed as a targz file gb compressed gb uncompressed it contains  deleted triples in  files there is no particular meaning to the individual files it is just easier to manipulate several smaller files than one huge file thanks to chun how tan and john giannandrea for making this data release possible total triples  million updated june   data format csv license ccby  gb gzip gb uncompressed download the data format is essentially csv with one important caveat the object field may contain any characters including commas as well as any other reasonable delimiters you could think of however all the other fields are guaranteed not to contain commas so the data can still be parsed unambiguously the columns in the dataset are defined as creationtimestamp unix epoch time in milliseconds creator deletiontimestamp unix epoch time in milliseconds deletor subject mid predicate mid object midliteral languagecode csv usermwclwikipediaenusermwclwikipediaenmrtypeobjectkeywikipediaenben usermwclmusicbrainzuserturtlewaxbotmnncpzmusicrecordingartistmvbfmen usermwclimagesusergardeningbotmwmcommonimagesizemklyen usermwclmusicbrainzusermbzpipelinemergebotmfvvltypeobjecttypecommontopicen usermwclimagesusergardeningbotmxsczcommonlicensedobjectlicensemxben usercontentadministratorusergardeningbotmgkbytypeobjecttypetypecontenten usermwclimagesusergardeningbotmhcommontopicimagemcsen usermwclchefmozuserdeletebotmzcztypeobjectnamela casa rosa mexican restauranten freebasewikidata mappings the data has been created based on the wikidatadump of october   and contains only those links that have at least two common wikipedialinks and not a single disagreeing wikipedialink furthermore the lines are sorted by the number of common wikipedialinks although in turtle this does not really matter total triples m updated october   data format ntriples rdf license cc  mb gzip mb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsmj httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmnrg httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmjgd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmgd httpwwwworgowlsameas httpwwwwikidataorgentityq  license freebase data dumps are provided free of charge for any purpose with regular updates by google they are distributed like freebase itself under the creative commons attribution aka ccby and use is subject to the terms of service the freebasewikidata id mappings are provided under cc and can be used without restrictions citing if youd like to cite these data dumps in a publication you may use google freebase data dumps httpsdevelopersgooglecomfreebasedata month day year or as bibtex bibtex misc except as otherwise noted the content of this page is licensed under the creative commons attribution  license and code samples are licensed under the apache  license for details see our site policies java is a registered trademark of oracle andor its affiliates last updated february   send feedback about this page documentation feedback freebase api deprecated product feedback cancel